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Multi-host life cycles of eukaryotic parasites are fundamentally important for their success 
because they are linked to the way that these parasites replicate, disseminate, transmit, and cause 
disease in each host. As parasites of this nature progress through their life cycle, they transition 
between different developmental stages that function to promote survival and transmission in a 
specific host environment. The transitions between these life stages are especially important for 
the parasites Toxoplasma gondii and Hammondia hammondi. T. gondii and H. hammondi are 
closely related Apicomplexans that share a large majority of their genes in near perfect synteny. 
Despite this genomic similarity, these parasites have stark differences in their life cycle flexibility 
and virulence. To begin to understand the mechanisms for these differences, we have compared 
the developmental programs of these parasite species in head-to-head experiments and identified 
critical differences in the timing of stage conversion and response to stress. We were able to exploit 
this knowledge to produce the first ever transgenic H. hammondi line. We also used the 
developmental differences between T. gondii and H. hammondi and thorough transcriptional 
comparisons to identify new factors driving life stage conversion in T. gondii. Specifically, we 
identified the gene Regulator of Cystogenesis 1 (ROCY1), which encodes a zinc finger CCCH 
motif containing protein that plays a critical role in in vitro tissue cyst formation and is required 
 v 
for tissue cyst formation in vivo. Our data also suggest that ROCY1 is regulated, at least in part, 
by a T. gondii transcription factor that serves as a regulator of differentiation, Bradyzoite-
Formation Deficient 1 (BFD1). Together, our findings begin to elucidate the regulatory networks 
driving stage conversion in T. gondii and H. hammondi.  
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the Coccidian Apicomplexans Toxoplasma gondii, Hammondia hammondi, and 
Neospora caninum. Front. Cell. Infect. Microbiol. 10, 608283. Additional 
information has been added.  
 
Eukaryotic parasites with multi-host life cycles have the unique challenge of persisting in 
a variety of environments. Parasites of this nature must exist in a life form that is permissible and 
optimized for growth, survival, and transmission in a given host. The ability to adopt these specific 
life forms is critical for Toxoplasma gondii and Hammondia hammondi, members of the 
Sarcosystidae family coccidia. These mammalian parasites follow heteroxenous, two-host life 
cycles (1–5) where they must survive in a variety of cell types and experience an array of host-
derived immune pressures. To deal with changing environments, these parasites undergo stage 
conversion where they transition to life forms that each serve an important function for survival 
and fitness (ultimately defined as transmission). Stage conversion is essential for the success of 
both T. gondii and H. hammondi, however the mechanisms and networks underlying this process 
are only starting to be understood. Investigating and comparing how both parasites transition 
between their shared life stages has the potential to improve our understanding of stage conversion 
and reveal novel factors involved in the mechanisms driving such a critical process for T. gondii 
and H. hammondi.  
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1.1 Toxoplasma gondii 
Toxoplasma gondii is an obligate, intracellular, eukaryotic parasite belonging to the 
phylum Apicomplexa. T. gondii was discovered in 1908 in the tissue of the rodent Ctenodactylus 
gundi by Nicolle and Manceaux in Tunisia (6) and by Splendor in the tissues of a rabbit in Brazil 
(7). Nicolle and Manceaux named this newly discovered organism Toxoplasma gondii after its 
morphology, with toxo meaning bow and plasma meaning life, and the host organism from which 
they believed it was originally identified, Ctenodactylus gondi (8), which was misidentified at the 
time of naming (9, 10). T. gondii follows a complicated two-host life cycle (described below) 
where it transitions between varying life forms optimized for success in a given host or 
environment (1, 2, 11). T. gondii is a zoonotic pathogen capable of infecting all warm-blooded 
animals and can cause severe disease in humans, especially in individuals with a compromised 
immune system (12) and in the developing fetus (13). T. gondii infects approximately one third of 
humans worldwide (14, 15), and in the United States, it is estimated that congenital infection with 
T. gondii ranges from 1 in 3,000 to 1 in 10,000 live births (13). T. gondii can also cause severe 
disease in other animals including but not limited to cats, dogs, monkeys, and sheep (16). All in 
all, T. gondii is a global health concern for both humans and other animals.  
1.1.1 Life cycle of T. gondii  
Toxoplasma gondii follows a facultative homoxenous/heteroxenous two-host life cycle 
(Figure 1A). Sexual reproduction of T. gondii occurs in its definitive hosts which includes 
members of the Felidae genus. This specific developmental process produces millions of orally 
infectious, environmentally stable oocysts. Each oocyst contains 8 sporozoites contained within 2 
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sporocysts that are surrounded by an oocyst wall (1, 2, 11). When oocysts are ingested by an 
intermediate host, the sporozoites will excyst within the host digestive system and invade the 
intestinal epithelium. Once in the intestinal epithelium, sporozoites differentiate into tachyzoites, 
which are the fast-growing life stage responsible for acute infection. Eventually, T. gondii 
tachyzoites differentiate into bradyzoites, the slow growing life stage associated with chronic 
infection. Bradyzoites are found within tissue cysts which typically reside in the central nervous 
system or in skeletal and cardiac muscle (17). Bradyzoite tissue cysts are orally infectious to the 
definitive host. When ingested by a definitive host, tissue cysts will differentiate into the sexual 
stages resulting in the production of oocysts, thus completing the life cycle (18). Additionally, cats 
have been described as complete hosts for T. gondii, meaning that they can support the entire life 
cycle, because they support proliferation of tachyzoites and bradyzoites in tissues outside of the 
intestine in addition to supporting sexual life stages and sexual reproduction in intestinal tissues 
(19). One of the most unique components of the T. gondii life cycle is that its life cycle is flexible 
because it can bypass both asexual and sexual reproduction The bypass of sexual reproduction 
allows T. gondii to continually persist in only its intermediate hosts (11) and likely underlies its 
broad host range.  
 
Figure 1. Life cycle of Toxoplasma gondii and Hammondia hammondi.  
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A) T. gondii follows a facultative heteroxenous/homoxenous life cycle where during a given cycle it can bypass both 
sexual or asexual replication. H. hammondi follows a strict obligate heteroxenous life cycle and lacks bypasses found 
in the T. gondii life cycle. Sexual reproduction for both T. gondii and H. hammondi occurs in members of the Felidae 
genus. B) Neighbor-joining tree depicting relationship between ITS1 (Internal transcribed spacer 1) sequences of T. 
gondii, H. hammondi, and N. caninum. P. falciparum is used as an outgroup. Sequences were obtained from GenBank. 
Bootstrap values for 1000 replicates are indicated. Scale bar represents the substitutions per site.  
1.1.2 Toxoplasma gondii - host range, transmission, and pathogenesis  
Toxoplasma gondii has a broad intermediate host range and can infect all warm-blooded 
animals including birds (12). Transmission of T. gondii occurs through the fecal-oral route, when 
oocysts, shed in cat feces, are ingested by an intermediate host. Transmission can also occur when 
an intermediate host consumes tissues infected with bradyzoite-containing tissue cysts (9). 
Additionally, vertical transmission of T. gondii can occur during primary infection of a mother, as 
tachyzoites are able to cross the placenta (13). Although infections are often asymptomatic, T. 
gondii infections persist in the host in the form of tissue cysts, the life stage that contributes to 
chronic infection (20). Tissue cysts cannot be cleared by the host immune response nor can they 
be eliminated by known antiparasitic drugs (21–24). T. gondii infections are thought to be long 
term, as bradyzoite containing tissue cysts reside in host tissue for extended periods of time and 
can reactivate causing clinical disease (12, 25, 26). Reactivation can occur when 1) a chronically 
infected host becomes immunocompromised which results in rapid proliferation and dissemination 
of tachyzoites, 2) when a naïve intermediate host ingests T. gondii tissue cysts, the bradyzoites 
contained within these tissue cysts are released during digestion and transition back to tachyzoites 
which then disseminate and cause acute infection in the host before encysting during chronic 
infection, or 3) as a result of transplantation of an organ that was previously infected with T. gondii. 
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Reactivation results in expanded transmission for T. gondii, as it allows for the parasites to be 
continually propagated through asexual reproduction in intermediate hosts and underlies disease 
progression in immunocompromised hosts (17). To date, the molecular determinants of this unique 
ability have not been elucidated, but this ability has likely had a dramatic impact on the global 
distribution and broad host range of T. gondii.  
1.1.3 Toxoplasma gondii in humans – global prevalence, disease, and treatment 
T. gondii is the causative agent for the human disease toxoplasmosis, has a worldwide 
distribution, and is estimated to have infected 2 billion people (27). It is estimated to infect 1 
million new individuals in the United States each year (28). Recent studies have calculated the 
global seroprevalence of T. gondii infection to be 25.7%, with estimated seroprevalence ranging 
from 16.4% in Asia to 61.4% in Africa (14).  
T. gondii is one of the leading causes of hospitalization and the second leading cause of 
death caused by a food borne illness in the United States (29). Typically, infections with T. gondii 
are asymptomatic or results in fever, muscle aches, malaise, headache, sore throat, and mild 
lymphadenopathy (16, 30). However, as previously mentioned, infection with T. gondii can 
become problematic for individuals with compromised immune systems, such as HIV/AIDS 
patients or organ transplant patients, when latent infections reactivate into highly replicative life 
forms and result in tissue damage (23, 30–36). Infection with T. gondii can also be problematic 
when infection occurs for the first time in pregnant women. Congenitally acquired toxoplasmosis 
can result in spontaneous abortion or severe birth defects, typically impacting the central nervous 
system. The effects of congenitally acquired toxoplasmosis can develop in utero or months to years 
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after birth (13). Additionally, T. gondii is capable of invading and replicating in the retina, resulting 
in ocular toxoplasmosis, which can cause severe retinal damage that can lead to blindness (37).  
Following infection with oocyst-derived sporozoites or bradyzoites, T. gondii disseminates 
to its host’s lymph nodes and distant organs by traveling through the blood stream and the 
lymphatic system. Typically, disease associated with toxoplasmosis is caused by the intracellular 
replication of tachyzoites (either during primary infection or from a ruptured tissue cyst) that 
ultimately lead to tissue necrosis. Necrosis is usually followed by inflammation (16) that leads to 
killing of tachyzoites, primarily by interferon- and tumor necrosis factor activated macrophages 
and cytotoxic T cells (38). Typically, necrosis and associated abscesses give rise to the disease 
processes caused by T. gondii, including encephalitis and retionochoroiditis (16, 38).  
There are a variety of treatments for toxoplasmosis that target tachyzoites. Some of the 
most common treatments include sulfonamides, such as sulfadiazine, dapsone, and 
pyrimethamine, (24, 39, 40) which inhibit parasite folate metabolism (16, 24). Other treatments 
include macrolides (such as spiramycin and azithromycin) (24), clindamycin (41), minocycline, 
and rifabutin (24). However, there are no FDA approved antimicrobials that are able to target 
bradyzoite containing tissue cysts (16, 23, 24). The lack of antimicrobials targeting bradyzoites in 
combination with the sheer number of individuals infected with T. gondii make understanding the 
developmental processes needed to form bradyzoites fundamentally important for the development 
of novel therapeutics that can specifically act on these life stages to eliminate chronic infection. 
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1.2 Hammondia hammondi 
Hammondia hammondi is also an obligate, intracellular eukaryotic parasite and is the 
closest extant relative of T. gondii (42, 43). H. hammondi was first discovered in cats by J. K. 
Frenkel and J. P. Dubey in 1975 and is named in honor of Professor Datus M. Hammond for his 
contributions to the knowledge about coccidian parasites (5). Unlike its close relative, T. gondii, 
H. hammondi is thought to be avirulent as it is not known to cause disease in humans (42).  
1.2.1 Life cycle of H. hammondi  
Hammondia hammondi follows a strict obligate heteroxenous life cycle (Figure 1A). 
Sexual reproduction only occurs within the intestinal epithelium of the definitive host, which 
includes felids. H. hammondi oocysts, which are morphologically indistinguishable for T. gondii 
oocysts, are orally infectious to intermediate hosts (3, 5). H. hammondi oocysts, like T. gondii 
oocysts, excyst within the host digestive system and release sporozoites that invade the intestinal 
epithelium and differentiate into tachyzoite and bradyzoite life stages as infection progresses. 
Unlike T. gondii infections, feline hosts can only support H. hammondi enteroepithelial stages and 
do not support extraintestinal infections (42). Furthermore, during asexual reproduction H. 
hammondi tachyzoites remain infectious to intermediate hosts until they terminally differentiate 
into bradyzoite/tissue cyst life stages (42, 44) that are only orally infectious to definitive feline 
hosts. It is hypothesized that terminally differentiated H. hammondi parasites are incapable of 
reactivation, however, this has yet to be tested in head-to-head comparisons with T. gondii.  
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1.2.2 Hammondia hammondi - host range, transmission, and pathogenesis  
H. hammondi has a restricted host range, as its only known natural intermediate hosts are 
rodents (45), roe deer (46), and goats (47). Despite having a limited known natural host range, H. 
hammondi has been shown experimentally to infect monkeys (48), dogs (49), rabbits, and pigs 
(42), yet is unable to infect birds (50, 51). Despite this slight expansion in experimental host range, 
nonmurine animals are considered poor hosts for H. hammondi as infections do not result in robust 
chronic infection as H. hammondi-infected tissues from these animals lead to poor oocyst 
production when fed to cats compared to H. hammondi-infected murine tissues (51). H. hammondi 
is only transmitted by oocysts through the fecal-oral route (42) and is not known to be capable of 
horizontal (42) or vertical transmission (51). In rodents, H. hammondi is avirulent in comparison 
to T. gondii. H. hammondi is not known to infect humans and is not known to cause natural disease 
in any animal model (42). However, experimental oral infection with a high dose of 105 or 106 
oocysts can result in morbidity and mortality in mice during acute infection (5). While the true 
prevalence of H. hammondi is difficult to determine as it can only be accurately detected through 
assays analyzing DNA (see section 1.3.1 below), a study of feces from cats in Germany found that 
a similar number of cats shed H. hammondi oocysts in their feces as compared to T. gondii, 
suggesting that both parasite species occur similarly in the environment (52). Considering the 
similar environmental prevalence combined with the antigenic similarity between T. gondii and 
H. hammondi (discussed in section 1.3.1 below), it is possible that the natural host range for H. 
hammondi is broader than its current description, and it is possible that H. hammondi is capable of 
infecting humans. New serological based methods of distinguishing between these two parasites 
species are needed to thoroughly address this possibility. Appendix A describes the work that we 
have done to begin to develop assays of this nature.  
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1.3 Comparison between T. gondii and H. hammondi 
1.3.1 Parasite biology, morphology, and antigenicity  
Even though H. hammondi is now recognized as its own species (42), H. hammondi was 
previously described as a strain of T. gondii (53) and was even referred to as Toxoplasma 
hammondi (54) due to the extensive similarities between species. Morphologically, the various life 
stages of T. gondii and H. hammondi are highly similar. These parasites both contain the same 
classes of organelles (rhoptries, dense granules, micronemes, a conoid, a single mitochondrion, 
and a nucleus) and are indistinguishable by light microscopy (42). However, there are minor 
species-specific differences that can be observed with electron microscopy. H. hammondi rhoptries 
are electron-dense rhoptries and their sporozoites contain a crystalloid body. Conversely, T. gondii 
have electron-lucent rhoptries and their sporozoites lack a crystalloid body (42, 55). T. gondii 
tachyzoites, bradyzoites, and sporozoites are also slightly smaller (0.2-0.7µm) in length than the 
corresponding life stage in H. hammondi. There are no morphological differences in oocysts or in 
bradyzoite containing tissue cysts between parasite species. However, H. hammondi tissue cysts 
are rarely found  in the brains of infected mice whereas tissue cysts are commonly found in the 
brains of mice infected T. gondii (42).  
Another similarity between T. gondii and H. hammondi is that both parasite species are 
antigenically similar. While there are antibodies that can be identified that are specific for H. 
hammondi (56), the majority of antibodies raised against either T. gondii or H. hammondi 
demonstrate cross reactivity with parasite lysates and/or organelles to varying degrees (42, 57–
61). These likenesses suggest that these parasites also have extensive similarities in their antigenic 
protein repertoire. While these antigenic similarities are useful for immunostaining assays in H. 
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hammondi, the similarities with regards to antigenicity make serological distinctions between T. 
gondii infection and H. hammondi infection very challenging. The ideal method for determining 
if an infection is caused by T. gondii or H. hammondi is through PCR analysis of genomic parasite 
DNA. Various primers sets have been identified that are species-specific and can be used to 
distinguish between infection with these two parasites (62, 63). However, obtaining parasite DNA 
from infected hosts can be challenging, especially during the chronic stage of infection. PCR based 
diagnostic methods are not commonly used for detection (64).  
1.3.2 Life cycle differences between H. hammondi and T. gondii 
Despites sharing all life stages (sexual stages including schizonts, gamonts, and 
merozoites; oocysts; sporozoites; tachyzoites; and bradyzoites) with T. gondii that are 
morphologically indistinguishable with light microscopy, H. hammondi and T. gondii have 
important differences in their life cycle (Figure 1A). The main distinguishing factor is that H. 
hammondi follows a strict obligate heteroxenous life cycle where it must initiate infections in 
intermediate hosts from sporozoites contained within oocysts (the product of sexual replication), 
progress through its asexual life stages (tachyzoite to bradyzoite) in the intermediate host, and then 
only bradyzoites can initiate an infection in its definitive feline hosts to induce sexual reproduction. 
H. hammondi bradyzoites are not known to cause infection in other intermediate hosts, a common 
mode of transmission for T. gondii, and feline definitive hosts are not complete host (complete 
hosts are able to support both sexual and asexual replication) for H. hammondi as they are for T. 
gondii (3, 42).  
Unlike T. gondii, H. hammondi cannot be continuously propagated in tissue culture. A 
variety of cell types, including bovine monocytes, African Green monkey kidney cells, primary 
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rhesus monkey kidney cells, WI-38 human fibroblasts, feline kidney cells, and bovine kidney cells 
can be infected with oocyst-derived sporozoites or tachyzoites obtained from mesenteric lymph 
nodes of an orally infected mouse. All these host cells can support parasite replication. However, 
as infection progresses, the H. hammondi parasites form cyst like structures and eventually 
disappear from culture. (42, 55, 65). Furthermore, the cyst structure that form during in vitro 
cultivation of H. hammondi are only infectious to cats (55). The life cycle differences exhibited by 
H. hammondi, specifically its obligate nature, likely determine H. hammondi’s inability to 
continuously grow in in vitro tissue culture. Understanding the progression and timing of H. 
hammondi’s development in vitro is essential for facilitating studies in the parasite species 
designed to elucidate the mechanistic factors that determine its obligate life cycle.  
1.3.3 Genetic comparisons between T. gondii and H. hammondi 
In addition to the morphological and life cycle features described above, genetic 
comparisons between H. hammondi and T. gondii demonstrate that these two parasites species are 
very closely related (43, 66–68) (Figure 1B). Comparisons in the internal transcribed spacer 1 
sequences of T. gondii and H. hammondi revealed differences in less than 5% of nucleotide 
positions (43, 67). Furthermore, the overall genomic divergence between H. hammondi 
(HhCatGer041) and T. gondii (GT1) is predicted to be 4.9% and only 96 of 8,993 T. gondii genes 
queried had no significant reciprocal blast hits when compared to H. hammondi, demonstrating 
that these species share many of the same genes. Moreover, most of these genes (>95%) are found 
in the same order and orientation (68), suggesting that overall gene content and gene arrangement 
is highly similar between both species. Additional work has also found extensive genomic synteny 
(29 long syntenic blocks that contain >80% of genes, ~1 megabase reciprocal translocation with 
 12 
chromosomes Ia and IX, and a few rearranged blocks) when comparing T. gondii and H. 
hammondi. This study identified 7,095 shared orthologs using OrthoMCL analysis of shared 
proteomes between H. hammondi and T. gondii (43). The genomic similarities combined with the 
life cycle similarities (same life stages, yet T. gondii life cycle has bypasses and flexibility that is 
not a part of the H. hammondi life cycle) displayed by both parasite species makes it unlikely that 
gene content plays a major role in the phenotypic differences between these parasite species. 
Overall, H. hammondi and T. gondii have a very similar genetic tool kit but likely use those tools 
in different ways to support their distinct life cycles. Comparing how these two parasites use their 
shared genes is a promising approach for identifying the genetic components contributing to the 
development and life cycle restrictions in both parasites.  
1.3.4 Shared virulence factors 
Comparisons between different strains of T. gondii have revealed several genes that have 
differing impacts on T. gondii virulence in vivo (69–71), making it possible that virulence 
differences between H. hammondi and T. gondii could be explained by species-specific differences 
in key virulence factors. If true, this would mean that differences in these virulence factors are 
some of the major contributors to the phenotypic differences observed between T. gondii and H. 
hammondi. However, studies have revealed that the H. hammondi orthologs of critical virulence 
factors rhoptry protein (ROP) 18, ROP5, ROP16 and dense granule protein (GRA)15 are all 
functional when expressed in T. gondii (68, 72), suggesting that these virulence factors do not 
contribute to the differences displayed by T. gondii and H. hammondi. This finding is important 
because it further demonstrates that the genetic factors contributing to the developmental 
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difference between these species is likely the major driver for the virulence and life cycle 
differences observed between T gondii and H. hammondi.  
1.3.5 Transcriptional profile comparison 
While T. gondii transcriptomes at varying life stages have been extensively studied (73), 
transcriptional studies in H. hammondi are only beginning to be investigated, as working with H. 
hammondi is inherently more challenging because of its obligate two-host life cycle and terminal 
differentiation phenotype. The first of these studies used microarray analysis of T. gondii (VEG) 
and H. hammondi (HhCatGer041) sporulated oocysts to investigate transcriptional differences. 
This study revealed highly distinct transcriptional profiles between each species and found that 
several genes upregulated in H. hammondi are also upregulated in the bradyzoite life stage in T. 
gondii (72), suggesting that transcriptional differences may underlie the developmental differences 
identified between both species. These transcriptional differences, especially the early emergence 
of bradyzoite genes, could be fundamentally important for the life cycle differences observed 
between parasites. The transcriptional changes that occur during H. hammondi development 
represent a critical knowledge gap. Characterizing these transcriptional changes and comparing 
them to what we currently know about the transcriptional changes that occur between various 
stages of T. gondii will be useful for uncovering the mechanisms controlling development and the 
life cycle differences observed between these two parasites.  
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1.4 Biology of bradyzoite life stages in T. gondii 
Despite the fundamental phenotypic differences that exist between T. gondii and H. 
hammondi, the formation of bradyzoites is a critical step in the transmission of T. gondii and H. 
hammondi. Bradyzoites are necessary for transmission as their cyst wall provides protection during 
passage through the mammalian gut (74), and they are also required for sexual reproduction which 
dramatically expands the number of infectious oocysts available to infect new hosts. Even though 
the definitive hosts for T. gondii are complete hosts (hosts that can support both sexual and asexual 
replication), bradyzoite formation within these animals is still needed for sexual reproduction to 
occur. Bradyzoite-containing tissue cysts also allow the parasites to remain in a host for an 
extended period of time as it has been hypothesized that they cannot be cleared by the host immune 
system. However, recent studies suggest that tissue cysts are cleared from murine brains 20 months 
post-infection (75), however it is unclear if tissue cyst remain in other tissues. Finally, 
interconversion that occurs in T. gondii allows for these parasites to be transmitted independently 
of the definitive host, a remarkable trait given the vastly different species that can serve as 
intermediate hosts for these parasites. For these reasons, understanding the mechanisms driving 
the conversion of tachyzoites to bradyzoites and how it compares between species is necessary to 
manage the many manifestations of disease caused by these organisms. While few studies have 
directly compared H. hammondi and T. gondii (42, 72), the T. gondii bradyzoite has been 
extensively studied through intraspecies comparisons of varying life stages (22, 26, 76, 77). These 
studies have broadened our understanding of the T. gondii bradyzoite and are beginning to uncover 
the mechanisms governing stage conversion associated gene expression.  
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1.4.1 Triggers of bradyzoite formation 
While signals derived from the environment, such as from an infected host cell, are likely 
at the heart of stage conversion in T. gondii and its near relatives, the precise mechanisms used to 
respond to these signals have remained elusive. However, the effect of various signals on inducing 
life stage development, specifically tissue cyst formation, has been well studied in T. gondii. 
An important but underappreciated fact is that most strains of T. gondii are capable of 
spontaneously converting into bradyzoites when grown in vitro in a variety of different host cells 
(78, 79). When T. gondii infections are initiated with parasites derived from sporozoites or low-
passage tachyzoites or bradyzoites, the parasites will first grow as tachyzoites but will later form 
tissue cysts that express bradyzoite markers and/or are able to induce oocyst shedding when fed to 
cats (78, 80). This phenomenon of spontaneous stage conversion in T. gondii was most thoroughly 
studied in T. gondii strain VEG. When infections are initiated with T. gondii VEG sporozoites, the 
parasites transition into a rapidly growing tachyzoite stage resembling many lab-adapted strains 
like T. gondii RH, and after ~20 divisions they begin to differentiate into slower growing parasites 
that express bradyzoite markers, suggesting that there may be a developmental clock controlling 
this spontaneous conversion (80). Taken together, these findings suggest that there is a parasite 
intrinsic factor that enables sporozoite-derived tachyzoites to transition to bradyzoites following 
initial tachyzoite expansion, at least for the VEG strain. This parasite intrinsic factor could 
potentially be playing the same role in H. hammondi. Characterizing the developmental differences 
during this time period in T. gondii and H. hammondi is important for understanding this phenotype 
and how such a factor contributes to development.  
Host factors, specifically the differentiation state of a given host cell, can also impact T. 
gondii cystogenesis. T. gondii forms tissue cysts when grown in mouse primary skeletal muscle 
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cells that have been differentiated into polynucleated myotubes, which are withdrawn from cell 
cycle progression (81, 82). When these host cells are genetically manipulated to knock-down 
Testis-specific Y-encoded-like protein 2 (Tspyl2), a negative cell cycle regulator that contributes 
to withdrawal from host cell cycle progression in these myotubes, T. gondii fails to form tissue 
cysts in these cells (82). Additionally, expression levels of the host gene human cell division 
autoantigen-1 (CDA1) have been shown to be important for bradyzoite development. T. gondii 
grows slower and expresses bradyzoite-specific genes when grown in host cells treated with the 
trisubstituted pyrrole small molecule compound 1, which induces the expression of host CDA1 
(83). CDA1 is a negative regulator of cell growth and has regions with homology to testis protein 
TSPY (84). Additionally, T. gondii forms tissue cysts when grown in HeLa cells that overexpress 
a transgene encoding CDA1 (83). Moreover, T. gondii forms tissue cysts when grown in neuronal 
cells, which like polynucleated myotubes are withdrawn from the cell cycle (85–87). The ability 
of cells that have withdrawn from their cell cycle to promote tissue cyst formation in T. gondii is 
a likely contributor to the preference T. gondii shows for muscular tissue and tissues of the central 
nervous system.  
Several well characterized stressors are known to induce T. gondii tachyzoite-to-bradyzoite 
stage conversion in vitro (summarized in Table 1). Perhaps the most well-known stressor that leads 
to robust formation of T. gondii tissue cysts in vitro is alkaline pH (pH ~8 as compared to the 
standard pH growth conditions of 7.2-7.4). Multiple groups have shown that alkaline pH induces 
T. gondii cyst development either when applied to host cells after infection (88) or when applied 
to extracellular parasites prior to infection (89). Alkaline pH induces known bradyzoite markers, 
such as bradyzoite antigen 1 (BAG1) (80) and also induces cyst wall formation (90, 91). Despite 
robust induction of T. gondii tissue cyst development, the exact mechanism of pH-induced cyst 
 17 
formation in T. gondii remains unknown. Increases in extracellular pH can result in accelerated 
cell movements and cytoplasm contraction (92). Increased intracellular pH has been demonstrated 
to increase certain cellular processes, such as DNA and protein synthesis, mitotic events, and 
glycolysis, in mammalian cells (93, 94). However, it is not clear if alkaline pH treatment used to 
induced bradyzoite development results in increased intracellular pH. It is possible that alkaline 
pH-derived stress induces a myriad of both host- and parasite-derived signals that are needed in 
order to initiate bradyzoite development. Investigating the changes in gene expression that occur 
in the host in response to these bradyzoite conditions would be useful for understanding how 
alkaline pH induces bradyzoite development in T. gondii.  
Another inducer of bradyzoite development includes acidic pH stress. Treatment of 
infected host cells with pH 6.8 media induces the expression of bradyzoite markers, such as BAG1 
(95). In addition to changes in pH, heat shock (43C as opposed to 37C) and sodium arsenite 
treatment of infected host cells have also been shown to induce expression of bradyzoite genes in 
T. gondii. However, heat shock is not an optimal method for inducing bradyzoite development as 
it often results in decreased parasite invasion, parasite killing, and loss of host cell viability (88). 
Moreover, endoplasmic reticulum (ER) stress derived from treatment with tunicamycin has been 
shown to induce expression of bradyzoite transcripts as a result of both translational and 
transcriptional control derived from an unfolded protein response (96). 
Nutrient starvation can also induce stage conversion in T. gondii. Pyrimidine starvation 
achieved via deletion of the uracil phosphribosyl transferase (UPRT) gene in combination with 
growth in atmospheric CO2 (0.03% compared to 5%) also leads to a parasite growth reduction and 
expression of bradyzoite markers (97). Arginine starvation also decreases the replication of T. 
gondii and induced tissue cyst formation (98). Cholesterol depletion via growth in media 
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supplemented with lipoprotein-depleted serum (as compared to growth in 5% fetal bovine serum) 
has also been shown to induce bradyzoite gene expression (99).  
Additionally, interferon gamma (IFN-) treatment of T. gondii infected macrophages 
results in expression of bradyzoite specific antigens (100), however IFN- is not capable of 
inducing expression of bradyzoite specific antigens in human fibroblasts (88, 95, 101, 102). Other 
in vitro stressors that may mimic IFN- driven immune pressure also induce T. gondii cystogenesis, 
such as the production of nitric oxide. Exogeneous nitric oxide produced from sodium 
nitroprusside (SNP) treatment can induce expression of the bradyzoite marker BAG1 (100). 
Exogenous nitric oxide likely inhibits proteins involved in the electron transport chain, thus 
treatment with mitochondrial inhibitors oligomycin, antimycin A (100), and atovaquone (21) can 
also induce expression of bradyzoite antigens in T. gondii. Overall, the numerous and diverse 
exogenous stressors capable of inducing bradyzoite development in T. gondii suggest that multiple 
signals can be used as triggers to induce the fundamental process of bradyzoite formation. It is 
critical to compare these methods in terms of gene expression and tissue cyst formation to fully 
understand their function in cystogenesis.  
In comparison to in vitro systems, the in vivo factors required to induce cystogenesis are 
much less clear. One of the most well-studied potential inducers of cyst formation is IFN-. It is 
also thought that IFN- may play a critical role in cystogenesis. It is hypothesized that IFN- 
contributes to the initiation of tissue cyst formation in vivo, as it can induce cystogenesis in vitro 
(described above). However, IFN- knockout mice fail to control acute proliferation of parasites 
and succumb to acute infection (101, 103) even when infected with avirulent strains of T. gondii 
(104) making it difficult to determine if IFN- induces cystogenesis in vivo. It is also possible that 
T. gondii spontaneously forms tissue cysts during in vivo infections, but this spontaneous 
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development is again challenging to observe experimentally due to the lethality of T. gondii 
infections in mice with disrupted immune systems.  
In vivo factors have also been implicated in suppressive roles for cytogenesis. Tumor 
necrosis factor-alpha (TNF-) and inducible nitric oxide synthase (iNOS) may play a role in 
restricting cystogenesis, as TNF receptor p55- and p75-deficient mice and iNOS deficient mice 
develop more tissue cyst in the brain compared to wild type mice despite relatively equivalent 
parasite burden in peritoneal cells early in infection. Interestingly, mice deficient for TNF- 
receptors or iNOS succumb to chronic infection while the WT mice survive (105, 106). It is 
challenging to determine if the increase in tissue cysts in the brains of these mice is a result of 
TNF- and iNOS restricting tissue cyst development, or if more parasites make it to the brain prior 
to tissue cyst formation. Future experiments using live imaging that quantifies parasite burden 
could be useful to test these hypotheses. Additionally, CD4+ and CD8+ T-cells are important for 
the maintenance of chronic infection characterized by the bradyzoite/tissue cyst life stage. 
Depletion of these cells with neutralizing antibodies leads to reactivation of T. gondii infection 
resulting in parasite proliferation (107). Linking what is known about in vitro cyst development in 
T. gondii to what happens in vivo is a significant, but important, knowledge gap. Understanding 
how spontaneous development occurs in T. gondii and how immunity factors alter development in 
the context of an in vivo infection is important for understanding the pressures that result in the 
establishment of a chronic infection in natural settings. 
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1.4.2 Critical bradyzoite genes in T. gondii 
Studies investigating T. gondii bradyzoites have begun to identify parasite factors that may 
play a role in altering gene expression during stage conversion. Thus far, the parasite factors that 
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have been identified include signaling proteins, chromatin modifiers, transcription factors, and 
RNA-binding proteins involved in transcript stability and/or translation control, all of which play 
important roles in the tachyzoite to bradyzoite transition. Furthermore, several bradyzoite genes 
have also been identified that have functional roles in the bradyzoite/tissue cyst and can serve as 
markers for bradyzoite development and tissue cyst formation.  
1.4.2.1 Protein kinase A signaling and T. gondii bradyzoite development 
Cyclic nucleotide signaling, including cyclic adenosine monophosphate (cAMP) and cyclic 
guanosine monophosphate (cGMP) have been implicated in bradyzoite development in T. gondii. 
Transient levels of cAMP are able to induce bradyzoite development, while sustained levels of 
cAMP prevent bradyzoite formation and promotes tachyzoite growth (108–110). Generally, cAMP 
is a second messenger in signaling pathways and can interact with several proteins, including the 
effector protein kinase A (PKA) (111). T. gondii encodes three PKA catalytic subunits. When 
TgPKAc3 is deleted, parasites grow slower and have increased levels of spontaneous bradyzoite 
formation. Furthermore, parasites lacking TgPKAc3 are able to maintain tachyzoite growth when 
exposed to bradyzoite inducing growth conditions when cAMP levels are artificially elevated 
(112). These findings suggest that signaling through TgPKAc3 plays a critical role in bradyzoite 
formation in T. gondii and may be involved in transducing an external stress signal to induce 
changes in gene expression needed to induce bradyzoite formation.  
1.4.2.2 Chromatin associated gene products involved in bradyzoite development  
Stage conversion in eukaryotic parasites is accompanied by significant changes in patterns 
of gene expression (113, 114). The chromatin landscape of a given life stage plays a large role in 
what genes are expressed, therefore playing a critical role in stage conversion. Several chromatin 
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remodeling factors have been identified in T. gondii that play a role in altering the chromatin 
landscape during different life stages. One such factor is Histone Deacetylase 3 (HDAC3), which 
is a component of T. gondii’s corepressor complex. HDAC3 is associated with bradyzoite-specific 
promoters (115) and when its activity is inhibited with the compound FR235222, expression of 
bradyzoite genes increases (116). These findings suggest that histone deacetylation via HDAC3 
functions to repress the expression of bradyzoite genes and keeps T. gondii in a tachyzoite life 
form. HDAC3 has been shown to work with the recently discovered T. gondii microrchidia 
(MORC) protein. MORC interacts with several Apetala2 (AP2) transcription factors (described 
below) (117) (including AP2IX-4 and AP2XII-2 discussed below (118)) and recruits HDAC3 to 
chromatin, enabling the generation of hypo-acylated chromatin which represses gene expression. 
When MORC is depleted in T. gondii, the parasites begin to express transcripts typically expressed 
in other life stages, such as merozoite and oocysts specific genes, that are restricted to the T. gondii 
sexual stages (117). These findings suggest that MORC functions as a repressor of sexual 
development associated gene expression through chromatin modification in T. gondii.  
Another histone remodeling enzyme found in T. gondii is GCN5-A, a lysine histone 
acetyltransferase. This enzyme plays an oppositional role to HDAC3. GCN5-A is found at 
tachyzoite promoters when T. gondii is grown under tachyzoite growth conditions (115). 
Additionally, ChIP qPCR experiments have shown that when T. gondii is exposed to alkaline pH 
stress conditions, GCN5-A occupancy is enriched in the promotors of bradyzoite specific genes 
that are upregulated in response to stress. When GCN5-A is knocked out in T. gondii, the parasites 
are unable to upregulate 74% of known bradyzoite genes in response to alkaline pH induced stress 
(119). Together, these findings demonstrate that GCN5-A plays a critical role in T. gondii’s ability 
to alter its gene expression in response to alkaline pH stress. 
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Additional chromatin remodeling enzymes that play a role in the alteration of stage 
conversion associated gene expression have also been identified in T. gondii. These include 
TgCARM1 (115), TgSCRAP (120), and TgRSC8 (121, 122). TgCARM1 is a histone arginine 
methyltransferase protein that is essential for parasite replication. When N-methyltransferase 
activity is inhibited with the small molecule AMI-1 via pretreatment of extracellular parasites, T. 
gondii forms significantly more bradyzoites compared to a vehicle control (115). TgSCRAP, a 
Snf2-related CBP activator protein and SNF/SWI chromatin remodeler, upregulates the expression 
of the known bradyzoite gene BAG1 during alkaline pH induced stress, and has been shown to 
enhance CREB (cAMP response element binding protein) mediated transcription, which may 
suggest a role in the protein kinase A signaling pathway (see above) that has also been implicated 
in bradyzoite development for T. gondii (120). Another chromatin remodeling complex that 
contributes to bradyzoite development is TgRSC8, a homolog of the nucleosome remodeling 
complex Rsc8p protein in Saccharomyces cerevisiae. When this protein is mutated in T. gondii, 
some bradyzoite genes show a significant reduction in transcript abundance when exposed to 
alkaline pH stress conditions. However, these mutants did not show reduced Dolichos biflorus 
agglutinin (DBA) staining (122), which specifically recognizes the glycosylated cyst wall protein 
CST1 (91). In addition to chromatin remodelers, histone variants have also been implicated in 
stage conversion in T. gondii. The histone variant H2AZ transcript is expressed in mature, in vivo 
bradyzoites. H2AX transcript is also expressed in mature, in vivo bradyzoites and displays 
increased expression in vitro during alkaline pH stress. H2AX is typically enriched in silent regions 
of DNA, suggesting that histone variants are important for altering gene expression during 
differentiation (123). All together, these findings suggest that the alteration of chromatin is an 
important contributor to stage conversion associated gene expression in T. gondii.  
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1.4.2.3 Transcription factors implicated in bradyzoite development 
Transcription factors are an important class of proteins that play a significant role in the 
control of stage conversion specific gene expression and have long been investigated for their role 
in stage conversion associated gene expression in T. gondii. One of the first major classes of 
transcription factors investigated for their role in stage conversion in T. gondii were the AP2 
transcription factors. AP2 factors were first identified in Apicomplexans in 2005. These 
transcription factors share the Apetala2 (AP2) integrase DNA binding domain typically found in 
transcription factors of numerous plant species (124). AP2 transcription factors are known to play 
a major role in stage conversion in Plasmodium species (125). There are currently 67 AP2 factors 
(66 annotated as AP2 domain transcription factors and 1 annotated as an AP2 domain-containing 
protein) annotated in the T. gondii ME49 genome (126). However, only 6 of these AP2 
transcription factors have been tied to bradyzoite development in T. gondii to date. The AP2 
transcription factor AP2IX-9 functions mainly as a repressor of bradyzoite development, 
maintaining parasites in an intermediate, pre-bradyzoite state. AP2IX-9 binds to the CAGTGT 
motif and functions to repress transcription (127). Furthermore, deletion of AP2IX-9 results in 
increased tissue cyst formation in parasites cultivated in normal growth conditions (128). Another 
AP2 factor, AP2XII-2, has been shown to interact with the MORC protein and results in increased 
tissue cyst formation in vitro upon knockdown in T. gondii, suggesting that this factor may be 
important for maintaining tachyzoites (118). Additionally, AP2 transcription factors have been 
identified in T. gondii that are involved in promoting bradyzoite development. These include 
AP2IV-4 (129), AP2IV-3 (128), and AP2IX-4 (130), and AP2XI-4 (131). When these AP2 
transcription factors are deleted, parasites have a decreased ability to form tissue cysts in vitro 
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and/or in vivo. Furthermore, alteration (either deletion or overexpression) of these factors result in 
significant differences in transcript abundance of known bradyzoite genes (128–131). 
In addition to AP2 transcription factors, T. gondii has additional transcription factors that 
are critical for stage conversion.  Once such transcription factor is Bradyzoite Formation Deficient 
1 (BFD1). BFD1 was recently identified as a master transcriptional regulator of bradyzoite 
development in T. gondii using a large-scale genetic screen. BFD1 is a nuclear localized Myb-like 
DNA binding protein that binds to the CACTGG motif near that transcriptional start site of 
differentially regulated genes. When BFD1 is deleted in T. gondii, these parasites fail to form tissue 
cysts both in vitro in response to alkaline pH derived stress and treatment with Compound 1. These 
knockout parasites also fail to form tissue cysts in vivo. Furthermore, BFD1 knockout parasites 
fail to express several bradyzoite specific genes when treated with alkaline pH, suggesting that 
BFD1 plays a major role in initiating stage conversion associated gene expression (132).  
Additional T. gondii proteins that may play a role in stage conversion are the glycolytic 
enzymes, Enolase1 (ENO1) and Enolase 2 (ENO2). ENO1 is specifically expressed in bradyzoites 
and is a known bradyzoite specific gene. ENO2 is expressed in tachyzoites and can be found 
localized in the cytoplasm and nucleus (133). When ENO1 is deleted in T. gondii, the ability of 
the parasite to form in vivo cysts is impaired. Both ENO1 and ENO2 have been shown to bind 
promoters in ChIPseq and ChIP qPCR experiments and ENO1 has been shown to bind the ENO2 
promoter. Furthermore, analysis of the ENO1 promoter revealed a stress response element that 
could be activated with nuclear extracts purified from bradyzoites (134). Together, these data 
demonstrate that ENO1 and ENO2 could have a role as transcription factors implicated in stage 
conversion. 
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1.4.2.4 Translational control involved in bradyzoite development 
Translational control also plays a critical role in stage conversion associated gene 
expression in T. gondii. Phosphorylation of eukaryotic initiation factor-2 (eIF2) inhibits its guanine 
exchange factor (eIF2B) which results in repression of general translation. Proteins involved in the 
translation control pathway in T. gondii include Eukaryotic initiation factor 2 alpha (TgIF2/eIF2) 
and initiation factor 2 kinase -A (TgIF2K-A), which can phosphorylate TgIF2, and TgIF2K-B. 
TgIF2 is phosphorylated in response to stress derived from both alkaline pH, heat shock, sodium 
arsenite treatment, calcium ionophore treatment, and tunicamycin treatment. TgIF2 
phosphorylation is maintained in bradyzoites and is accompanied by a global decrease in protein 
synthesis. When dephosphorylation of TgIF2 is inhibited, parasites both increase the 
transcriptional abundance of known bradyzoites genes as well as form DBA-positive tissue cysts 
(135, 136). Furthermore, when the activity of TgIF2K-A is inhibited in T. gondii, thus decreasing 
TgIF2 phosphorylation, these parasites form significantly fewer tissue cysts when exposed to 
alkaline pH stress (137). These findings suggest that translational control is critical for the 
maintenance of bradyzoites.  
Furthermore, T. gondii encodes two RNA binding proteins related to Alba proteins in 
archaea, TgAlba1 and TgAlba2. In response to alkaline pH derived stress, both TgAlba1 and 
TgAlba2 colocalize with RNA granules. These proteins bind greater than 30 RNAs, including their 
own. TgAlba1 bind to the promoter of TgAlba2. Upon deletion of TgAlba1, TgAlba2 is no longer 
translated. Moreover, deletion of TgAlba1 in T. gondii also leads to decreased tissue cyst formation 
in vitro (in response to alkaline pH stress) and in vivo (138). Together, these examples of RNA 
binding proteins found in T. gondii further demonstrate that translational control plays a critical 
role in stage conversion associated gene expression.  
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1.4.2.5 Other bradyzoite-specific genes 
In addition to the work described above, there has also been extensive research performed 
using T. gondii bradyzoites generated using various forms of bradyzoite induction (described 
above) to identify bradyzoite-specific genes along with their function (73, 76, 139). The majority 
of the most well-known bradyzoite genes that have been identified include surface proteins 
belonging to the SAG-family, components of the tissue cyst wall, heat shock proteins (HSP), and 
metabolic proteins. T. gondii bradyzoites express several genes encoding surface antigens that are 
bradyzoite-specific in addition to genes that give rise to components that comprise the tissue cyst 
wall. Some of the most notable of these bradyzoite markers include SAG-related surface protein 
(SRS) SRS35B/SAG4 (140), SRS9 (141, 142), SRS44/CST1 (91, 143), matrix antigen 1 (MAG1) 
(144), bradyzoite pseudokinase 1 (BPK1) (145), BAG1/HSP30 (146), and HSP60 (147). Common 
bradyzoite-specific genes encoding metabolic proteins, include lactate dehydrogenase 2 (LDH2) 
(148) and enolase 1 (ENO1) (149), that are needed to support metabolic processes that likely rely 
on a different carbon source stored in amylopectin granules (150). Many of these bradyzoite-
specific factors are commonly used for identifying bradyzoites and serving as markers of 
bradyzoite development or tissue cysts. They also play important roles for bradyzoites, such as 
forming a functional tissue cyst wall or functioning in metabolic processes. However, these types 
of bradyzoite specific genes are likely not genes that drive the global changes in stage conversion 
associated gene expression, with the exception of ENO1 (discussed above). Instead, the expression 
of these genes are likely controlled by regulatory factors in the network of stage conversion 
associated gene expression.  
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1.5 Conclusions 
Despite sharing extensive genomic and morphological features, T. gondii and H. hammondi 
display several phenotypic differences with regards to their life cycle flexibility and virulence. 
However, the tachyzoite to bradyzoite transition is a fundamental developmental process for the 
success of T. gondii and H. hammondi as it is necessary for the survival and transmission of these 
parasite species. Despite extensive knowledge about the T. gondii bradyzoite generated through 
intraspecies comparisons or varying life stages, the genetic components involved in the 
mechanisms governing stage conversion between tachyzoite and bradyzoite life stages are only 
starting to be uncovered. Comparative studies investigating how these developmental processes 
occur and compare using interspecies comparisons between T. gondii and H. hammondi have the 
potential to uncover novel factors that drive bradyzoite formation. These comparisons can also 
reveal the mechanisms parasites like T. gondii and H. hammondi use to initiate the global changes 
associated with stage conversion on a mechanistic level.  
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2.0 Dissection of in vitro developmental program of Hammondia hammondi reveals a link 
between stress sensitivity and life cycle flexibility in Toxoplasma gondii 
The contents of this chapter have been previously published: 
Sokol S.L., Primack A.S., Nair S.C., Wong Z.S., Tembo M., Verma S.K., Cerqueira
-Cezar C.K., Dubey J.P., Boyle J.P. 2018. Dissection of the in vitro developmental 
program of Hammondia hammondi reveals a link between stress sensitivity and life 
cycle flexibility in Toxoplasma gondii. elife 7. I am responsible for the 
experimentation and writing in sections 2.1, 2.2.1, 2.2.2, 2.2.4, 2.2.5, 2.2.6, 2.2.7, 
and 2.3. I have included section 2.2.3 as it is fundamental component of this work 
which my future work has built upon.  
2.1 Introduction  
Toxoplasma gondii, the causative agent of toxoplasmosis, is a globally ubiquitous 
Apicomplexan parasite capable of infecting all warm-blooded animals, including approximately 
one-third of the human population (42, 151–153). Although generally asymptomatic in 
immunocompetent individuals, T. gondii is capable of causing disease in the immunocompromised 
(including HIV/AIDS patients), developing neonates, and occasionally healthy individuals (154–
157). The global ubiquity of T. gondii is due, at least in part, to its broad host range and ability to 
persist undetected in an immunocompetent host where it is either capable of being transmitted to 
a new intermediate host or recrudescing in the original host (158, 159). These characteristics are 
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lacking in the nearest extant relative of T. gondii, Hammondia hammondi. Despite sharing the vast 
majority of their genes in near perfect synteny (68) and the same definitive felid host (42), H. 
hammondi is known to infect rodents, goats, and roe deer (42, 43), and at least in mice it is naturally 
avirulent compared to T. gondii. Unlike T. gondii, H. hammondi has an obligately heteroxenous 
life cycle (42), where intermediate host stages (i.e., tissue cysts) are only capable of infecting the 
definitive host, and definitive host stages (i.e., oocysts) are limited to infection of an intermediate 
host.  
In addition to these life cycle differences, these two parasite species have in vitro behaviors 
that mirror their in vivo differences. Specifically, when T. gondii sporozoites (VEG strain (80)) are 
used to initiate infections in human host cells in vitro, they undergo a period of rapid replication, 
after which their growth rate slows and a subpopulation of parasites spontaneously convert to 
bradyzoite (e.g., cyst-like) stages (160). However, T. gondii parasites cultivated in this manner still 
undergo multiple cycles of replication, egress and reinvasion, and indefinite propagation (80). In 
contrast, when H. hammondi sporozoites are put into tissue culture they replicate slower than T. 
gondii (55, 80) and do not appear to be capable of subculture (either via passage of culture 
supernatants or after scraping and trypsinization. Ultimately in vitro cultivated H. hammondi form 
bradyzoite cyst-like stages that are infectious only to the definitive host (55, 65). 
While the molecular determinants that control these dramatic phenotypic differences are 
unknown, the fact that life cycle restriction in H. hammondi occurs in vitro provides a unique 
opportunity to identify key aspects of H. hammondi biology that underlie its restrictive life cycle. 
By contrast, the life cycle restrictions in H. hammondi will allow for elucidation of the cellular and 
molecular differences in T. gondii that determine its comparatively flexible life cycle. It is 
important to note that with respect to other Apicomplexans (including N. caninum and Plasmodium 
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spp.), it is the T. gondii life cycle that is atypical; the majority of coccidian Apicomplexans are 
obligately heteroxenous (11, 42, 161). The most parsimonious explanation is that the obligately 
heteroxenous life cycle of H. hammondi is the ancestral state, and that during speciation T. gondii 
acquired novel traits linked to any number of key parasite processes (regulation of development, 
stress sensitivity, interactions with the host environment) that underlie its life cycle flexibility.  
The obligately heteroxenous life cycle of H. hammondi makes experimentally 
characterizing and manipulating this parasite species difficult in comparison to other closely 
related apicomplexan parasites. We have characterized the invasion and replication rates of T. 
gondii (VEG strain (162, 163)) and H. hammondi (HhCatEth1 and HhCatAmer (43, 164)) from 
sporozoite-initiated infections, representing the most thorough head-to-head comparison of the 
intermediate host life stages of these distinct parasite species. Using sporozoite derived infections, 
we have also compared the timing and frequency of in vitro differentiation and report the first ever 
transcriptome from replicating H. hammondi. Together, these data reveal previously unknown 
features of H. hammondi development. Using information gleaned from these experiments, we 
were able to successfully subculture H. hammondi both in vitro and in a murine model during a 
highly predictable window of infectivity and replicative capacity. Additionally, we generated the 
first ever transgenic H. hammondi, opening up the door to future molecular and genetic studies in 
this poorly understood parasite species. These data provide fundamental insight for understanding 
how virulence and pathogenicity have evolved in T. gondii through interspecies comparisons with 
its closest extant relative. Finally, we found that H. hammondi is resistant to alkaline pH-induced 
tissue cyst formation and determined that the H. hammondi transcriptome is refractory to alkaline 
pH exposure. Our data indicate that H. hammondi exists as a unique zoite life stage and follows a 
developmental path that is distinct from the canonical tachyzoite and bradyzoite life stages 
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described for T. gondii. Moreover, our work has identified sensitivity to external stressors as a 
likely culprit contributing to the intriguing developmental and virulence differences between T. 
gondii and H. hammondi, a finding that we speculate may have a direct impact on the ability of T. 
gondii to cause disease in immunocompromised humans and may also underlie its extensive host 
and geographic range.  
2.2 Results 
2.2.1 T. gondii replicates 2-3X faster than H. hammondi, but both species have equal 
invasion rates 
While T. gondii oocysts and sporozoites have been studied extensively in vitro and in 
multiple hosts (80, 162, 163), H. hammondi and T. gondii have been directly compared in only a 
handful of studies (42). Therefore, we performed a head-to-head characterization of sporozoite 
derived infections from both species during in vitro infections. As expected from previous work, 
we found that HhCatEth1 replicated significantly slower than TgVEG in multiple replicate assays 
(Figure 2A,B; ** P= <0.01, **** P= <0.0001). Based on median vacuole size (Table 2, Figure 
2A,B), TgVEG replicated ~2-3X faster than HhCatEth1, with a maximum division time of 9.6 
hours compared to 18 hours for HhCathEth1 (Table 2). Despite these differences in replication, 
TgVEG and HhCatEth1 sporozoites had similar infectivity rates in human foreskin fibroblasts 
(HFFs), defined as the number of vacuoles counted as a fraction of the number of input sporozoites 
(HhCatEth1 0.12 +/- 0.02 N=2; TgVEG; 0.10 +/- 0.04 N=2 P=0.64; Figure 2C-D). These data 
highlight parasite replication as a potentially important component in determining differences in 
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virulence between these species, since pathogenesis in vivo is often (but not always) linked to 
parasite burden (165). 
 
Figure 2. T. gondii and H. hammondi maintains similar infection rates, but T. gondii replicates at significantly 
higher rates.  
A-B) Confluent monolayers of HFFs were infected with either HhCatEth1 or TgVEG sporozoites, obtained via in 
vitro excystation at an MOI of 0.5. Infected monolayers were fixed at 1, 2, and 3 DPI and assayed for the number of 
parasites observed in each vacuole for infection with T. gondii and H. hammondi for a total of 2 replicates, Replicate 
1 (A) and Replicate 2 (B). Vacuoles containing more than 16 parasites were binned at 16 as it was defined as the limit 
of confident detection. Bars represent mean ± SD. For both Biological Replicate 1 & 2, there was a significant 
difference between the number of parasites per vacuole on Days 1, 2, &3 PI for TgVEG. For Biological replicate 1, 
there was no significant difference between the number of parasites per vacuole for HhCatEth1 on Days 1, 2 & 3 PI. 
For Biological Replicate 2, there was a significant difference in the number of parasites per vacuole between 1 and 3 
DPI for HhCatEth1. Statistical significance was determined with a 2-Way ANOVA and Tukey's multiple comparison 
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test. C-D) There is no significant difference in sporozoite infectivity between HhEthCat1 and TgVEG. Graphs 
demonstrate the in vitro percent viability of excysted HhCatEth1 and TgVEG sporozoites 2 and 3 days, respectively, 
post excystation. Bars show the mean ± SD of three technical replicates. The viability assay was repeated with two 
biological replicates and there was no significance in viability between species within experiments, determined via 
unpaired t-test with Welch's correction. 
Table 2. Median and maximum parasites per vacuoles during 1, 2, and 3 DPI for TgVEG and HHCatEth1 
 Day 1 Day 2 Day 3 
 Median, Maximum Median, Maximum Median, Maximum 
HhCatEth1 
Replicate 1 
1, 1 1, 2 2, 4 
HhCatEth1 
Replicate 2 
1, 2 2, 4 2, 16 
TgVEG 
Replicate 1 
2, 2 2, 16 4, 16+ 
TgVEG 
Replicate 2 
2, 4 4, 16+ 8, 16+ 
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2.2.2 Both T. gondii and H. hammondi spontaneously form tissue cysts, but do so with 
different dynamics and efficiency 
All T. gondii strains studied to date can be cultured indefinitely by serial passage in rodent 
intermediate hosts or in tissue/cell culture (166). In contrast, when grown in tissue culture H. 
hammondi ultimately differentiates into a cyst form that is only orally infectious to the definitive 
feline host (42). Interestingly, some strains of T. gondii (e.g., strains VEG and EGS (80, 162, 167)) 
are known to spontaneously form cysts in tissue culture. To elucidate the temporal dynamics of 
differentiation and tissue cyst formation in H. hammondi and compare them to T. gondii, we 
infected HFFs with TgVEG or HhCatEth1 sporozoites and stained them with Dolichos biflorus 
Agglutinin (DBA) at 4 and 15 days post-infection (DPI) to identify tissue cysts (Figure 3A). While 
all TgVEG and HhCatEth1 vacuoles were DBA-negative at 4 DPI, at 15 DPI ~80% (152/182) of 
H. hammondi vacuoles were DBA-positive, compared to 15% (34/355) of TgVEG vacuoles 
(P<0.0001; Figure 3B). To more precisely determine the temporal dynamics of tissue cyst 
formation, we quantified spontaneous cyst formation with TgVEG (Figure 3C) or HhCatAmer 
(Figure 3D) over the course of 23 days. Both TgVEG and HhCatAmer spontaneously formed 
DBA-positive tissue cysts as early as 8 and 12 DPI, respectively. By 23 DPI 100% of all 
HhCatAmer vacuoles were DBA-positive, while the percentage of DBA-positive TgVEG vacuoles 
never exceeded 20% (Figure 3C, D). TgVEG cultures had to be passed 3 times over the course of 
the experiment to prevent complete lysis of the host cell monolayers, which is consistent with their 
propagation as a mixed population of tachyzoites and bradyzoites. These data demonstrate that H. 
hammondi undergoes a much more rigid developmental program during in vitro cultivation 
compared to T. gondii, resulting in 100% tissue cyst conversion and what is likely a near complete 
arrest in growth. 
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Figure 3. T. gondii and H. hammondi spontaneously form tissue cysts in vitro, but do so with different 
dymanics.  
A) Representative images of cells infected with T. gondii (TgVEG) and H. hammondi (HhCatEth1) sporozoites that 
were fixed and stained with DBA after 4 and 15 DPI. Scale bar represents 5µm. B) Quantification of T. gondii and H. 
hammondi infection described in A demonstrating that after 4 days, neither H. hammondi or T. gondii spontaneously 
form tissue cysts, but both parasite species form tissue cysts after 15 DPI. However, the percentage of H. hammondi 
tissue cysts is significantly increased after 15 DPI when compared to T. gondii. Numbers above bars indicate number 
of DBA-positive vacuoles out of total vacuoles quantified. Statistical significance was determined using a 2-way 
ANOVA with Sidak’s multiple comparison test. (****=P<0.0001). C and D) Average percentage of DBA-positive 
vacuoles in 15 FOV over a course of a 23 day infection with T. gondii (TgVEG) & H. hammondi (HhCatAmer). 
Arrows in (C) indicate when T. gondii was passed onto new host cells to prevent complete lysis. D) H. hammondi 
form tissue cysts after 12 DPI. The percentage of DBA-positive vacuoles increases until all vacuoles are DBA-positive 
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at 23 DPI. C) T. gondii forms tissue cysts at 8 DPI, however, the percentage of DBA-positive vacuoles does not reach 
100% during the 23 day infection. 
2.2.3 The spontaneous differentiation process in H. hammondi is characterized by the 
increased abundance of hundreds of known bradyzoite-specific genes 
Our previous work showed that the H. hammondi oocyst transcriptome (consisting of 
sporulated and unsporulated oocysts) was significantly more “bradyzoite-like” than T. gondii 
sporozoites (72), and we reasoned that this was consistent with the propensity of this species to 
spontaneously form cysts during in vitro cultivation. However, these transcriptome studies were 
from the quiescent oocyst life stage and provided no insight into the developmental dynamics of 
the H. hammondi transcriptome compared to T. gondii. To compare the dynamics of the replicating 
H. hammondi and T. gondii transcriptomes during in vitro development, we used RNAseq on day 
4 (D4) and day 15 (D15) in vitro cultured H. hammondi and T. gondii. Using existing genome 
annotations (43), we identified 7372 putatively orthologous genes between T. gondii and H. 
hammondi (ToxoDB.org; likely a conservative estimate of shared gene content between these 
species). As expected based on their in vitro growth rates (Figure 2), the number of reads mapping 
to the H. hammondi transcriptome was lower overall compared to those mapping to T. gondii 
(Figure 4A), and this was particularly pronounced at 15 DPI. To mitigate the effect this could have 
on falsely categorizing transcripts as being of higher abundance in T. gondii compared to H. 
hammondi, we included a given gene in downstream analyses only if one H. hammondi D4 and 
one H. hammondi D15 sample had at least 5 reads. This reduced the overall size of the queried 
gene set to 4146, and all analyses were performed with this subset.  
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Figure 4. Transcriptional profiling and Gene Set Enrichment Analysis of T. gondii and H. hammondi 
A) Summary of reads obtained for each parasite species and life stage, and the percentage of reads from each that 
mapped to the respective parasite genomes or transcriptomes. B) Log2-transformed and normalized Fragments Per 
Million (FPM) data for the 4276 shared genes between T. gondii and H. hammondi that passed thresholds for detection 
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in both species. Genes of significantly different abundance (based on criteria as listed in inset) are blue. C) Hierarchical 
cluster (Euclidean distance, complete) of all detectable genes belonging to the IN VITRO TACHYZOITE gene set. 
Raw Log2 transformed FPM values (taken from DESeq2 following normalization and transformation using “rlog”) 
are shown. D) Hierarchical cluster (Euclidean distance, complete) of all detectable genes belonging to the IN VITRO 
BRADYZOITE gene set. Raw Log2 transformed FPM values (taken from DESeq2 following normalization and 
transformation using “rlog”) are shown. Gene sets are described in Table 3. 
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Figure 5. mRNAseq comparisons between T. gondii and H. hammondi indentify unique aspects of the H. 
hammondi transcriptome. 
A) Venn diagrams indicating the degree of overlap in genes of significantly different transcript abundance between T. 
gondii and H. hammondi at D4 and D15 post-infection. B) Gene Sets found to be significantly (FDR q-value < 0.05) 
enriched in H. hammondi high-abundance transcripts (top) or T. gondii high-abundance transcripts (bottom) at either 
4 or 15 days in culture. Gene Set Details can be found in Table 2. *: P<0.05; **: P<0.01; ***: P<0.001. C) GSEA 
plots of the in vitro bradyzoite, in vitro tachyzoite, and Cat stage specific 1 gene sets, showing enrichment profiles 
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between H. hammondi and T. gondii at 15 DPI. NES; Normalized enrichment score. FDR q: False discovery rate q-
value. D) Hierarchically clustered expression data for detectable genes in the CAT STAGE SPECIFIC 1 gene set in 
H. hammondi or T. gondii grown for 4 or 15 days in vitro, or for T. gondii grown as tachyzoites or merozoites (in cat 
enteroepithelial cells). 
When log2 transformed and DESeq2-normalized RPM (mapping Reads Per Million) values 
were plotted for D4 and D15 between species we observed a high correlation in transcript levels 
at both time points (Figure 4B). While the majority of genes were expressed at similar levels 
between T. gondii and H. hammondi, we identified multiple transcripts of significantly different 
abundance (Figure 5A and blue data points in Figure 4B).  
We used Gene Set Enrichment Analysis (GSEA(168)) with previously published(169) and 
our own curated gene sets (Table 3) to identify gene classes with species-specific enrichment on 
D4 and D15 (see Methods and Table 2 for Gene Sets). We identified 7 gene sets that showed 
significant species-specific enrichment (FDR q-value<0.01; NES scores shown in Figure 3B). H. 
hammondi profiles showed significant enrichment for in vitro (D4, D15) and in vivo (D15) 
bradyzoite gene sets (Figure 5B,C; heat maps shown in Figure 4D), showing that replicating H. 
hammondi zoites maintain the “bradyzoite-like” transcriptional profile previously observed in 
sporozoites after at least 15 days in culture (25). Moreover, T. gondii showed significant 
enrichment compared to H. hammondi for in vitro tachyzoite genes at 15 DPI (Figure 5B; heatmap 
shown in Figure 4C), a time point at which VEG is <10% DBA-positive while H. hammondi is 
between 40-80% DBA-positive (Figure 3B,C). Overall, these data are consistent with our general 
understanding of transcript abundance changes that occur during the tachyzoite to bradyzoite 
transition (albeit entirely from studies using T. gondii).  
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Table 3. Additional gene sets used in Gene Set Enrichment analyses 
Gene Set Name Search Strategy on ToxoDB Size 
SRS_Family Text search for "SAG-related sequence SRS" 111 
AP2_family Text search for "AP2 domain transcription 
factor" 
66 
CAT STAGE SPECIFIC 1 Cat enteroepithelial stages at least 40-fold 
higher than Tachyzoite at D3, D5 or D7 
293 
CAT STAGE SPECIFIC 2 Cat enteroepithelial stages >90th percentile in 
any of D3, D5 or D7; Tachyzoite expression 
between 0 and 50th percentile 
81 
 
A more unexpected finding was that at both D4 and D15, H. hammondi had a 
transcriptional profile that was significantly enriched for genes of high transcript abundance in T. 
gondii merozoites replicating in cat enteroepithelial cells but poorly expressed in other life 
stages(169, 170) (CAT STAGE SPECIFIC 1, 2; Figure 5C,D). Specifically, out of the 21 
detectable members of the “CAT STAGE SPECIFIC 1” gene set, 18 were ranked in the top 
308/4146 (7.4%) and 174/4146 (4.2%) of genes of greater abundance in H. hammondi D4 and D15 
zoites, respectively (Figure 5C). To validate this finding we performed RNAseq on T. gondii and 
H. hammondi-infected THP-1 cells 24 hours post-infection and found a consistent and highly 
significant enrichment for these same gene sets (Figure 6A-C), and in this case a similar number 
of reads from H. hammondi and T. gondii mapped to their respective parasite transcriptomes 
(Figure 6D). These data suggest that H. hammondi has aspects of its transcriptional profile that are 
independent of its spontaneous conversion to bradyzoites and that a subset of genes that are 
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uniquely expressed in T. gondii merozoites and sporozoites may not share these same profiles in 
H. hammondi. 
 
Figure 6. mRNA-seq comparisons between TgVEG and HhCatAmer sporozoites identify unique H. 
hammondi transcriptome profiles 
A) A heat map illustrates differential expression profiles of cat stage specific genes enriched for TgVEG and 
HhCatAmer. The relative levels of gene expression (mean-centered log2-fold change) are depicted using a color scale 
where blue indicates the lowest level of expression and yellow indicates the highest level of expression. B) Gene sets 
found to be enriched in H. hammondi high-abundance transcripts at 1 day post-excystation. Gene set details can be 
found in Table 2. (***: FDR q<0.001; **: FDR q<0.01). The AP2 transcription factor gene set is provided as a negative 
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control. C) GSEA plot of cat stage specific 1 gene set, showing enrichment profiles between H. hammondi and T. 
gondii at 1 day post-excystation. NES: Normalized enrichment score. FDR q: False discovery rate q-value. D) A 
summary of reads obtained for each parasite species, and the percentage of reads from each that mapped to the 
respective parasite genomes or transcriptomes. A total of 8912 genes that had at least 1 read in both TgVEG and 
HhCatAmer samples were selected for analysis. 
We also validated a subset of transcripts that were of greater abundance in D4 and D15 
cultivated H. hammondi parasites using qPCR (heatmap of selected genes in Figure 7A). We used 
ROP18 as a control for a gene that was of significantly higher abundance in H. hammondi 
compared to T. gondii (TgVEG and other Type III strains express very little ROP18 transcript due 
to a promoter indel (68, 72, 171) and CDPK1 and AMA1 as control genes of similar abundance 
between the two species. GRA1 transcript levels were used as loading controls. We used validated 
primer sets for 8 genes (which had to be made separately for each species) to quantify 8 transcripts 
(plus ROP18) using qPCR on RNA freshly isolated from D4 and D15 HhCatEth1 and TgVEG 
cultures. As expected ROP18 transcript was found to be >1000-fold greater in abundance in 
HhCatEth1 compared to TgVEG, while CDPK1 and AMA1 transcript levels were not significantly 
different between species (Figure 7B). The remaining 9 queried transcripts showed significantly 
higher abundance in H. hammondi compared to T. gondii (Figure 7B) confirming the validity of 
our approach to analyze, normalize and filter cross-species RNAseq data with significant 
differences in read counts.  
 47 
 
Figure 7. qPCR validation for nine transcripts that were found to be of higher abundance in D4 or D15 H. 
hammondi compared to T. gondii. 
A) Clustered Log2(TPM) value taken from RNAseq expression profiles of HhCatEth1 and TgVEG at 4 and 15 DPI. 
Gene models are from TgME49 since that is the most well-annotated T. gondii genome and upon which our synteny 
maps were based. B) qPCR for 9 transcripts show significantly higher transcript level in HhCatEth1 compared to 
TgVEG at D4 pi. Fold difference of HhCatEth1 genes relative to TgVEG is shown; bars represent mean and SD from 
three biological replicates. Significance was determined from ΔCt values using multiple t-tests and the Holm-Sidak 
method, with alpha=5.0%. Apical membrane antigen 1 (AMA1) and calcium dependent protein kinase 1 (CDPK1) 
genes served as examples of transcripts found to not differ between species and transcript abundance values were 
normalized using parasite GAPDH genes. All genes were queried using species-specific primers. 
2.2.4 H. hammondi can be subcultured successfully in vitro 
From a phylogenetic standpoint, H. hammondi is a good model to understand the genetic 
basis for traits that are unique to T. gondii. However, unlike all T. gondii strains studied to date, 
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sporozoite-initiated cultures of H. hammondi in host cells from multiple organisms including 
humans, cattle, and non-human primates lose their ability to be subcultured in vitro (55, 65). In 
order to precisely define when H. hammondi sporozoites lose the ability to infect new cells, we 
attempted to subculture H. hammondi zoites after defined periods of cultivation (Figure 8A-B). 
We found that H. hammondi zoites were capable of infecting and replicating within new host cells 
for up to 8 days post-excystation (Figure 8C-F), while we did not observe any evidence of growth 
when subcultures were initiated on days 11 and 15 post-excystation (Figure 8G-H). In agreement 
with previous studies (42, 55, 65), we also observed that the number of visible H. hammondi 
vacuoles disappear over time (Figure 8C-E). We did not identify any vacuoles derived from lysing 
and re-invading parasites (which would have comparatively smaller sizes) after 10 DPI as we only 
observed a general increase in vacuole size prior to their disappearance from culture (Figure 9). 
Together, our data support previous work showing that H. hammondi cannot be subcultured with 
high efficiency after approximately one week or longer in culture (55, 65), but importantly we 
identified a previously unknown window prior to spontaneous tissue cyst formation where this 
parasite can be effectively subcultured.  
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Figure 8. H. hammondi can be successfully subcultured in vitro for a limited period of time. 
A) Monolayers containing HhCatAmer with oocyst debris were needle passaged, filtered, and used to infect a 
confluent monolayer of HFFs seven days post-excystation. Vacuoles were observed in subcultured monolayers after 
6 DPI. B-H) Confluent monolayers of HFFs were infected with HhCatAmer sporozoites at an MOI of ~2. (2,812,500 
sporozoites). After a three-hour incubation at 37° C, the Day 0 transfer flask was scraped, needle passaged, filtered, 
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and transferred to a new host cells. This process was repeated after 2, 5, 8, and 15 days of growth. Each flask was 
monitored daily for the number (C-H) for 13 DPI, or until visible vacuoles were no longer detected. The number of 
visible vacuoles increased in number for the first week post-excystation then began to decrease. Replicative capacity 
was greatest for sporozoites transferred to new host cells at Day 0 (C) and decreased during each subsequent passage. 
(D-H). 
 
Figure 9. H. hammondi vacuole sizes following subculture. 
A-D) Visible vacuoles sizes were measured using ImageJ (NIH) for each day of attempted subculture. Vacuole size 
progressively increases over the course of in vitro cultivation, after which the size plateaus. 
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When we performed similar experiments in vivo, we observed that the ability to be 
subcultured in vitro and infectivity in a mouse model of infection were temporally correlated. We 
cultivated H. hammondi sporozoites in HFFs for 5 days and used them to infect mice 
intraperitoneally (50,000 zoites). As early as 2 DPI, we measured interferon-gamma (IFNγ) 
production indicative of an active infection (Figure 10A). We used PCR to detect H. hammondi 
DNA in spleens and resident peritoneal cells in these same mice 3 weeks post-infection (PI) 
(Figure 10B). Histological examination of muscle from infected mice using anti-Toxoplasma 
antibodies that cross-react with H. hammondi showed the presence of the parasites in the muscle 
tissue of the mouse infected with in vitro-passed H. hammondi (right panel, Figure 10C) which 
were similar to those observed after oral inoculation with H. hammondi sporulated oocysts (middle 
panel; Figure 10C). Overall, these data show that H. hammondi parasites grown in vitro are capable 
of a) inducing an immune response in mice during the acute phase of infection, and b) 
disseminating to multiple mouse tissues and establishing a chronic infection that resembles an 
infection resulting from oral gavage with sporulated oocysts. To determine how long mouse 
infectivity was retained in in vitro cultivated H. hammondi, mice were injected intraperitoneally 
with 50,000 zoites grown in vitro for 6, 8, 10, 13, and 15 days, and monitored for signs of infection 
by measuring serum IFNγ levels. The ability to be subcultured in vitro correlated perfectly with 
the ability to initiate infections in mice in vivo. Specifically, we observed an increase in IFNγ levels 
in mice infected with 6 DPI or 8 DPI in vitro zoites (Figure 10D), while we did not see an increase 
in IFNγ levels in those infected with parasites cultured for 10, 13, and 15 days (Figure 10D). To 
our knowledge this is the first time that sporozoite-derived growth stages of H. hammondi have 
been used to initiate infections in an intermediate host, since all previous studies focused on 
parasite that had already terminally differentiated. 
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Figure 10. H. hammondi parasites can be grown in vitro and then used to successfully infect mice. 
A-C) Two Balb/C mice were infected with ~50,000 H. hammondi zoites grown in vitro for 5 days. A) Serum was 
collected on days 2 and 3 and assayed for interferon-γ. B) Three weeks post-infection, DNA was harvested from 
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peritoneal lavage cells and spleen and assayed for H. hammondi DNA using H. hammondi-specific primers. Arrow 
indicates primary band for H. hammondi-specific PCR, although we also routinely see larger bands after PCR 
amplification. Samples were only considered positive if the 234 bp band was present (arrowhead). C) Leg muscles 
from infected mice were sectioned and stained with H. hammondi-reactive anti Toxoplasma antibodies and compared 
to uninfected mice and mice infected with H. hammondi by oral gavage with 50,000 sporulated oocysts. D) In vitro 
cultivation leads to a dramatic and predictable loss in the ability to infect mice. Two BALB/C mice were infected with 
50,000 H. hammondi American parasites after 6, 8, 10, 13, and 15 days of in vitro growth. The mass of the mice was 
monitored and a serum sample was obtained daily for 9 days post-infection. Analysis of IFN-γ production was 
analyzed in serum samples using an ELISA. Mice infected with parasites grown in vitro for 6 days (1 of 2) showed 
spikes in IFN-γ levels. This IFN-γ spike was also observed in mice infected with parasites grown in vitro for 8 days 
(2 of 2), while no IFN-γ was observed in mice infected with parasite grown in vitro for 10, 13, or 15 days. 
2.2.5 Generation of transgeneic Hammondia hammondi 
Genetic manipulation of H. hammondi has not been reported in the literature. Given the 
genetic similarity between T. gondii and H. hammondi (43, 68)  and the apparent interchangeability 
of promoter sequences between them (68, 72), we transfected ~4 million HhCatAmer sporozoites 
with a UPRT-targeting CRISPR/CAS9-GFP plasmid (172) along with a PCR2.1 Topo-cloned 
dsRED cassette with 20 bp sequences flanking the CAS9 nuclease cut site within the H. hammondi 
UPRT gene. We used the Toxoplasma-specific plasmid to target H. hammondi UPRT as the gRNA 
sequence is identical between T. gondii and H. hammondi. Both plasmids were taken up and 
expressed by H. hammondi, as evidenced by GFP-fluorescence in the parasite nuclei and red 
fluorescence in the cytoplasm (Figure 11A). Importantly, transgenic parasites replicated in vitro 
as evidenced by the presence of multicellular vacuoles in the infected monolayer (Figure 11A). 
Transfection efficiency of viable parasites (as evidenced by those replicating in vitro with CAS9-
GFP and/or dsRED staining) was ~4% (15 out of 350 vacuoles at 48 h post-transfection, data not 
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shown), which is consistent with typical transfection efficiencies observed with most strains of T. 
gondii (173).  
 
Figure 11. Generation of stable transgenic Hammondia hammondi. 
A) H. hammondi zoites co-transfected with CRISPR/CAS9-GFP and a plasmid harboring a T. gondii dsRED 
expression cassette. We identified multiple parasites with both GFP-tagged nuclei (due to CAS9-GFP expression) and 
dsRED-tagged cytoplasm, indicating uptake of both plasmids within the same parasites. B) Protocol for generating 
stably transgenic H. hammondi using flow cytometry and drug selection to enrich for transgenic parasites prior to cat 
infections. C,D) Testing FUDR resistance in transgenic H. hammondi parasites. WT and transgenic H. hammondi 
sporozoites were incubated in the presence or absence of 20 µM FUDR, and vacuole size and presence/absence of 
dsRED was quantified in at least 100 vacuoles per treatment condition. While WT and non-dsRED-expressing H. 
hammondi from the transgenic population were highly susceptible to FUDR treatment (as evidenced by the fact that 
the majority of vacuoles contained only 1 parasite), dsRED expressing transgenic parasites were resistant to FUDR 
treatment, confirming that the parasites harbored two genetic markers. 
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To make a stable transgenic parasite line, we transfected ~4 million parasites with the 
HhUPRT:dsRED repair cassette and the HhUPRTgRNA:CAS9:GFP plasmid and cultured them in 
10 µM FUDR for 5 days. After FACS sorting ~12,000 dsRED-expressing zoites (~3% of the total 
parasite population; Figure 11B), we injected two female Balb/c mice intraperitoneally with ~6000 
dsRED-expressing zoites each. For the first week of the infection, mice were injected 1X daily 
with 200 µL of 1 mM FUDR, and mice were euthanized and fed to a cat 4 weeks PI. Fecal floats 
showed the presence of dsRED-expressing sporozoites within some of the oocysts (Figure 11B), 
and ~32% of isolated sporozoites expressed dsRED based on FACS analysis (Figure 11B, bottom 
FACS plot). PCR screening (Figure 12) and the inability to grow parasites long term in vitro 
confirmed the identity of the fluorescent parasites as H. hammondi. 
 
Figure 12. Validation of transgeneic H. hammondi. 
 56 
A) PCR validation of H. hammondi dsRED-expressing parasites using primers targeting the UPRTdsREDcassette 
(1607bp product), dsRED (75 and 391bp products, respectively), and an H. hammondi specific sequence (234bp 
product). PCR reactions were conducted with 45ng of template DNA from linearly amplified Hham dsRED genomic 
DNA, WT Hham genomic DNA, of ddH2O control. B) Schematic of UPRT dsRED cassette (generated using APE). 
Arrows indicate sequence features, arrowheads indicate location of primers. Colored lines indicate expected product. 
To determine if our transgenic approach to disrupt the UPRT gene and insert a dsRED 
expression cassette was successful, we quantified the growth of dsRED+ and dsRED(-) parasites in 
the presence of FUDR and compared it to wild type HhCatAmer. Fixed and permeabilized 
parasites were stained with cross-reactive anti-Toxoplasma antibodies to identify all vacuoles. 
After 4 DPI, we quantified vacuole size and dsRED-expression status in >100 vacuoles for each 
strain (WT and dsRED) and condition (Vehicle or 20 µM FUDR). As expected, HhCatAmer:WT 
grew poorly in FUDR (Figure 11C), while HhCatAmer:dsRED parasites grew similarly to 
untreated parasites (Figure 11C). When we separated parasite growth in FUDR based on dsRED 
expression, we found that dsRED(-) parasites in the H. hammondi population were just as 
susceptible to FUDR as were HhCatAmer:WT parasites (Figure 11D, first 4 bars), while dsRED+ 
parasites grew equally well in FUDR compared to Vehicle (Figure 11D, right 2 bars). These data 
suggest that most, if not all, of the dsRED-expressing parasites are also null for the UPRT gene, 
either by direct replacement of the UPRT gene with the dsRED cassette or by incorrect non-
homologous end joining and insertion of the dsRED cassette at another genomic location. This 
represents the first stably transgenic H. hammondi line. Furthermore, PCR analysis of linearly 
amplified genomic DNA from the HhCatAmer population expressing dsRED demonstrated that 
the HhUPRT:dsRED repair cassette was incorporated into the genomic DNA of parasite within 
this population (Figure 12).  
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2.2.6 H. hammondi is completely resistant to pH-induced cysts formation 
While T. gondii can spontaneously form tissue cysts following an in vitro sporozoite 
infection, it can also be chemically induced to form bradyzoites using a variety of treatments (80). 
Given the dramatic developmental differences between T. gondii and H. hammondi in vitro and in 
vivo, we reasoned that these parasite species may respond differently to external stressors that 
induced cyst formation. We therefore exposed T. gondii and H. hammondi zoites to alkaline pH 
bradyzoite induction media and identified cysts using DBA staining as above. As expected we 
found that TgVEG vacuoles grown in bradyzoite induction media were ~55% DBA-positive after 
2 days of exposure and ~90% positive after 4 days of alkaline pH treatment (Figure 13A-B). 
However, we did not find a single DBA-positive H. hammondi vacuole at any time point (out of 
297 total vacuoles; Figure 13A-B). Given the importance of parasite replication events and 
bradyzoite conversion (174), it is possible that the lack of cyst conversion in H. hammondi over a 
4 day treatment was due to fewer replication cycles. While vacuole sizes for T. gondii and H. 
hammondi differed significantly after 2 days of growth in standard and bradyzoite induction media 
(Figure 13 C), pH treatment had no significant effect on vacuole size in either species (Figure 13C; 
P=0.63, 1.0, respectively). This result suggests that bradyzoite conversion occurs independently 
of changes or differences in replication rate and provides strong support for the fact that H. 
hammondi are immune to cellular stresses induced by bradyzoite induction conditions.  
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Figure 13. Conditions that induced T. gondii tissue cyst formation in vitro did not induce tissue cyst formation 
in H. hammondi. 
A) Representative images of cells infected with T. gondii (TgVEG) and H. hammondi (HhCatAmer) sporozoites that 
were grown for 2 days in pH 7.2 media and switched to pH 8.2 media (bradyzoite induction conditions) for 2 days, 
fixed and stained with an Anti-Toxoplasma gondii/Hammondia hammondi antibody and DBA. Scale bar represents 
5µm. B) Quantification of T. gondii and H. hammondi tissue cyst formation described in A demonstrating that H. 
hammondi does not form tissue cysts when exposed to conditions that promote tissue cyst formation in T. gondii. 
Number above bars indicated number of vacuoles quantified for each condition. Statistical significance was 
determined using a 2-way ANOVA with Tukey’s multiple comparison test. (****=P<0.0001). C) Number of parasites 
per vacuole for both T. gondii & H. hammondi grown at pH 7.2 and pH 8.2. T. gondii has significantly more parasites 
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per vacuole than H. hammondi at both pH 7.2 and pH 8.2. There is no statistically significant difference between either 
T. gondii or H. hammondi between pH 7.2 and pH 8.2. Statistical significance was determined using a 2-way ANOVA 
with Sidak’s multiple comparison test. (**=P<0.01 & ****=P<0.0001). 
2.2.7 The H. hammondi transcriptome is mostly non-responsive to high pH exposure 
Given the well-established impact of alkaline pH media on T. gondii cyst formation in vitro 
and the propensity of H. hammondi to spontaneously form cysts in vitro, we found it remarkable 
that we did not identify a single DBA-positive H. hammondi cyst after even 4 days of alkaline pH 
exposure. An intriguing hypothesis emerging from this result is that T. gondii is more adept than 
H. hammondi at responding to stress signals in its environment. To test this hypothesis with respect 
to pH exposure, we treated T. gondii and H. hammondi sporozoites with bradyzoite induction 
media for 2 days and performed RNAseq analysis to identify changes in their respective 
transcriptomes (Figure 14A). For T. gondii treated with alkaline pH, we observed significant 
enrichment in the IN VITRO BRADYZOITE and IN VIVO BRADYZOITE(169)  gene sets (NES 
= -2.4902, -1.800, respectively; FDR q = ~0.00 for both) for TgVEG treated with alkaline pH 
(Figure 15 A-B), and the IN VITRO TACHYZOITE and IN VIVO TACHYZOITE gene sets under 
control conditions (NES = 1.94, FDR q = 0.001; NES = 1.87, FDR q=0.002, respectively; Figure 
15A). This was in stark contrast to HhCatAmer in which members of the IN VITRO 
BRADYZOITE gene set showed no enrichment after alkaline pH exposure (NES = -1.1681, FDR 
q = 0.2078; Figure 15A-B). For the H. hammondi transcriptome, the IN VITRO BRADYZOITE 
gene set seemed to consist of two classes of genes: a) those that were not induced upon pH 
exposure in H. hammondi but were in T. gondii (top half of heatmap in Figure 15C) and b) those 
that were of high abundance in H. hammondi prior to exposure to high pH (lower half of heatmap 
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in Figure 15C). While we identified 90 transcripts that significantly differed in TgVEG following 
pH exposure (fold change value ≥ 2 and Padj value < 0.01), we only identified 24 H. hammondi 
transcripts with pH-altered abundance (these are shown in Figure 15D). Importantly while the 
majority of pH-altered transcripts were of higher abundance in T. gondii, 21 out of 24 pH-altered 
transcripts in H. hammondi were of lower abundance, indicating that H. hammondi and T. gondii 
have distinct responses to high pH bradyzoite induction (Figure 15C,D; See supplementary file 2 
for normalized RNAseq data). Since transcripts for the canonical bradyzoite genes BAG1, LDH2, 
and ENO1 (26, 175)  were below the levels of detection defined for H. hammondi samples in our 
RNAseq analysis (see section 2.4.19), we conducted qPCR analysis of these genes in TgVEG and 
HhCatAmer treated with alkaline pH for 2 (TgVEG only) and 3 days. We found a significant 
increase in transcript abundance for all three genes in TgVEG exposed to pH 8.2 for 2 days (BAG1 
P=0.0023, ENO1 P=0.0047, LDH2 P=0.0079). In HhCatAmer, we did observe a significant pH-
dependent increase in transcript abundance for BAG1 (2 Days P=0.0261 and 3 Days P=0.0276), 
while ENO1 and LDH2 transcript levels remained statistically unchanged (Figure 14B). Taken 
together, our DBA staining, RNAseq and qPCR data strongly support the hypothesis that H. 
hammondi is refractory to alkaline pH induced stress at the transcriptional level, and this is 
correlates well with the complete lack of high pH-induced cyst wall formation in this species.  
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Figure 14. Transcriptional profiling and qPCR of pH vs control RNAseq data.  
A) Summary of reads mapping from each sample for T. gondii and H. hammondi zoites treated with control or 
bradyzoite-induction media. B) Fold change in transcript abundance relative to control of canonical bradyzoite genes 




Figure 15. The H. hammondi transcriptome is refractory to pH-indued stress. 
A) GSEA analysis comparing TgVEG (blue) and HhCatAmer (red) treated with control media to TgVEG and 
HhCatAmer treated with pH 8.2 media. Not all gene sets are significantly enriched. NES: Normalized enrichment 
score FDR q: False discovery rate q-value. See table supplement for FDR q-values for all analyses. Nominal p-value 
is indicated by * <0.05, ** <0.01, and ***<0.001. B) GSEA plots of the IN VITRO BRADYZOITE gene set comparing 
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control versus pH 8.2 treated TgVEG and HhCatAmer. C) Heat map showing mean centered log2(FPM) values for all 
detectable genes from the IN VITRO BRADYZOITE gene set. D) Mean centered, hierarchically clustered heatmap of 
log2(FPM) values of the 24 genes that significantly differed in transcript abundance (fold-change ≥ 1; Padj<0.01) 
between control and pH 8.2 treated H. hammondi. As shown only 3 transcripts were found to be of higher abundance 
in pH-treated H. hammondi, while the remaining genes were of significantly lower abundance after pH exposure. 
2.3 Discussion and conclusions 
Parasites with multi-host life cycles undergo stereotyped patterns of development and 
growth in a given host, reaching a unique and often terminal developmental state that is then 
transmissible to the next host. With few exceptions, parasites with heteroxenous life cycles are 
obligately so; life stages that are infectious to one host (e.g., the definitive host) are not infectious 
to another host (e.g., an intermediate host). Among the Sarcocystidae (including such parasites as 
Sarcocystis spp., Besnoitia spp., Neospora spp.), all have exogenous life cycles for which they are 
obligately heteroxenous with the exception of T. gondii. Only in T. gondii oocysts and tissue cysts 
(i.e., bradyzoites) can infect, and ultimately be transmitted by, both intermediate and definitive 
hosts. 
Given that the molecular determinants of life cycle dynamics such as those listed above are 
poorly understood in most parasite species, we have used the T. gondii/H. hammondi system as a 
means to better understand the genetic underpinnings of complex life cycles in Apicomplexa. In 
the present study, we conducted comparisons between one strain of T. gondii (VEG strain) and 2 
strains of H. hammondi (HhCatEth1 and HhCatAmer), quantifying differences in in vitro and in 
vivo infectivity, replication rate, and in stage conversion. We identified dramatic differences in 
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parasite biology between these two species that likely contribute to their significant life cycle 
differences.  
2.3.1 Stress-induced cyst formation is a unique trait in T. gondii compared to H. hammondi 
While spontaneous cyst formation during growth in vitro has been reported for a handful 
of T. gondii strains (80, 167), T. gondii of most genetic backgrounds can be induced to form tissue 
cysts in vitro through the application of a variety of chemical modifications (e.g., alkaline pH, 
nitric oxide donors, serum starvation (80, 110, 145)) and these cysts are infectious to both the 
definitive and intermediate host (11). H. hammondi was resistant to high pH exposure at the 
transcriptome level, and 100% resistant with respect to tissue cyst formation. This highlights a key 
distinction between T. gondii and H. hammondi biology: the dynamic nature of the T. gondii 
tachyzoite permits movement in both directions along the tachyzoite-bradyzoite continuum which 
is at least partly driven by sensing changes in the external environment. The ability to dynamically 
alter (and even delay) stage conversion may be made possible by the existence of T. gondii 
effectors that block responses to host immune effectors like IFN-γ (e.g., Toxoplasma inhibitor of 
STAT1-dependent transcription (TgIST) (176)) or otherwise manipulate the host response. If the 
progression from replicating H. hammondi zoite to tissue cyst is as predictable in vivo as it is in 
vitro (which is unknown but likely given that even IFN-γ knockout mice survive infection with H. 
hammondi (42)), and H. hammondi has non- or less-functional orthologs of genes like TgIST  (177–
179), this may prevent the fixation of any polymorphisms in the population that might result in the 
suppression of spontaneous bradyzoite conversion. Given that bradyzoites induce less 
inflammation (180) and are protected from immune assaults by the tissue cyst wall (181, 182), the 
timing of these events may be under very strong selective pressure in H. hammondi. It will be 
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interesting to see how the developmental dynamics of H. hammondi in vivo are timed with that of 
the intermediate host immune response, particularly in rodents (5, 45, 55), since this may have 
directly impacted the timing of cyst formation during the evolution of this parasite. It is likely that 
H. hammondi is capable of sensing the stresses that are induced upon high pH exposure of the host 
cell (as evidenced by significantly reduced transcript abundance for 24 H. hammondi genes), but 
if so it is clear that this species responds quite differently than T. gondii.  
The link between stage conversion and parasite replication (174) makes it possible that the 
lack of cyst wall formation after pH stress in H. hammondi is because the parasite is arrested in a 
phase of the cell cycle that prevents conversion. However, in the present study there were no 
significant differences in vacuole and/or tissue cyst size between T. gondii and H. hammondi after 
pH exposure, indicating that parasite replication continued in both species at a similar (albeit 
slightly slower) rate. Moreover, in T. gondii stress-induced (100) or spontaneous (80) cyst 
formation, slowed replication is a requirement for expression of bradyzoite antigens and ultimately 
stage conversion.  
2.3.2 H. hammondi possesses unique life stages 
When taken together with the dynamics of spontaneous differentiation in H. hammondi, 
these data further demonstrate that H. hammondi terminally differentiates into a unique life stage 
that is no longer infectious to anything but the definitive host. While we did not conduct any formal 
analyses of the cell cycle stage(s) found within replicating and tissue cyst-like forms of H. 
hammondi, we would predict that spontaneous H. hammondi in vitro-derived tissue cysts form 
after a set number of division and would be homogenous in terms of cell cycle stage (likely G0 and 
1N) given their terminal differentiation phenotype. It is also not known if terminally differentiated 
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parasites are capable of reinvading neighboring cells after egress, nor if they could be coaxed to 
infect cat gut epithelial cells in vitro, although the existence of cat intestinal organoids (183) might 
allow for this to be tested directly in an accessible in vitro system.  
Some insight into the H. hammondi developmental processes underlying these unique life 
stages can be gleaned from the D4 and D15 transcriptional profiling data. H. hammondi 
consistently had higher transcript levels for genes previously defined as being uniquely expressed 
in T. gondii bradyzoites (whether in vivo or in vitro) as early as 4 DPI, indicating that there is a 
high degree of similarity between the spontaneous differentiation process that occurs in H. 
hammondi and the stress-induced process observed in T. gondii (26, 80, 166, 169, 175, 184). 
Importantly, this enrichment for bradyzoite genes became more robust by 15 DPI compared to 4 
DPI, indicating that the parasites are changing their transcriptional profiles throughout in vitro 
development (rather than becoming less viable or dying). Less expected, however, was the higher 
expression of genes in H. hammondi (observed in 24 hours PI, 4 DPI, and 15 DPI zoites) that have 
been found previously to be expressed more abundantly in T. gondii cat enteroepithelial stages and 
sporozoites (170, 185). While the exact role of these gene products in determining life cycle and 
growth differences between T. gondii and H. hammondi are unknown, this provides strong 
evidence that sporozoite-derived life stages of T. gondii and H. hammondi are distinct, at least 
when grown in vitro. Importantly, this enrichment becomes more apparent at 15 DPI, indicating 
that this is not entirely due to residual transcript from the sporozoite stage. Assuming that the 
majority of these transcript expression differences are manifested at the protein level (which is 
expected based on multiple studies in T. gondii (186, 187), it is exciting to consider what impact 
these distinct expression profiles might have on parasite development and even the host response.  
Expression of these T. gondii merozoite-specific genes in H. hammondi zoites may reflect its 
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terminally differentiated state, being infectious only the felid host (42). At a minimum our data 
may implicate only a subset of so-called “merozoite-specific” genes (170, 185) as being truly key 
distinguishing features of the T. gondii merozoite, since a number of them are highly expressed in 
H. hammondi zoites growing in HFFs.  
2.3.3 Developmental predictability allows for genetic manipulation in H. hammondi  
In contrast to previously published work, we identified a short but very predictable 
replicative window during which H. hammondi could be used to infect new host cells and identified 
the precise timing of what appears to be an inevitable developmental program towards cyst 
formation. This finding is in contrast to previous studies where subculture was unsuccessful (55, 
65), although in these studies subculture was attempted after 1, 2, 4, and 6 weeks of growth and 
therefore most were outside of the window of infectivity we identified for H. hammondi. We 
exploited this window to genetically manipulate H. hammondi using transfection and gene editing 
strategies developed for T. gondii (172). Our transgenic H. hammondi parasite line expresses 
dsRED (30-40% after the first round of selection) and is >99% resistant to FUDR. This represents 
a new tool in the arsenal to track H. hammondi biology in vitro and in vivo, and opens up the door 
for the development of genetic screens to potentially disrupt spontaneous differentiation in H. 
hammondi to generate a mutant that can be cultured indefinitely, as well as utilized in gene-by-
gene phenotypic screens.  
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2.3.4 Replication rate and tissue cyst formation may contribute to limited virulence and 
dissemination of H. hammondi  
The nearly 3-fold difference in replication rate is likely a major determinant of reduced H. 
hammondi virulence (Table 2, Figure 2D-E), assuming this phenotype is recapitulated in vivo. 
Besides the impact that a slower replication rate would have on acute virulence, it may also impact 
infection outcome in the chronic phase. While H. hammondi parasites can at times be detected in 
the brains of mice after infection with oocysts (42), central nervous system (CNS) infection which 
is a hallmark of T. gondii infection (42, 173) is much less common after exposure to H. hammondi 
(although H. hammondi parasites have been detected in mouse brains) (42). A simple explanation 
for reduced CNS infection in H. hammondi is that it never reaches a high enough burden to infect 
the CNS at any significant level. It is also possible that H. hammondi has additional deficiencies 
that underlie differences in tropism (such as poor trafficking by innate immune cells and/or 
inability to cross the blood-brain barrier (188–190)), although these have yet to be thoroughly 
explored. In contrast to differences in replication rate, we observed no substantial differences in 
the ability of T. gondii and H. hammondi to invade and form vacuoles within HFFs, suggesting 
that their invasion machinery is mostly conserved and intact. This idea finds some support in our 
transcriptome data, where we detected no enrichment for gene sets consisting of microneme, 
rhoptry or dense granule genes, and detected similar amounts of crucial invasion genes like AMA1, 
SpAMA1, as well as multiple rhoptry neck proteins. Moreover, all genes known to be a part of the 
cellular invasion machinery appear to be well-conserved in both sequence and expression between 
these species (43). 
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2.3.5 Potential for human exposure to and infection by H. hammondi  
T. gondii and H. hammondi oocysts co-occur in the natural environment. A study 
conducted in Germany and surrounding countries found that the number feline fecal samples that 
contained either T. gondii or H. hammondi oocysts was strikingly similar (52), meaning that 
humans would be just as likely to encounter H. hammondi oocysts as those of T. gondii. While 
more studies are needed to determine if co-occurrence is a widespread phenomenon, it raises 
important questions about the likelihood that H. hammondi is capable of infecting humans. 
Importantly, at present all serological tests would be expected to misdiagnose a H. hammondi 
infection as a T. gondii infection due to antibody cross-reactivity (42). While this is a very poorly 
explored line of research, based on our data we would predict that an infection with H. hammondi 
should be less lethal than one with T. gondii since we would not expect a significant amount of 
recrudescence to occur. To further address the question of human infection and associated disease, 
mouse reactivation models and the development of differential diagnostic serological tests will be 
required in order to further determine human and animal infection rate differences between H. 
hammondi and T. gondii in the field.  
2.4 Materials and methods 
2.4.1 Parasite strains and oocyst isolation 
Oocysts of Hammondia hammondi strain HhCatEth1(164), HhCatAmer (5), and 
Toxoplasma gondii strain VEG (162) were isolated from experimentally infected cats as described 
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previously. Ideally, one H. hammondi strain would be used for all experiments, but two strains of 
H. hammondi were utilized due to oocyst availability at the time of experimentation. Briefly, wild 
type (for T. gondii) or interferon-γ (IFN-γ) knockout (for H. hammondi) mice were orally infected 
with 104 sporulated oocysts and sacrificed 4-6 weeks post-infection, and leg muscle (for H. 
hammondi) or brain (T. gondii) tissue were fed to 10-20 week old specific pathogen-free cats. 
Feces were collected during days 7-11 post-infection, and unsporulated oocysts were isolated via 
sucrose flotation. Oocysts were placed at 4°C in 2% H2SO4 to allow for sporulation to occur and 
for long-term storage.  
Due to the limited availability and difficulty associated with the generation of oocysts, two 
strains (HhCatEth1 and HhCatAmer) of H. hammondi generated from multiple cat-derived oocysts 
preparations were used in experiments described below. Furthermore, various MOIs were utilized 
throughout the experiments described below to compensate for differences in replication between 
T. gondii and H. hammondi.  
2.4.2 Excystation of T. gondii and H. hammondi oocysts 
Sporulated oocysts were washed 3X in Hanks’ balanced salt solution (HBSS; Life 
Technologies, 14175145) and treated with 10% bleach in PBS for 30 minutes while shaking at 
room temperature. Washed pellets were resuspended in 3 mL of HBSS in a 15-mL falcon tube, 
and 4g sterile glass beads (710-1,180 µM; Sigma-Aldrich, G1152) were added. Parasites were 
vortexed on high speed for 15 seconds on/15 seconds off, 4X. Supernatant was removed and 
pelleted by centrifugation. The pellet was resuspended and syringe-lysed using a 25 gauge needle 
in 5 mLs of pre-warmed (37°C) and freshly made, sterile-filtered excystation buffer (40 mL PBS, 
0.1 g Porcine Trypsin (Sigma-Aldrich, T4799), 2 g Taurocholic Acid (Sigma-Aldrich, T4009), pH 
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7.5). After 45 minutes in a 37°C water bath, the suspension was syringe lysed again, and 7 mLs of 
cDMEM (100U/mL penicillin, 100µg/mL streptomycin, 2mM L-glutamine, 10% FBS, 3.7g 
NaH2CO3/L, pH 7.2) was added to quench the excystation media. The mixture was centrifuged, 
the pellet was resuspended in cDMEM, and used in downstream applications described in more 
detail below.  
 
2.4.3 Fixing parasites for immunofluorescence assays  
Parasites were washed twice with PBS, fixed with 4% paraformaldehyde in PBS 
(Affymetrix, 19943), washed twice with PBS, and blocked/permeabilized in blocking buffer 
(50mL PBS, 5% BSA, 0.1% Triton X-100).  
2.4.4 Quantification of sporozoite viability and replication rate 
After 10 minutes incubation on HFFs at 37°C in 5% CO2, monolayers containing freshly 
excysted parasites were scraped, serially syringe lysed (25 and 27 gauge needles), and pelleted. 
The pelleted parasites were resuspended in cDMEM, filtered through a 5 μM syringe-driven filter 
(Fisher Scientific, SLSV025LS) and used to infect 4-chambered slides (Lab-Tek® II, 154526) 
containing a confluent monolayer of HFFs at an MOI of 0.5 for both H. hammondi CatEth1 and 
T. gondii VEG. After 1, 2, and 3 days of growth, cells and parasites were fixed as described above 
and stored in blocking buffer at 4°C until needed. Cells were immunostained with goat polyclonal 
Toxoplasma gondii Antibody (ThermoFisher Scientific, PA1-7256, RRID: AB_561769) at 1:500. 
The secondary antibody, Alexa Fluor® 594 Donkey anti-Goat IgG (H+L) (ThermoFisher 
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Scientific, A-11037, RRID: AB_2534105) was used at 1:1000. Coverslips were mounted to 4-
chambered slides using VECTASHIELD Antifade Mounting Medium with or without DAPI, 
depending on the application (Vector labs, H-1000).  
Vacuole formation was used as a proxy for sporozoite invasive capacity. To quantify this, 
the number of vacuoles with at least 1 parasite was determined in 100 random FOVs (1000x 
magnification) for 3 technical replicates for each parasite species at 1, 2, and 3 DPI. The entire 
experiment was repeated twice with different cat-derived oocyst preparations. For replication rate 
quantification, images of parasite-containing vacuoles were taken with an Axiovert 100 inverted 
fluorescent microscope with Zen lite 2012 software. The number of parasites per vacuole was 
determined for each image (biological replicates 1 & 2), and vacuole size (Biological replicate 1 
only) was determined for each image using ImageJ software (NIH).  
2.4.5 Quantification of spontaneous Dolichos biflorus-positive cyst formation in vitro 
For Dolichos Biflorus Agglutinin (DBA) staining, monolayers containing freshly excysted 
parasites were scraped, syringe lysed, and pelleted 24 hours after growth. The pellet was 
resuspended in cDMEM, filtered through a 5 µM syringe-driven filter (Fisher Scientific, 
SLSV025LS), and passed at MOIs of 0.3 (HhCatEth1) and 0.001 for (TgVEG) onto coverslips 
containing a confluent monolayer of HFFs. Three coverslips were infected per strain for each time 
point analyzed. At 4 and 15 DPI, cells and parasites were fixed as described above and stored in 
blocking buffer at 4°C until immunostaining was conducted.  
In addition to being stained with rabbit Toxoplasma gondii Polyclonal Antibody 
(Invitrogen, PA1-7252 RRID: AB_561769) at a dilution of 1:500 and a 1:1000 dilution of Alexa 
Fluor® 594 goat anti-rabbit IgG (H+L) (ThermoFisher Scientific, A-11037, RRID: AB_2534095), 
 73 
coverslips were stained with Fluorescein labeled Dolichos biflorus Agglutinin (DBA; Vector Labs, 
FL-1031) at a dilution of 1:250. Coverslips were then mounted to microscope slides using 
ProLong® Diamond Antifade Mountant with DAPI (ThermoFisher Scientific, P36962). 
The number of DBA-positive vacuoles and total vacuoles were quantified in 20 FOVs in 3 
coverslips for each parasite at 4 and 15 DPI. Images were obtained with an Axiovert 100 inverted 
fluorescent microscope with Zen lite 2012 software and edited using ImageJ software (NIH).  
For time course tissue cyst formation analysis, freshly excysted and filtered HhCatAmer 
and TgVEG sporozoites were used to infect confluent monolayers of HFFs grown on glass 
coverslips at an MOI of 0.5. After three days of growth, the media was changed every 2 to 3 days. 
At designated time points, coverslips were was twice with PBS, fixed with 4% formaldehyde in 
PBS, washed twice with PBS, and stored in blocking buffer 4°C until immunostaining was 
conducted using Rhodamine labeled DBA. The number of DBA-positive vacuoles and number of 
total vacuoles were quantified in 15 parasite-containing FOVs for each time point.  
2.4.6 Induction of bradyzoite formation in T. gondii and H. hammondi 
Monolayers containing freshly excysted parasites were scraped, syringe lysed, and filtered 
through a 5 µM syringe-driven filter (Fisher Scientific, SLSV025LS) after 24 hours of growth. 
Filtered parasites were pelleted and passed at MOIs of 0.5 (H. hammondi) and 0.1 for (T. gondii) 
onto coverslips containing a monolayer of HFFs. Three coverslips were infected per parasite per 
treatment group. After 2 days, media was changed to pH 8.2 bradyzoite switch media (DMEM 
with 100U/mL penicillin, 100µg/mL streptomycin, 2mM L-glutamine 10mM HEPES, 2g/L 
NaHCO3, and 1% FBS)(145) or cDMEM. Coverslips with pH 8.2 media were grown at 37°C in 
the absence of CO2. Media was changed again at 3 DPI. After 4 DPI, cells and parasites were fixed 
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as described above and stored in blocking buffer at 4°C until needed. DBA and counter-staining 
was conducted using Fluorescein or Rhodamine labeled DBA and rabbit Toxoplasma gondii 
Polyclonal Antibody as described above. The number of DBA-positive vacuoles was quantified in 
15 FOVs in 3 coverslips for each strain grown at either pH 7.2 or pH 8.2 and the percentage of 
DBA-positive vacuoles was determined. Images were obtained and analyzed as described above. 
2.4.7 Subculture of H. hammondi  
Sporozoites were obtained using the excystation protocol described above with the 
exception of syringe lysis and previously described host cell incubation. Six confluent monolayers 
of HFFs grown in T-25’s were infected with H. hammondi American (HhCatAmer) sporozoites at 
an MOI of ~2 (2.8 million sporozoites). After a three-hour incubation at 37°C, the Day 0 Transfer 
flask was scraped, syringed lysed 5X with 25 gauge needle, filtered through a 5 µM syringe-driven 
filter (Fisher Scientific, SLSV025LS), and passed to a new confluent monolayer of HFFs grown 
in a T-25. This process was repeated after 2, 5, 8, 11, and 15 days post-excystation. After 3 days 
of growth following passage, 4.17cm2 of the T-25 was monitored daily. Images of vacuoles were 
obtained with an Axiovert 100 inverted fluorescent microscope with Zen lite 2012 software with 
a 40X objective, and vacuole sizes were quantified using ImageJ software (NIH). Similar methods 
were used to generate parasite samples for RNAseq analysis, except cells were processed for RNA 
harvest using methods described below.  
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2.4.8 Characterizing limits of in vivo infectivity of H. hammondi grown in vitro 
Sporozoites were obtained using the excystation protocol described above. After 24 hours, 
HFF monolayers infected with excysted sporozoites were scraped, syringe lysed 5X with a 25-
gauge needle, and pelleted. The pellet was resuspended in cDMEM, filtered through a 5µM 
syringe-driven filter (Fisher Scientific, SLSV025LS) and passed onto confluent monolayers of 
HFFs grown in T-25s. Infected host cells were incubated at 37 °C 5% CO2 from 6, 8, 10, 13, and 
15 days. The media was replenished after 5-7 days. At each time point, infected host cells were 
scraped, syringe lysed 3X with a 25-gauge needle and 3X with a 27 gauge needle, and pelleted. 
Parasites were counted and diluted in PBS, and a dose of 50,000 parasites was injected 
intraperitoneally in 2 BALB/C mice for each time point. Serum samples were obtained from 
infected mice daily for 9 days post-infection and the mass of the mice was also monitored daily. 
After 9 days of infection, the mice were sacrificed and dissected. Tissue samples were preserved 
in 10% neutral buffered formalin (Sigma HT501128) until immunohistochemistry analysis was 
performed.  
2.4.9 Tissue sectioning and staining 
Fixed tissue samples were embedded in paraffin, sectioned, and stained using rabbit anti-
Toxoplasma antibody (ThermoScientific Cat# RB-9423-R7) by Research Histology Services at 
the University of Pittsburgh. For antigen retrieval, deparaffinized slides were steamed at pH=6.0 
in 10 mM Citrate buffer. After exposure to 3% H2O2, slides were washed in Tris-buffered saline 
with 2.5% Tween-20 (TBST), and blocked for 20 min each with Avidin and Biotin blocking 
reagents (Vector labs; SP-2001) with TBST washes in between. Slides were blocked in 0.25% 
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casein:PBS for 15 min, and incubated overnight in primary antibody (1:100 dilution in 3% goat 
serum in PBS). Slides were washed in PBST and incubated for 30 minutes with biotinylated goat 
anti-rabbit (Vector laboratories; BA-1000; 1:200 dilution in 3% goat serum in PBS). Following 3 
washes with PBST, slides were incubated for 30 minutes with streptavidin-HRP (Vector 
laboratories; PK-6100), washed 3X with PBST, and incubated with AEC substrate (Skytec; ACE-
500/ACD-015) for 15 minutes. Following rinses in water, slides were counterstained with aqueous 
hematoxylin and blued using Scott’s tapwater substitute. Slides were mounted in Crystal Mount. 
2.4.10 Interferon-gamma (IFNγ) ELISA  
Blood samples were obtained from mice daily via submandibular bleed, allowed to clot for 
4-24h at 4°C, and centrifuged at 100xg. Serum was stored at -20°C until ELISAs were performed. 
IFN-γ levels were determined using the BD OptEIATM Set Mouse IFN-γ kit (Cat.# 555138) 
according to manufacturer's instructions. Serum samples were diluted 1:20.  
2.4.11 Transfection of Hammondia parasites and selection of recombinant parasites 
Excysted sporozoites were prepared as described above and incubated overnight in a T-25 
flask with confluent monolayer of HFFs. After 24 hours, the monolayer was scraped, syringe lysed 
3X with a 25 gauge and 27 gauge needle and filtered using a 5 μM syringe-driven filter (Fisher 
Scientific, SLSV025LS). The filtered contents were pelleted by centrifugation at 800 x g for 10 
min, and the pellet was resuspended in 450 µl of cytomix with 2 mM ATP and 5 mM glutathione. 
Resuspended parasites were transferred to a cuvette, electroporated at 1.6 KV and a capacitance 
of 25 µF and used to infect confluent HFF monolayers on coverslips. The coverslips were fixed 5 
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DPI as described above and mounted using ProLong® Diamond Antifade Mountant with DAPI 
(ThermoFisher Scientific, P36962). 
To create stable transgenic H. hammondi parasite lines, the CRISPR/CAS9 plasmid 
expressing a gRNA sequence targeting the uracil phosphoribosyl transferase gene (UPRT;(172)  
kindly provided by David Sibley, Washington University) and a repair template consisting of 20 
bp UPRT-targeting sequences flanking a PCR-amplified a dsRED expression cassette driven by 
the T. gondii GRA1 promoter with a GRA2 3’ UTR (amplified from the dsRED:LUC:BLEO 
plasmid(191, 192) were used for transfection. Following centrifugation (800 x g, 10 min), 24 h H. 
hammondi zoites were resuspended in 450 μl of cytomix with ATP and glutathione containing 20 
μg of the CRISPR/CAS9:UPRT:gRNA plasmid and 20 μg of PCR2.1 TOPO vector containing the 
dsRED repair template. The parasites were electroporated as above and each transfection contained 
at least 4 million parasites. Transfected parasites were then transferred to HFFs and grown for 2 
days in cDMEM, then selected for 3 days by incubation in cDMEM containing 10 μM FUDR 
(Figure 11B). Parasites were again scraped, syringe lysed and filtered, and dsRED-expressing 
parasites were collected in PBS using flow cytometry. Sorted parasites were injected 
intraperitoneally into 2 BALB/c mice. After 3 weeks of infection, mice were euthanized, skinned, 
and the intestines were removed before feeding to specific pathogen-free cats. The oocysts were 
collected and purified as described above, and oocysts, sporozoites and replicating parasites were 
evaluated for dsRED fluorescence using microscopy, flow cytometry and FUDR resistance. 
2.4.12 FUDR resistance of transgenic parasites 
To test for deletion of the UPRT gene we quantified transgenic H. hammondi resistance to 
5-fluoro-2’-deoxyuridine (FUDR). To do this, sporozoites of wild type and dsRED-expressing 
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parasites were incubated overnight in a T25 flask with confluent monolayer of HFFs. After 24 
hours, parasites were isolated by needle passage and filtration as above. We infected coverslips 
containing confluent HFFs with 50,000 parasites, and parasites were exposed to media alone or 
media containing or 20 μM FUDR. The parasites were allowed to grow for 4 days and then fixed 
using 4%PFA for 20 minutes. After blocking overnight in PBS/BSA/triton, coverslips were stained 
with rabbit anti-Toxoplasma antibody at a 1:500 dilution for an hour and stained with Alexa-fluor 
488-labeled goat anti Rabbit antibody (RRID: AB_143165). For each treatment/strain 
combination, we counted the number of parasites in at least 100 vacuoles, and for HhdsRED 
parasites we also quantified growth in both red and wild type vacuoles (since the HhdsRED 
parasites were from a mixed population). 
2.4.13 Genomic DNA isolation 
To isolate genomic DNA from H. hammondi, freshly excysted parasites were used to infect 
HFFs. Following 7 days of growth, infected host cells were scraped, syringe lysed, pelleted and 
resuspended in 200µL of PBS. Genomic DNA was isolated with the GeneJET genomic DNA 
Purification kit (ThermoFisher, K0721) according to the manufacture. Alternatively, identical 
procedures were used on freshly excysted and filtered sporozoites. 
2.4.14 Linear amplification of HhamdsRED gDNA 
We used the Genomiphi Linear DNA amplification kit to linearly amplify DNA taken from 
our population of dsRED-expressing H. hammondi American parasites. We used ~5 ng of input 
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DNA in a single reaction, and ethanol precipitated amplified DNA prior to quantification and use 
in PCR reactions.  
2.4.15 PCR verification of dsRED cassette  
To verify that the dsRED cassette incorporated into the HhCatAmer genome, linearly 
amplified pure parasite genomic DNA (HhamdsRED) was amplified using primer sets targeting 
the UPRT homology arms of the dsRED cassette, the dsRED transgene, and a sequence 
specifically found in H. hammondi (63). (See supplementary file 3 for primer sequences) Controls 
included wild type HhCatAmer genomic DNA, purified from infected HFFs, and a water control. 
PCR reactions were conducted using 12.5µL of 2X BioMix Red (Bioline, BIO-25006), 1nM of 
both forward and reverse primers, 45ng of template DNA, and water to 25µL. Cycling conditions 
began with 5 minutes of 95 C denaturation, followed by 30 cycles of 95 C for 30 seconds, 50 C 
for 30 seconds, 72C for 1 minute and 30 seconds, followed by 72 C for 5 minutes and a 4C 
hold. PCR products were visualized on a 1% agarose gel. 
2.4.16 RNAseq data collection and enrichment analysis for D4 and D15 zoites 
Sporozoites were isolated from HhCatEth1 and TgVEG sporulated oocysts as described 
above and used to directly infect confluent HFF monolayers in 96 well tissue culture plates with 
MOIs of 3, 1 or 0.5 purified sporozoites for each species. On day 4 post-infection, wells were 
observed and chosen for RNA analysis based on similar numbers of parasite-containing vacuoles 
lack of significant host cell lysis in both species. For the Day 4 samples, the MOI=3 infected wells 
were chosen for H. hammondi, while the MOI=0.5-infected wells were chosen for T. gondii. Wells 
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were washed 3X with ~200 μL cDMEM, and RNA was harvested using Trizol (Invitrogen). 
Remaining H. hammondi wells were washed with 3X with cDMEM on Day 4 and then again on 
Day 9 prior to harvest on Day 15 post-infection. For T. gondii, remaining MOI=3 and 1-infected 
wells were scraped and syringe lysed on Day 4 and Day 9 and used to infect new monolayers in 
96 well plates at an MOI of either 0.5 (Day 4) or 0.3 (Day 9). On Day 15, wells for both H. 
hammondi (not subcultured) and T. gondii (subcultured 2x) were washed 1X with cDMEM and 
then harvested for RNAseq analysis. Two samples were harvested for each species on Day 4, and 
3 samples were harvested from each species on Day 15. Total RNA samples were processed for 
Illumina next generation sequencing using the Mobioo strand-specific RNAseq library 
construction kit. Samples were analyzed on an Illumina Nextseq and demultiplexed using NextSeq 
System Suite software. Reads were aligned to their respective species genome assembly (H. 
hammondi v10 or T. gondii strain ME49 v10; toxodb.org) using the Subread package for Linux (v. 
1.4.6) with subread-align using default parameters except for –u to keep only uniquely mapping 
reads. featureCounts from the subread package(192) was used to quantify the number of mapping 
reads per transcript, using default settings except for –s 2 (for stranded read mapping), –t CDS, –
g Parent (for specific compatibility with the T. gondii and H. hammondi gff files), –Q 10 (minimum 
mapping quality required). The –t CDS option was chosen for both T. gondii and H. hammondi 
because to date no 5’ or 3’ UTR sequences have been predicted for H. hammondi (in contrast to 
T. gondii). Fastq files have been deposited in the NCBI short read archive (SRX3734444-
SRX3734449).  
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2.4.17 RNA sequencing and differential expression analysis of 24h-infected THP-1 cells (a 
human monocyte cell line)  
To validate genesets that were significantly enriched in D4 and D15 H. hammondi 
compared to T. gondii, we extracted sporozoites from oocysts and grew them overnight in HFFs 
as described above. Parasites were released by scraping and needle passage as above, and then 
passed through a 5μm syringe-driven filter (Fisher Scientific, SLSV025LS). Filtered parasites 
were used to infect monocytes (THP-1, RRID: CVCL_X588) at MOI of 4. At 24 hours post-
infection, RNA was harvested using RNeasy Mini Kit (Qiagen; three samples for each species). 
Total RNA samples were processed for Illumina next generation strand-specific sequencing using 
the Illumina TruSeq stranded mRNA sequencing kit. Fastq files have been deposited in the NCBI 
short read archive (SRX3734421-SRX3734428). FASTQ reads were aligned to their respective 
species genome assembly (H. hammondi release 34 or T. gondii strain ME49 release 30; 
toxodb.org) with CLC Genomics Workbench v10.0.1 (http://www.qiagenbioinformatics.com/) 
using default parameters for reverse strand mapping. Raw count data (with at least 1 read in at all 
samples for HhCatAmer) generated by CLC Genomics Workbench were loaded into R statistical 
software and analyzed using the DESeq2 package.(193) Read count data of HhCatAmer were 
compared to TgVEG to identify genes of different abundance and genes were deemed 
differentially expressed according to the threshold of log2 (fold) > 1 and Padj<0.01. Log2 
transformed data were used for enrichment analysis using Gene Set Enrichment Analysis (GSEA) 
(168). Data were compared to previously curated gene sets (434 total; as previously published 
(170) as well as in 7 additional gene sets that we curated ourselves (listed in Table 3). All 
enrichment profiles were deemed significant if the FDR q-value was ≤0.01. We also identified 
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1069 genes that were of different abundance between HhCatAmer and TgVEG at this 24 h time 
point in THP-1 cells. 
2.4.18 RNAseq from pH-treated T. gondii and H. hammondi zoites 
Sporozoites were isolated from HhCatAmer and TgVEG sporulated oocysts as described 
above and used to directly infect confluent HFF monolayers in 24 well tissue culture plates with 
MOI of 1.3 for HhCatAmer and 1 for TgVEG. Infected host cells were maintained as described 
the induction of bradyzoite section above. On day 4 post-infection, wells were washed twice with 
1X PBS and RNA was harvested using the RNeasy Kit according to the manufacturer (Qiagen, 
74104) using QiaShredder spin columns (Qiagen, 79654) to homogenize samples, and RNase-free 
DNase to degrade contaminating DNA (Qiagen, 79254). Total RNA samples were ethanol 
precipitated and processed for Illumina next generation strand specific sequencing as described for 
infected THP-1 RNAseq experiments. Library preparation and read alignment were performed as 
described in infected THP-1 RNAseq experiments. 
2.4.19 Identification of differentially expressed genes using DESeq2 and gene set 
enrichment analysis  
Raw count data per transcript (generated by featureCounts or CLC genomics) were loaded 
into R statistical software and analyzed using the DESeq2 package (193, 194). Comparisons of D4 
and D15 read count data were used to identify transcripts of different abundance at each time point, 
and differences were deemed significant at Padj<0.05. Data were log2 transformed and normalized 
using the rlog (with the blind=TRUE option) function in DESeq2 for use in downstream analyses. 
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Log2 transformed, normalized data from DESeq2 (hereafter referred to as Log2 (FPM)) were 
analyzed for enrichment using Gene Set Enrichment Analysis (GSEA) (168). Since read count 
overall from the T. gondii libraries were much greater than those from the H. hammondi libraries, 
we took the 7372 genes matched based on the previously published gene-by-gene annotation (43) 
and selected only those that had at least 1 day 4 sample and 1 day 15 sample with >5 reads for the 
D4 and D15 data and samples that had reads for each replicate and a total read average of 5 reads 
per three replicates for pH 8.2 analysis. In total, 4146 genes for the D4 and D15 analysis and 907 
genes for the pH 8.2 analysis passed these benchmarks and were used in subsequent analyses. We 
used this approach to identify gene sets that were significantly different between days 4 and day 
15 in culture in both species and those that were different between species at both day 4 and day 
15 and in pH 8.2 treated and control samples. We compared these data using previously curated 
gene sets (169) (434 total) as well as 7 additional gene sets that we curated ourselves. These are 
listed in Table 2. All enrichment profiles were deemed significant if the FDR q-value was ≤ 0.05.  
2.4.20 cDNA synthesis and qPCR  
For qPCR analysis, after 24 hours of growth, monolayers containing excysted sporozoites 
were scraped, syringe lysed, and pelleted. The pellet was resuspended in cDMEM, filtered through 
a 5 μM syringe-driven filter (Fisher Scientific, SLSV025LS) and passed at MOIs of 1 (T. gondii) 
and 7 (H. hammondi) into 96-well plates or 24-well plates containing HFF monolayers. Mock-
infected controls consisted of filtering parasites through a 0.22 μM syringe-driven filter (Fisher 
Scientific, SLGL0250S). Three replicates were made for each sample per isolation time point. 
RNA for D4 and D15 RNAseq validation was collected at day 4 and day 15 post-infection, 
(equivalent to day 5 and day 16 post-excystation) from parasites and mock infections grown in 96-
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well plates. RNA for pH induced bradyzoite transcript analysis was collected from day 4 and 5 
post-infection samples grown in 24-well plates. RNA was collected using the RNeasy Kit 
according to the manufacturer (Qiagen, 74104) using QiaShredder spin columns (Qiagen, 79654) 
to homogenize samples, and RNase-free DNase to degrade contaminating DNA (Qiagen, 79254). 
Isolated RNA was ethanol precipitated, resuspended in RNase-free water, and these preparations 
were used to create cDNA using Superscript III Reverse Transcriptase Kit using Oligo(dT) primers 
according to the manufacturer (ThermoFisher Scientific, 18080051). All RNA samples were kept 
at -80°C, and all cDNA reactions were kept at -20°C. Prior to qPCR use, cDNA was diluted 1:10 
(for RNAseq validation) or 1:5 (for bradyzoite transcript analysis) with H20. 
qPCR assays were performed on a QuantStudio 3 Real-Time PCR System in a 10 μl 
reaction volume containing 5 μl 2x SYBR Green Master Mix (VWR International, 95030-216), 3 
μl of cDNA template, 1 μl H20, and 1 μl 5 μM primer. Controls included a reverse transcription 
negative control and a water-template control. The thermal cycling protocol was 95°C, 10 min; 40 
cycles of (95°C, 15s; 60°C, 1 min); 4°C hold. The melt curve protocol was 95°C, 15 s; 60°C 1 
min, 95°C 15 s. The control gene was dense granule 1 (GRA1), and samples were tested in 
duplicate or triplicate. Melt curves were performed on each plate (with the exception of 2 plates). 
Data were analyzed using the 2-∆∆Ct method(195), and statistical analyses were conducted on the 
∆Ct values.(196) 
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3.0 Cross-species comparisons between Toxoplasma gondii and Hammondia hammondi 
identify ROCY1 as a regulator of cystogenesis 
3.1 Introduction 
A fundamental characteristic of all organisms is that they must be able to respond to stimuli 
from their environment. This characteristic is especially true for parasitic organisms with multi-
stage life cycles that occur in different environments or different hosts, such as in tissue cyst 
forming Apicomplexan parasites. Toxoplasma gondii and Hammondia hammondi are both 
coccidian Apicomplexans that exist as multiple life stages optimized for growth and survival in a 
variety of environments and hosts. T. gondii and H. hammondi are closely related, sharing over 
7,000 orthologous genes (43) in near perfect genomic synteny (68). These two parasite species are 
morphologically and antigenically similar, share the same definitive host and organelles, and 
transition between similar life stages as they progress through their life cycle (3, 5, 42). 
Even though these parasites have many similarities, H. hammondi follows a strictly 
obligate heteroxenous life cycle (3, 5) while T. gondii has a facultative heteroxenous/homoxenous 
life cycle. This is driven by the unique ability of T. gondii bradyzoites, the slow-growing tissue 
cyst forming life stage of the parasite responsible for chronic infection, to convert back to 
tachyzoites, the rapidly replicating life stage that can lead to disease (2, 11). This unique 
interconversion phenomenon is not shared with H. hammondi. Bradyzoite to tachyzoite 
interconversion allows for T. gondii to pass between intermediate hosts, thus expanding its 
transmission dynamics (17). Furthermore, this interconversion can be lethal or result in severe 
disease in immune compromised organ transplant patients, cancer patients, and individuals with 
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HIV/AIDS (35, 36). Despite their importance for transmission and disease, the genetic components 
and regulatory network comprising the mechanisms used by T. gondii to transition to the 
bradyzoite life stage are only starting to be discovered.  
The similarities between T. gondii and H. hammondi bradyzoites paired with the stark 
contrast in when and how bradyzoites form in each species makes interspecies comparison a 
promising strategy for uncovering critical components driving the bradyzoite developmental 
program. H. hammondi’s strict obligate heteroxenous life cycle restricts its ability to initiate 
infection in organisms other than its definitive feline host after it transitions into its bradyzoite life 
form (42, 44, 55, 65). Moreover, H. hammondi cannot be induced to form bradyzoites in its early 
life stages when treated with alkaline pH stress (44), a known and potent inducer of cystogenesis 
in T. gondii (88, 89, 95). Yet, H. hammondi predictably and reliably forms tissue cysts 
spontaneously which is also accompanied by robust transcriptional changes resembling those 
observed in T. gondii as they differentiate into bradyzoites (42, 44). 
Numerous studies designed to characterize the T. gondii bradyzoite have led to the 
identification of several bradyzoite specific proteins along with their function (76) and have 
characterized the major transcriptional differences that occur during bradyzoite development in T. 
gondii (73, 114, 169, 197–199). However, until recently the mechanisms used by T. gondii to 
initiate bradyzoite development were elusive. The first major class of transcription factors 
identified in Apicomplexans were AP2 transcription factors (124), which begun to broaden our 
understanding of the regulation of bradyzoite development. These transcription factors play 
fundamental roles in regulating stage conversion associated gene expression in closely related 
Plasmodium species (125, 200). In T. gondii, this family of proteins are important for cystogenesis 
and function as activators and repressors of stage conversion associated gene expression (118, 
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127–131). In addition to AP2 factors, another T. gondii transcription factor that regulates the 
tachyzoite to bradyzoite transition, Bradyzoite-Formation Deficient-1 (BFD1) was recently 
identified as a transcription factor that completely abolishes tissue cyst formation in vitro and in 
vivo when depleted (132). The identification of BFD1 as a regulator of differentiation was a 
fundamental finding and has greatly contributed to our understanding of the bradyzoite 
developmental pathway in T. gondii. However, our understanding of this process and all its major 
contributors remains unclear.  
Primarily, the identification of factors controlling bradyzoite development occurred 
through identification of parasite factors with homology to other known transcriptional regulators 
(AP2 factors) (124) or from genome-wide Cas9-mediated knockout screens (BFD1) (132) in T. 
gondii. Here, we used a novel interspecies comparative approach that exploits our knowledge of 
the critical differences in tissue cyst formation between T. gondii and H. hammondi to identify 
factors that are important for driving cystogenesis. Using this system, we identified a T. gondii 
gene, Regulator of Cystogenesis 1 (ROCY1), as a gene that plays a critical role in tissue cyst 
formation both in vitro and in vivo, is an important factor for T. gondii’s alkaline pH induced 
transcriptional response, and may be a downstream target of BFD1. 
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3.2 Results 
3.2.1 Comparative transcriptomics between T. gondii and H. hammondi identifies candidate 
genes involved in tissue cyst development  
To identify candidate T. gondii genes implicated in tissue cyst development, we leveraged 
species-specific differences in spontaneous and alkaline pH-induced tissue cyst formation that we 
previously identified in T. gondii and H. hammondi parasites (44). When T. gondii sporozoites 
(VEG) are exposed to alkaline pH-induced stress conditions at 3 days post excystation (DPE), they 
robustly form Dolichos biflorus agglutinin (DBA)-positive tissue cysts in vitro. However, H. 
hammondi fails to form DBA-positive tissue cysts under these conditions. But, H. hammondi 
spontaneously forms DBA-positive tissue cysts beginning at 12DPE and the percentage of tissue 
cysts increases to 100% over a 23-day time course, while only low levels (<20%) of tissue cyst 
formation is observed in T. gondii during this time (Summarized in Figure 16A) (44).  
We hypothesized that some of the genes that change in transcript abundance during alkaline 
pH stress exposure in T. gondii and during spontaneous development in H. hammondi would have 
critical regulatory roles in tissue cyst development. To identify candidate genes that could be 
driving tissue cyst formation, we performed RNA sequencing experiments on T. gondii and H. 
hammondi sporozoite-derived infections exposed to alkaline pH, low serum, and CO2 starvation 
for 48 hours beginning at 3DPE and on T. gondii and H. hammondi grown in control conditions. 
We then used this new transcriptional data in combination with our previously published data (44) 
to identify genes that had 1) significant changes in transcript abundance (|Log2FC| > 1, Padj < 0.01) 
in T. gondii in alkaline pH stress conditions compared to control condition in at least 1 of 2 
experiments, 2) genes that did not have significant changes (|Log2FC| < 1 and/or Padj > 0.01) in H. 
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hammondi during stressed conditions relative to control conditions in at least one of 2 experiments 
as H. hammondi fails to form DBA-positive tissue cysts in response to this treatment, and 3) genes 
with significant changes in transcript abundance (|Log2FC| > 1, Padj < 0.01) during spontaneous 
tissue cyst development in H. hammondi (D4 vs D15). We identified 80 candidate genes fitting 
these criteria (Figure 16 A-B). To prioritize these 80 candidates for further investigation, we sought 
to identify potential transcription factors that could be responsible for driving the global 
transcriptional changes needed for the transition from tachyzoite to bradyzoite. To do this we first 
removed candidates with a predicted signal peptide or transmembrane domains, leaving 48 
candidates. Next, we identified 22 genes containing predicted nuclear localization sequences using 
NLSmapper (201) and NLStradamus (202) using default settings. Finally, to further prioritize our 
candidate genes, we utilized data from a genome-wide CRISPR screen in T. gondii that predicts 
whether a gene contributes to tachyzoite fitness by calculating a CRISPR phenotype score from 
the ratio of the abundance of gRNAs present following in vitro growth in tachyzoite conditions to 
the abundance of gRNAs present in the initial library (203). We then selected bradyzoite induction 
factors (BIFs) if their transcript abundance increased during tissue cyst formation (stress-induced 
and spontaneous) in both species that also had a CRISPR phenotype score > -1, as we hypothesized 
that these factors would not be needed during tachyzoite growth. We also selected bradyzoite 
suppression factors (BSFs), genes whose transcript abundance decreased during tissue cyst 
formation, with low (< -1) CRISPR phenotype scores, as we predicted that these factors would be 
required for the maintenance of tachyzoite growth and therefore have poor fitness in vitro. After 
selecting candidates that fit these criteria, we had 17 final high priority candidates. (16 BIFs and 1 
BSF) (Figure 16 C-D). 
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Figure 16. Comparative transcriptomics between T. gondii and H. hammondi identifies candidate genes 
involved in tissue cyst development. 
Schematic depicting spontaneous and alkaline pH induced tissue cyst formation phenotype over a 23-day time course 
in T. gondii VEG and H. hammondi Amer (44). B) Venn diagram showing genes with significant (|Log2 Fold Change| 
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≥ 1, Padj < 0.01) differences in transcript abundance during alkaline pH induced stress in H. hammondi and T. gondii 
(at least 1 of 2 independent experiments) and during spontaneous development in H. hammondi. *=7, **=22 C) 
Schematic representing the prioritization strategy used to identify priority candidates predicted to be involved in tissue 
cyst formation. D) Mean centered heat map showing 16 priority candidate BIFs and 1 priority candidate BSF. 
3.2.2 Disruption of candidate genes using CRISPR/Cas9 gene editing  
To determine if our candidate genes were involved in tissue cyst formation, we sought to 
disrupt the locus of select genes using CRISPR/Cas9. We disrupted our candidate genes by 
transfecting parasites with a plasmid expressing Cas9-GFP under the control of the T. gondii SAG1 
promoter as well as U6 gRNA expression cassette (204) that we modified to express a guide 
specific for our candidate gene or a non-targeting gRNA for control transfections. We co-
transfected parasites with a linear repair cassette encoding either the HXGPRT selectable marker 
for use in CEPHXGRPT-GFP-LUC (TgCEP) parasites or the DHFR-TS selectable marker for 
use in oocyst derived TgVEG parasites. We isolated clonal parasite strains using limiting dilution 
and used a series of PCR reactions to verify the incorporation of the linear repair cassette in our 
candidate gene (knockout and repair strategy depicted in Figure 17A). We generated and validated 
successful disruptions for TgCEP_221840 (TgME49_221840) (Figure 17B), TgVEG_207210 
(TgME49_207210) (Figure 17C), TgVEG_311100 (TgME49_311100) (Figure 17D), and 
TgVEG_200385 (TgME49_200385) (Figure 17D). Although TgVEG_207210 was not a final 
candidate in our screen, we were originally interested in this gene because of its transcriptional 
profile in H. hammondi. For the disruption of TgCEP_221840, we observed an insertion of the 
HXGPRT linear repair cassette in the TgCEP221840 parasites as indicated by a ~3,000bp band 
in RXN1 that was not present in TgCEP WT parasites (RXN5), which amplified across the cut site 
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of the TgCEP_221840 locus, suggesting that a single copy of the repair cassette was inserted 
(Figure 17B). For TgVEG_207210 (Figure 2C), TgVEG_311100 (Figure 17D), and 
TgVEG_200385 (Figure 17D) we observed amplification of appropriately sized bands with a gene 
specific forward primer starting in the gene’s coding sequence upstream of the cut site and a 
reverse primer (DHFR-TS_R or DHFT-TS_F as the linear repair cassette could incorporate in 
either orientation, see Figure 17A). These bands were also sequenced to verify that they contained 
the correct product. Moreover, these products were not present in the passaged-matched WT 
parasites. These data indicate that the DHFR-TS repair cassette inserted into the locus of each gene 
candidate. Furthermore, we were no longer able to amplify across the cut site with only gene 
specific primers for the parasite clones that indicated locus disruption via amplification with a gene 
specific primer and a DHFR primer, suggesting that a large insertion of potentially multiple repair 
cassettes occurred at a given locus.  
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Figure 17. Generation of knockout of high priority candidate genes using CRISPR/Cas9. 
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Schematic of CRISPR/Cas9 knockout and repair strategy and diagram of predicted loci of gene of interest (GOI) after 
incorporation of linear repair cassettes of selectable markers (SM) HXGPRT or DHFR-TS. Arrows indicate general 
location of primers. B) Gel image and PCR reactions used to identify disruption of the TgCEP_221840 locus along 
with passaged-matched control. C) Gel image and PCR reactions used to identify disruption of the TgVEG_207210 
locus along with passage-matched control. E) Gel image and PCR reactions used to identify disruption of the 
TgVEG_311100 (ROCY1) locus and TgVEG_200385 (BFD1) and passaged matched controls. 
3.2.3 Disruption of the ROCY1 locus impairs in vitro tissue cyst formation 
After validating locus disruption of our candidate genes (Figure 17), we determined the 
impact of each gene disruption on alkaline-pH-stress-induced tissue cyst formation. After 48 hours 
of stress, we identified no significant differences in the number of DBA-positive tissue cysts 
between the TgCEP221840 (Figure 18A) and TgVEG207210 (Figure 18B) knockouts relative 
to their passage-matched control. However, we did observe a significant decrease (P=0.0011) in 
the number of DBA-positive vacuoles for the TgVEG311100 parasites (~25%) as compared to 
their WT controls (~65%) (Figure 18C). These data suggest that TgVEG_311100 is an important 
factor for the stress-induction of cystogenesis. We named this factor Regulator of Cystogenesis 1 
(ROCY1). Previous work has identified another transcription factor, Bradyzoite-formation 
Deficient 1 (BFD1), that drives cystogenesis in T. gondii and results in a complete loss of tissue 
cyst formation in response to alkaline pH stress (132). Due to the importance of BFD1 in 
differentiation, we wanted to determine how disruption of ROCY1 compared to disruption of 
BFD1. Therefore, we generated TgVEG strains with a disruption in the BFD1 locus (Figure 17D) 
with the same passage history as our TgVEGROCY1 parasite strain to eliminate any impact of 
passage history on tissue cyst formation. We then performed a head-to-head comparison of tissue 
cyst formation in response to alkaline pH stress and found that the TgVEGBFD1 parasites failed 
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to form DBA-positive tissue cysts (Figure 18D), consistent with previously published results in 
type II strains of T. gondii (132). While a larger number of TgVEGROCY1 parasites were capable 
of forming DBA-positive vacuoles in response to pH compared to TgVEGBFD1 parasites, they 
again formed significantly fewer tissue cysts compared to the WT control (P=0.026). Furthermore, 
when quantifying tissue cyst formation, we observed that for those TgVEGROCY1 parasites that 
were DBA-positive the observed staining was less robust than the staining in WT parasites (Figure 
18F). Therefore, we quantified the DBA fluorescence intensity of all parasites and found a 
significant decrease in fluorescence intensity between TgVEGROCY1 and WT parasites 
(P<0.001), between TgVEGBFD1 and WT parasites (P<0.001), and between TgVEGROCY1 
and TgVEGBFD1 parasites (P=0.006) (Figures 18E-F). Together, this data suggests that ROCY1 
plays an important role in the development of tissue cysts in vitro. Furthermore, the 
partial/impaired tissue cyst formation phenotype in the TgVEGROCY1 parasites, as opposed to 
the near complete loss of DBA staining in the TgVEGBFD1 parasites, led us to hypothesize that 
ROCY1 may function downstream of BFD1.  
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Figure 18. Disruption of the ROCY1 locus impairs in vitro tissue cyst formation. 
A-C) Quantification of tissue cyst formation in knockout parasites A) TgCEPΔ221840 B) TgVEGΔ207210 C) 
TgVEGΔ311100 (ROCY1) and passaged matched WT strains after 48 hours of alkaline pH induced stress. The mean 
and standard deviation (N=3 biological replicates) of the percentage of DBA-positive vacuoles observed in 15 parasite 
containing fields of view is plotted. Statistical significance was determined using a Student’s one-tailed t-test on 
arcsine transformed percentage data. D) Quantification of tissue cyst formation in TgVEGΔROCY1, TgVEGΔBFD1, 
and passaged matched TgVEG WT strains after growth in control conditions or after 48 hours of alkaline pH induced 
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stress (pH 8.2). The mean and standard deviation (N=3 biological replicates) of the percentage of DBA-positive 
vacuoles observed in 15 parasite containing fields of view is plotted. Statistical significance was determined for the 
alkaline pH condition using a One-Way ANOVA with Tukey’s multiple comparisons tests on arcsine transformed 
percentage data. *P=0.0255, ****P <0.0001 E) Quantification of fluorescence intensity TgVEGΔROCY1 and 
TgVEGΔBFD1 from E. The mean and standard deviation of the fluorescence intensity (background corrected) is 
plotted. Each point represents a single vacuole. Black, gray, and white symbols indicate from which replicate (N=3) 
the intensity measurement was derived. Statistical significance was determined for alkaline pH conditions using a 
Brown-Forsythe and Welch ANOVA test with Dunn’s T3 multiple comparisons. ***P=0.0006 ****P <0.0001 G) 
Representative images of vacuoles exposed to alkaline pH stress for 48 hours. DNA was stained with DAPI (blue), 
the parasitophorous vacuole membrane (PVM) was stain with an anti-MAF1-b mouse polyclonal antibody (green), 
and tissue cysts were stained with rhodamine-labeled Dohlichos biflorus Agglutinin (DBA) (red). Scale bar represents 
10 µm. 
3.2.4 Disruption of the ROCY1 locus dramatically alters the alkaline pH-stress-induced 
transcriptional response  
To better understand how ROCY1 alters tissue cyst formation and compares with BFD1, 
we performed RNAseq on human foreskin fibroblasts (HFFs) infected with TgVEGROCY1, 
TgVEGBFD1, and TgVEG WT parasites exposed to either control growth conditions (pH 7.2) 
alkaline pH stress conditions (pH 8.2) for 48 hours. Using principal component analysis (PCA) to 
take a broad look at the transcriptional responses of these parasites (Figure 19A), we found that 
separation along PC1 (62%) mostly represented the effect of pH and nutrient stress. All parasites 
grown in control conditions (WT, TgVEGROCY1, TgVEGBFD1) clustered together along PC1 
with minor separation in TgVEGROCY1 and TgVEGBFD1 parasites from our TgVEG WT 
parasites along PCA2. Interestingly, we also saw a clear separation between TgVEG WT, 
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TgVEGROCY1, and TgVEGBFD1 exposed to stressed conditions on both PC1(62% of 
variance) and PC2 (9% of variance). Stressed TgVEG WT parasites were the most separated on 
PC1 compared to the control grouping but the least separated on PC2, while TgVEGBFD1 
stressed parasites separated the least on PC1 but were the most separated on PC2 (Figure 19A). 
TgVEGROCY1 parasites fell in the middle between the TgVEG WT and TgVEGBFD1 
parasites exposed to stressed conditions. This transcriptional data is consistent with the 
intermediate DBA-staining phenotype that we observed in our immunofluorescence assays (Figure 
18D-E).  
We next compared changes in transcript abundance by conducting differential expression 
analysis using differential expression analysis with DESeq2. We found that both TgVEGROCY1 
parasites and TgVEGBFD1 parasites exposed to control conditions had similar transcriptional 
profiles to TgVEG WT parasites exposed to control conditions as we did not identify any genes 
with significant changes in transcriptional abundance in either TgVEGROCY1 parasites or 
TgVEGBFD1 parasites in comparison to WT parasites (|Log2FC| > 1, Padj < 0.01) (Figure 19C-
D). These data suggest that disruption of ROCY1 or BFD1 does not play a significant role during 
tachyzoite growth. We next looked at the transcriptional changes that occur in TgVEGROCY1, 
TgVEGBFD1, and WT parasites in alkaline pH stress conditions (pH 8.2) relative to control 
conditions (pH 7.2). For WT parasites, as expected, we identified hundreds (265) genes with 
significant differences in transcriptional abundance in response to treatment with alkaline stress as 
compared to control conditions (|Log2FC| > 1, Padj < 0.01) (Figure 19B and E). However, the 
alkaline-stress-induced transcriptional response was dramatically impaired for both the 
TgVEGROCY1 parasites (54 genes with significant changes in abundance in stress conditions as 
compared to control conditions; Figure 19B and F) and TgVEGBFD1 parasites (43 genes with 
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significant changes in abundance in stress conditions as compared to control conditions; Figure 
19B and G). Overall, we found that 82% of the transcripts that change significantly in response to 
alkaline stress in WT parasites failed to change significantly when the ROCY1 locus was disrupted 
and 87% of those genes failed to change significantly when the BFD1 locus was disrupted (Figure 
19H). These findings suggest that ROCY1 is another critical regulatory factor involved in initiating 
and/or mediating the early alkaline pH stress response in T. gondii. Strikingly, we also found that 
74% of the transcripts that change in WT parasites no longer change significantly when either the 
ROCY1 locus or the BFD1 locus is disrupted (Figure 19H), suggesting that BFD1 and ROCY1 
regulate transcriptional abundance of the same set of genes or that BFD1 activates the expression 
of ROCY1 very early in the bradyzoite developmental pathway. This finding, along with the 
intermediate phenotype observed from in vitro tissue cyst formation and PCA analysis, led us to 
hypothesize that ROCY1 may be regulated by BFD1 and function immediately (or nearly 
immediately) downstream to alter the transcriptional response to alkaline stress. To begin to 
address this hypothesis, we took a closer look at ROCY1 and found that it is predicted to encode 
a 920-amino acid protein (126) that contains a predicted nuclear localization signal (diagramed in 
blue in Figure 19J) and 3 CCCH type Zinc finger domains (SMART accession SM000356; 
diagramed in yellow in Figure 19J, the second CCCH motif is split between exons 2 and 3). When 
we examined the upstream region predicted to include the promoter and transcriptional start site 
(2,300bp directly before the start codon) of ROCY1 (identified using our transcriptional data and 
BFD1 Cleavage Under Targets and Release Using Nuclease CUT&RUN data (132)) we found 3 
occurrences of a predicted BFD1 binding motif (CACTGG) within the previously identified 
CUT&RUN peaks (132), two of which were found downstream of the predicted transcriptional 
start site (TSS) and another found upstream of the TSS (diagramed in pink in Figure 19J). The 
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presence of BFD1 binding motifs, along with our transcriptional data, suggest that ROCY1 
transcription could be directly regulated by BFD1. To further investigate the hypothesis that BFD1 
is responsible for the regulation of ROCY1, we used DESeq2 to compare TgVEGROCY1 
parasites and TgVEGBFD1 parasites grown in alkaline pH stress conditions to TgVEG WT 
parasites grown in alkaline stress conditions to identify dysregulated genes. We found that in stress 
conditions, TgROCY1 transcript abundance is significantly decreased (Log2FC = -1.46, Padj < 
0.001) in TgVEGBFD1 parasites relative to WT parasites but TgBFD1 transcript did not change 
significantly in TgVEGROCY1 parasites relative to WT parasites (Log2FC = -0.58, Padj = 0.04) 
(Table 4). Furthermore, we found that the majority of the dysregulated genes (23 of 26) in 
TgVEGROCY1 parasites were also dysregulated in TgVEGBFD1 (Figure 19I). Most of the 
dysregulated genes were down regulated (18 of 26 in TgVEGROCY1 and 53 of 74 in 
TgVEGBFD1) and many of those genes are known bradyzoite genes such as CST1, BPK1, and 
MCP4 that are components of the cyst wall (91, 199, 205) (Table 4). Taken together these data 
suggest that ROCY1 functions as a positive regulator of bradyzoite transcription and is a likely 
downstream target of BFD1, and the significant overlap between BFD1- and ROCY1-dependent 




Figure 19. Disruption of the ROCY1 locus dramatically alters the alkaline pH-stress-induced transcriptional 
response. 
A) Principal components (PC) 1 and 2 of cells infected with TgVEG WT, TgVEGΔROCY1, and TgVEGΔBFD1 
expose to either control (●) or alkaline pH stress (▲) conditions for 48 hours. (B) Number of significantly different 
transcript observed for infection with TgVEG WT, TgVEGΔROCY1, and TgVEGΔBFD1 (|Log2 Fold Change| ≥ 1, 
Padj < 0.01). C-D) MA-plots representing changes in transcript abundance in TgVEGΔROCY1 (C) or TgVEGΔBFD1 
(D) infection compared to TgVEG WT infection in control conditions. Red dots (●) genes with a Padj value < 0.01. E-
G) MA-plots representing changes in transcript abundance in TgVEG WT (E), TgVEGΔROCY1 (F), or 
TgVEGΔBFD1 (G) infections in alkaline stress conditions compared to control conditions. Red dots (●) genes with a 
Padj value < 0.01. H) Venn diagram of genes with significant differences in transcript abundance in alkaline stress 
conditions compared to control conditions (|Log2 Fold Change| ≥ 1, Padj < 0.01). I) Venn diagram of genes with 
significant differences in transcript abundance in TgVEGΔBFD1 (pink) and TgVEGΔROCY1 (green) parasites 
compared to TgVEG WT parasites in alkaline stress conditions (|Log2 Fold Change| ≥ 1, Padj < 0.01). (J) Diagram of 
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ROCY1 locus showing predicted BFD1 binding sites both upstream and downstream of the predicted transcriptional 
start site, a predicted NLS, and 3 zinc finger CCCH motifs (second motif is split between exon 2 and 3). 
Table 4. Significantly dysregulated genes in TgVEGΔROCY1 and/or in TgVEGΔBFD1 parasites compared to 
TgVEG WT parasites in alkaine stress conditions 








TGME49_209755 hypothetical protein -4.14 4.31E-35 -9.30 1.04E-12 
TGME49_202020 DnAK-TPR -3.21 2.06E-20 -3.94 4.22E-16 
TGME49_280570 SRS35A -3.02 1.39E-34 -5.09 1.56E-26 
TGME49_311100 
zinc finger (CCCH type) 
motif-containing protein 
(ROCY1) 
-2.99* 3.75E-26* -1.46 4.69E-08 
TGME49_207160 SRS49D -2.91 2.99E-16 -8.83 3.57E-11 








-1.70 1.61E-09 -8.77 3.50E-11 










-1.52 6.67E-32 -3.91 3.17E-67 
TGME49_208730 MCP4 -1.51 2.15E-22 -6.90 5.87E-32 
TGME49_293780 hypothetical protein -1.46 2.56E-08 -2.64 6.23E-12 




-1.19 6.79E-04 --- --- 
TGME49_262710 
Ctr copper transporter 
family protein 
-1.17 6.60E-06 --- --- 
TGME49_275320 penicillin amidase -1.15 3.88E-07 --- --- 
TGME49_237170 hypothetical protein -1.11 2.68E-04 -1.62 1.23E-04 





1.12 8.80E-06 1.33 1.02E-05 
TGME49_315320 SRS52A 1.18 6.97E-09 1.12 9.32E-06 
TGME49_249300 hypothetical protein 1.21 5.80E-04 1.34 4.61E-03 
TGME49_276930 hypothetical protein 1.32 3.66E-04 1.38 5.89E-03 
TGME49_244280 hypothetical protein 1.39 1.05E-09 1.16 8.70E-05 
TGME49_250955 KRUF family protein 1.60 4.29E-05 2.08 5.43E-06 
TGME49_294990 hypothetical protein 1.96 5.81E-05 2.33 7.47E-05 
TGME49_253790 
zinc finger (CCCH type) 
motif-containing protein 
--- --- -7.77 9.28E-09 
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TGME49_259020 
bradyzoite antigen 1 
(BAG1) 
--- --- -7.61 5.23E-08 
TGME49_291040 
lactate dehydrogenase 2 
(LDH2) 
--- --- -7.40 5.47E-08 
TGME49_293790 hypothetical protein --- --- -7.34 1.17E-07 
TGME49_312330 hypothetical protein --- --- -4.48 1.14E-27 
TGME49_295960 hypothetical protein --- --- -4.02 8.18E-12 
TGME49_208740 MCP3 --- --- -3.80 1.02E-62 
TGME49_295950 KRUF family protein --- --- -3.42 1.45E-09 
TGME49_261650 hypothetical protein --- --- -2.75 1.10E-10 




--- --- -2.11 1.08E-08 
TGME49_315270 hypothetical protein --- --- -2.08 2.63E-13 
TGME49_225540 hypothetical protein --- --- -2.02 5.43E-10 
TGME49_249770 Nmda1 protein --- --- -1.82 5.83E-03 
TGME49_268790 hypothetical protein --- --- -1.77 3.11E-13 
TGME49_269660 
TFIIH basal transcription 
factor complex helicase 
XPB subunit 
--- --- -1.70 2.47E-03 
TGME49_213445 hypothetical protein --- --- -1.68 2.73E-06 
TGME49_260520 hypothetical protein --- --- -1.62 2.40E-04 
TGME49_290300 hypothetical protein --- --- -1.58 1.44E-04 
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TGME49_201840 aspartyl protease ASP1 --- --- -1.56 6.02E-06 
TGME49_297710 hypothetical protein --- --- -1.53 9.00E-03 
TGME49_226420 peptidase family M3 protein --- --- -1.42 6.65E-05 
TGME49_248990 hypothetical protein --- --- -1.36 1.04E-06 
TGME49_261970 hypothetical protein --- --- -1.36 1.44E-04 
TGME49_236010 prenylcysteine oxidase --- --- -1.31 5.07E-07 
TGME49_299030 
RNA recognition motif 2 
protein 
--- --- -1.27 1.55E-03 
TGME49_269690 hypothetical protein --- --- -1.27 2.62E-04 
TGME49_297340 hypothetical protein --- --- -1.24 1.04E-07 
TGME49_200385 
Myb family DNA-binding 
domain-containing protein 
(BFD1) 
--- --- -1.22* 1.39E-05* 
TGME49_262970 hypothetical protein --- --- -1.15 2.26E-03 
TGME49_269420 hypothetical protein --- --- -1.14 2.05E-03 
TGME49_296121 hypothetical protein --- --- -1.13 9.04E-05 
TGME49_245530 hypothetical protein --- --- -1.11 5.83E-03 
TGME49_247440 hypothetical protein --- --- -1.10 2.23E-07 
TGME49_262560 hypothetical protein --- --- -1.06 4.27E-04 
TGME49_215910 hypothetical protein --- --- -1.03 3.98E-05 




--- --- -1.02 2.82E-05 
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TGME49_203630 ribosomal protein RPL44 --- --- 1.01 6.70E-04 
TGME49_250115 hypothetical protein --- --- 1.06 1.20E-03 
TGME49_241300 hypothetical protein --- --- 1.06 8.92E-03 
TGME49_234550 ribosomal protein RPL29 --- --- 1.08 8.17E-10 
TGME49_211720 
AP2 domain transcription 
factor AP2IV-5 
--- --- 1.09 1.23E-04 
TGME49_308090 rhoptry protein ROP5 --- --- 1.15 2.59E-14 
TGME49_299780 hypothetical protein --- --- 1.17 6.65E-05 
TGME49_291890 microneme protein MIC1 --- --- 1.24 4.85E-19 
TGME49_241240 hypothetical protein --- --- 1.40 3.74E-25 
TGME49_239010 hypothetical protein --- --- 1.41 4.83E-04 
TGME49_252065 KRUF family protein --- --- 1.92 3.47E-06 
TGME49_233450 SRS29A (SUS1,SRS1) --- --- 2.09 7.43E-05 
TGME49_250950 KRUF family protein --- --- 2.12 5.44E-03 
*Transcriptional difference due to disruption of the TgVEGROCY1 and TgVEGBFD1 loci.  
3.2.5 Engineering TgVEG WT, TgVEGROCY1, and TgVEGBFD1 parasites to express 
GFP and luciferase 
To facilitate future experiments comparing TgVEG WT, TgVEGROCY1, and 
TgVEGBFD1 parasites, we inserted GFP under the control of the SAG1 promoter and Click 
Beetle Luciferase under the control of the DHFR promoter from the pClickLUC-GFP-SNR1HA 
plasmid via co-transfection with the pCRISPR-SNR1 plasmid (see materials and methods and 
 107 
Figure 20A), to disrupt the SNR1 gene which is a negative selectable marker that confers resistance 
to sinefungin, an known inhibitor of parasite growth (206). We then generated clonal parasites for 
each sinefungin resistant strain using limiting dilution and validated that these parasite strains 
expressed both luciferase (LUC) (Figure 20B) and GFP (Figure 20C). Because the SNR1 gene is 
a putative amino acid transporter and nutrient stress can impact differentiation (206), we verified 
that the tissue cyst formation phenotype in response to alkaline pH induced stress was the same as 
the non-GFP-LUC strains with an intact SNR1 gene by exposing these parasites to alkaline stress 
(pH 8.2) for 48 hours and quantifying tissue cyst formation as indicated by DBA (Figure 20D) 
staining and DBA fluorescence intensity (Figure 20E and 20F). We observed the same tissue cyst 
formation phenotype as we did for our non-GFP-LUC strains (Figure 20D-F), which demonstrates 
that the addition of GFP and luciferase to these parasite strains did not impact their ability to form 
tissue cysts in response to alkaline pH derived stress.  
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Figure 20. Engineering TgVEG WT, TgVEGROCY1, and TgVEGBFD1 parasites to express GFP and 
luciferase. 
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A) Schematic representing the strategy used to insert GFP and luciferase into the SNR1 gene (TgVEG_ 290860). B) 
Quantification of luciferase signal (photons/sec) after incubating 100,000, 50,000, and 25,000 parasites (TgVEG WT-
GFP-LUC, TgVEGΔROCY1-GFP-LUC, TgVEGΔBFD1-GFP-LUC, and TgVEG; PBS was used as a control) with d-
Luciferin for 10 minutes. C) Representative images showing GFP expressing parasites. Scale bar represents 100µm. 
D) Quantification of tissue cyst formation in TgVEGΔROCY1-GFP-LUC, TgVEGΔBFD1-GFP-LUC, and passaged 
matched TgVEG WT-GFP-LUC strains after growth in control conditions or after 48 hours of alkaline pH induced 
stress (pH 8.2). The mean and standard deviation (N=3 biological replicates) of the percentage of DBA-positive 
vacuoles observed in 15 parasite containing fields of view is plotted. Statistical significance was determined for the 
alkaline pH condition using a One-Way ANOVA with Tukey’s multiple comparisons tests on arcsine transformed 
percentage data. *P=0.0118, ****P <0.0001 E) Quantification of fluorescence intensity TgVEG WT-GFP-LUC, 
TgVEGΔROCY1-GFP-LUC, and TgVEGΔBFD1-GFP-LUC from E. The mean and standard deviation of the 
fluorescence intensity (background corrected) is plotted. Each point represents a single vacuole. Black, gray, and white 
symbols indicate from which replicate (N=3) the intensity measurement was derived. Statistical significance was 
determined for alkaline pH conditions using a Brown-Forsythe and Welch ANOVA test with Dunn’s T3 multiple 
comparisons. *P=0.0112, **P =0.0076 (WT vs ΔROCY1), and **P=0.0010 (WT vs ΔBFD1) G) Representative 
images of vacuoles exposed to alkaline pH stress for 48 hours. DNA was stained with DAPI (blue), parasites expressed 
GFP, and tissue cysts were stained with rhodamine labeled Dohlichos Biflorus Agglutinin (DBA) (red). Scale bar 
represents 10 µm. 
3.2.6 ROCY1 is necessary for brain tissue cyst formation during murine infections 
Our in vitro data as well our transcriptional data suggest that ROCY1 is an important 
regulator of cystogenesis and is likely induced early in the BFD1-driven cyst formation process. 
To determine if ROCY1 is also important for cyst formation in animals, we infected CBA/J mice 
with TgVEG WT-GFP-LUC, TgVEGROCY1-GFP-LUC, and TgVEGBFD1-GFP-LUC 
parasites and monitored pathogenesis, morbidity and mortality using multiple approaches 
including weight loss and in vivo bioluminescence imaging. Mice were first imaged at 3 h post-
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infection and we observed no significant differences in luciferase signal at this time point (P= 
0.089 TgVEG WT-GFP-LUC vs TgVEGROCY1-GFP-LUC, P=0.36 TgVEG WT-GFP-LUC vs 
TgVEGBFD1-GFP-LUC, and P=0.71 TgVEGROCY1-GFP-LUC vs TgVEGBFD1-GFP-
LUC). Parasite proliferation for all 3 strains were similar during the first 5 days of infection. At 
days 7 and 8 post infection, we observed a significant decrease in luciferase signal in the 
TgVEGROCY1-GFP-LUC parasites as compared to the TgVEG WT-GFP-LUC parasites 
(P=0.0350 at day 7 and P=0.0203 at day 8) (Figure 21A). All mice survived for the entire 21-day 
infection, demonstrating that there are no substantial differences in mortality between these 
parasite strains (Figure 21E-G). Interestingly, we observed a significant difference in the mass of 
the TgVEGBFD1-GFP-LUC infected mice as compared to the TgVEG WT-GFP-LUC infected 
mice at days 16 and 18 post-infection (P=0.0033 at day 16 post infection and P=0.032 at day 18 
post infection) (Figure21D). These data suggest that BFD1 knockout parasites may cause more 
severe disease at this late time point. 
After 3 weeks, we euthanized the infected mice and quantified the number of parasites per 
brain using quantitative PCR and the number of tissue cysts per brain using fluorescence 
microscopy. Mice infected with TgVEGROCY1-GFP-LUC parasites had significantly fewer 
parasites per brain as compared to both TgVEG WT-GFP-LUC and TgVEGBFD1-GFP-LUC 
infected mice (P=0.0001 for TgVEGROCY1-GFP-LUC vs TgVEG WT-GFP-LUC and P=0.0085 
for TgVEGROCY1-GFP-LUC vs TgVEGBFD1-GFP-LUC) (Figure 21B). These data suggest 
that ROCY1 is important for either 1) survival of the parasites during chronic infection or 2) for 
the parasites ability to colonize the brain. Despite being able to isolate and quantify tissue cysts 
from the brains of mice infected with TgVEG WT-GFP-LUC we failed to isolate tissue cyst from 
the brains of mice infected with either TgVEGROCY1-GFP-LUC and TgVEGBFD1-GFP-LUC 
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(limit of detection = 40) (Figure 21C). This result demonstrates that, like BFD1, ROCY1 is 
necessary for tissue cyst formation in murine brains. These data suggest that ROCY1 is also a 
critical parasite factor needed for the establishment of a chronic infection in vivo, and again 
emphasizes that its position in the bradyzoite development pathway may be very proximal to BFD1 
as suggested by our transcriptional analyses. 
 
Figure 21. ROCY1 is necessary for tissue cyst formation and the establishment of chronic infection in mice. 
A) Quantification of bioluminescent imaging of mice infected with TgVEG WT-GFP-LUC, TgVEGROCY1-GFP-
LUC, and TgVEGBFD1-GFP-LUC parasite (N=6). Each point represents an individual mouse and the line represents 
the mean. Statistical significance was determine using a repeated-measures two-way ANOVA with Geisser-
Greenhouse correction and Tukey’s multiple comparisons test on log transformed total flux data. *P=0.0350 (D7) 
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*P=0.0203 (D8). A-Inset) Luciferase signal from 250,000 extracellular parasites immediately after infection. 
Statistical significance was determined using a Brown-Forsythe and Welch ANOVA with Dunn’s T3 multiple 
comparisons test. ****P <0.0001 B) Quantification of parasite genomes per brain in infected mice at 3 weeks post 
infection. Mean and standard deviation are plotted. Each point represents and individual mouse. Statistical significance 
was determined using a one-way ANOVA with Tukey’s multiple comparison test on ΔCt values. **Padj=0.0085 
***Padj=0.0001 C) Brain tissue cysts burden observed in infected mice at 3 weeks post infection. Mean and standard 
deviation are plotted. Each point represents and individual mouse. Limit of detection = 40. Statistical significance was 
determined using a Kruskal-Wallis test with Dunn’s multiple comparisons. **P=0.0015 D) Average mass of infected 
mice normalized to initial mass during the 3-week infection. Mean (line) and standard deviation are plotted. Statistical 
significance was determined using using a repeated-measures two-way ANOVA with Geisser-Greenhouse correction 
and Tukey’s multiple comparisons test.  *P=0.0324 **P=0.0033 E-G) Survival curves for mice infected with E) 
TgVEG WT-GFP-LUC, F) TgVEGROCY1-GFP-LUC, and G) TgVEGBFD1-GFP-LUC. 
3.2.7 Reactivation in ROCY1 parasites is delayed compared to wild type and BFD1 
parasites 
Even though we failed to observe tissue cysts in the brains of either the TgVEGROCY1-
GFP-LUC and TgVEGBFD1-GFP-LUC parasites, we wanted to determine if these parasite 
strains were able to establish a chronic infection that could reactivate and lead to morbidity and 
mortality in mice. To determine if reactivation was possible, we infected mice with TgVEG WT-
GFP-LUC, TgVEGROCY1-GFP-LUC, and TgVEGBFD1-GFP-LUC parasites and assigned 
them to either the control group (N=6) or the reactivation group (N=6). On day 30 post infection, 
mice in the reactivation group were given dexamethasone in their drinking water to induce 
reactivation and subsequent reactivation was monitored using bioluminescence imaging (165, 
207). We monitored reactivation by imaging the infected mice on days 4, 6, 7, 8, 10, 12, and 14 
 113 
after dexamethasone treatment (Figure 22A-B). On day 4 post-dexamethasone treatment, one 
mouse in the TgVEGROCY1-GFP-LUC infection/dexamethasone treatment group died likely 
due to handling or because of an adverse reaction to anesthesia (Figure 22B, indicated by ☨). We 
removed this mouse from future analyses quantifying parasite burden using luminescence. We 
observed a significant increase in luciferase signal measured as total flux in dexamethasone-treated 
mice infected with TgVEG WT-GFP-LUC parasites as compared to control mice at day 4 post-
dexamethasone treatment (Padj=0.038) and at day 8 post dexamethasone treatment (Padj=0.0466) 
(Table 4), indicative of reactivation. We observed similar results for the dexamethasone-treated 
mice infected with TgVEGBFD1-GFP-LUC parasites, where we found a significant increase in 
luciferase signal on days 6, 7, 8, 10, and 14 post-dexamethasone treatment in dexamethasone-
treated mice compared to controls (Figure 22B, Table 5). However, for dexamethasone-treated 
mice infected with TgVEGROCY1-GFP-LUC parasites, reactivation was delayed in comparison 
to mice infected with TgVEG WT-GFP-LUC and TgVEGBFD1-GFP-LUC, as we only found a 
significant difference in luciferase signal between control and dexamethasone-treated mice 
infected with TgVEGROCY1-GFP-LUC on day 8 post dexamethasone treatment, 4 days later 
than initially observed for TgVEG WT-GFP-LUC infection and 2 days later than initially observed 
for TgVEGBFD1-GFP-LUC infection, and this increase in average luciferase signal for 
TgVEGROCY1-GFP-LUC parasites continued to be observed on days 10 and 12 post-
dexamethasone treatment (Figure 22B). We also observed a significant increase in luciferase signal 
in dexamethasone-treated mice infected with TgVEGBFD1-GFP-LUC as compared to 
dexamethasone treated mice infected with TgVEGROCY1-GFP-LUC on days 7, 8, 10, and 14 
following dexamethasone treatment (Table 5). Overall, these data indicate that ROCY1 parasites 
are significantly impaired in their brain colonization during the acute phase of infection and/or in 
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their ability to persist in the brain (Figure 21B), and that this results in a delayed reactivation 
phenotype compared to WT and BFD1 parasites.  






















0 0.3239 0.0677 0.9865 0.599 0.1604 0.832 
4 0.038 0.1201 0.1762 0.7631 0.8724 0.9986 
6 0.2192 0.2778 0.0157 0.5238 0.9569 0.0858 
7 0.0712 0.0731 0.0033 0.7577 0.4502 0.0225 
8 0.0446 0.0306 <0.0001 0.9977 0.7285 0.0702 
10 0.0578 0.091 0.0062 0.8985 0.2222 0.0275 
12 0.0816 0.0816 0.0922 0.8056 0.5897 0.069 
14 0.0732 0.0666 0.0016 0.652 0.796 0.0217 
Repeated measures two-way ANOVA with Geisser-Greenhouse correction and Sidak’s multiple comparisons 
performed on log transformed total flux data from reactivation infection. 
We also looked at the difference in the survival of mice infected with TgVEG WT-GFP-
LUC, TgVEGROCY1-GFP-LUC, and TgVEGBFD1-GFP-LUC and treated with 
dexamethasone. We found that dexamethasone treated mice infected with TgVEGBFD1-GFP-
LUC died significantly sooner than dexamethasone treated mice infected with TgVEG WT-GFP-
LUC (Log-rank (Mantel-Cox) test, Bonferroni-corrected threshold for multiple comparisons = 
0.017, P=0.0020) and dexamethasone-treated mice infected with TgVEGROCY1-GFP-LUC 
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(P=0.0136) (Figure 22C). We observed no difference in survival for dexamethasone-treated mice 
infected with TgVEG WT-GFP-LUC and TgVEGROCY1-GFP-LUC. Taken together, our data 
suggest that despite having a delayed reactivation phenotype, infection with parasites lacking 
ROCY1 does not seem to have a significant impact on survival.  
In addition to monitoring reactivation, we also quantified the number of parasites in the 
brain as well as the number of brain cysts from the mice in our control (normal drinking water) 
group at 9 weeks post infection. We found significantly fewer TgVEGROCY1-GFP-LUC and 
TgVEGBFD1-GFP-LUC parasites in the brain as compared to TgVEG WT-GFP-LUC (Figure 
22E). This result differed from our quantification of parasites in the brain at 3 weeks post infection, 
where we only found fewer TgVEGROCY1-GFP-LUC parasites compared to TgVEG WT-GFP-
LUC (while TgVEGBFD1-GFP-LUC parasite numbers were similar to TgVEG WT-GFP-LUC 
parasite numbers) (Figure 21B). While these results are not directly comparable, as they are from 
two different experiments, they suggest that parasites lacking BFD1 are eliminated from the brain 
as infection progresses while those lacking ROCY1 may be primarily impaired in brain 
colonization. Similar to our experiment performed at 3 weeks post-infection, we again were unable 
to identify any tissue cysts in the brains of mice infected with either TgVEGROCY1-GFP-LUC 
and TgVEGBFD1-GFP-LUC parasites (limit of detection = 7) at 9 weeks post infection (Figure 
22F). This result further demonstrates that ROCY1, like BFD1, is necessary for tissue cyst 




Figure 22. TgVEGΔROCY1 parasites display a delayed reactivation phenotype 
A) Select bioluminescent images showing parasites-derived luciferase signal in CBA/J mice infected with TgVEG 
WT-GFP-LUC, TgVEGROCY1-GFP-LUC, and TgVEGBFD1-GFP-LUC parasites and treated with 
dexamethasone (20mg/L) provided in their drinking water.  B) Quantification of bioluminescent imaging of mice 
infected with TgVEG WT-GFP-LUC, TgVEGROCY1-GFP-LUC, and TgVEGBFD1-GFP-LUC parasite 
belonging to either the control group (N=6 per parasite strain) or the dexamethasone treatment group (N=6 per parasite 
strain). Each point represents an individual mouse, and the line represents the mean. The double cross symbol (☨) 
represents death due to handling/anesthesia. Statistical significance was determined using a repeated measures two-
way ANOVA with Geisser-Greenhouse correction and Tukey’s multiple comparisons performed on log transformed 
total flux data. Annotations represent dexamethasone group compared to control group for each parasites strain. Blue 
annotations represent TgVEG WT-GFP-LUC, green annotations represent TgVEGROCY1-GFP-LUC, and pink 
annotations represent TgVEGBFD1-GFP-LUC. C) Survival of mice in the infection described in A and B. D) 
Average mass of infected mice normalized to initial mass during the infection. Mean and standard deviation are 
plotted. E) Quantification of parasite genomes per brain in infected mice from the control group at 9 weeks post 
infection. Mean and standard deviation are plotted. Each point represents and individual mouse. Statistical significance 
was determined using a one-way ANOVA with Tukey’s multiple comparison test on ΔCt values. ****Padj<0.001 F) 
Brain tissue cysts burden observed in infected mice from the control group at 9 weeks post infection. Mean and 
standard deviation are plotted. Each point represents and individual mouse. Limit of detection =7. Statistical 
significance was determined using a Kruskal-Wallis test with Dunn’s multiple comparisons. **Padj=0.0017 for TgVEG 
WT-GFP-LUC vs TgVEGROCY1-GFP-LUC, **Padj=0.0032 for TgVEG WT-GFP-LUC vs TgVEGBFD1-GFP-
LUC. 
3.3 Discussion and conclusions  
The formation of bradyzoites and tissue cysts are fundamental for the success of T. gondii 
as these life stages play a critical role in transmission, reproduction, and disease progression. The 
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formation of bradyzoites is necessary for the establishment of chronic infection which is 
fundamentally important for persistence of the parasite within its host and transmission to the next 
host (11, 12, 76, 151). Despite the importance of bradyzoites, our understanding of the 
developmental pathways and the regulatory networks used by T. gondii to differentiate into these 
life stages is only starting to be elucidated. By using cross-species comparisons with H. hammondi 
at critical developmental time points, we have identified a previously uncharacterized parasite 
gene, ROCY1, that is important for tissue cyst formation in vitro and in vivo.  
Our in vitro cyst induction assays along with our transcriptional analysis suggest that 
ROCY1 is critical for bradyzoite development. Our transcriptional data suggests that ROCY1 has 
a role in increasing the transcriptional abundance of key bradyzoites transcripts, such as DnAK-
TPR, CST1, BPK1, and MCP4. Some of these bradyzoite specific transcripts have also been shown 
to be regulated by other known transcription factors such as the bradyzoite transcriptional 
repressors AP2IX-4 (130) AP2IV-4 (129), AP2IX-9 (127), and bradyzoite transcriptional 
activators AP2XI-4 (131) and AP2IV-3 (128). We identified extensive overlap in the dysregulated 
genes in TgVEGROCY1 parasites as compared to TgVEGBFD1 parasites (Figure 19 H and L), 
implying that ROCY1 functions downstream of BFD1. Moreover, our data suggests that ROCY1 
is partially regulated by BFD1. This regulation is further supported by the presence of multiple 
BFD1 binding motifs in the promoter of ROCY1 (132). These findings demonstrate that ROCY1 
is proximal to BFD1 in the bradyzoite developmental pathway and plays a critical role in regulating 
the formation of tissue cysts. The potential link between BFD1 and ROCY1 provides a foundation 
for the identification of a gene regulatory network utilized by T. gondii to transition to the 
bradyzoite life stage. 
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The mechanistic role of ROCY1 in bradyzoite development is currently unclear. Our 
efforts to complement our TgVEGROCY1 parasites have not yet been successful, despite 
numerous attempts. The predicted amino acid sequence of ROCY1 indicates that this protein 
contains 3 tandem CCCH zinc finger domains (diagramed in Figure 19I). While zinc finger 
proteins are typically viewed as DNA-binding transcription factors, proteins containing CCCH 
zinc finger domains are known to bind RNA (208, 209). Interestingly, RNA binding proteins with 
CCCH zinc finger domains have been implicated in the regulation of growth and stress responses 
in plants, response to oxidative stress in mammalian cells, and the regulation of immune responses 
(209). CCCH zinc fingers have also been known to promote RNA deadenylation and degradation 
by binding to AU rich elements in the 3’ UTRs of mRNA transcripts (210). T. gondii RNA binding 
proteins, such as TgAlba1, and TgAlba2, are involved in bradyzoite development and function in 
translational control (138). These findings along with the functions of CCCH zinc fingers suggest 
that ROCY1 could interact with mRNA and regulate transcripts of key developmental genes 
induced during the alkaline pH stress response in T. gondii. 
In addition to our transcriptional data, our in vivo data from mice infected with parasites 
lacking ROCY1 demonstrated that ROCY1 is a poor colonizer of the murine brain. We failed to 
isolate brain cysts from mice infected with TgVEGROCY1 parasites (Figure 21C and Figure 
22F). The complete lack of in vivo brain tissue cyst formation is not commonly observed when 
other important bradyzoite genes, such as CST1 (143), BAG1 (211), AP2XI-4 (131), AP2IX-4 
(130), BPK1 (145), LDH2 (212), and MAG1 (213), are ablated. These findings make the ROCY1 
phenotype so striking and suggest that it is a necessary factor for differentiation. A complete loss 
of in vivo brain cyst formation has been previously observed following infection with parasites 
lacking BFD1 (132) and AP2IV-4 (129), both an inducer and repressor of tissue cyst formation, 
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respectively. In addition to the complete loss of tissue cyst formation in the murine brain, we also 
observed a significant decrease in the number of parasites found in the brains of mice infected with 
TgVEGROCY1 parasites. This significant decrease in the number of parasites in the brain is also 
found in parasites lacking AP2IV-4 and has been attributed to an increase in inflammatory 
monocytes in mice infected with these parasites. It is possible that mice infected with parasites 
lacking ROCY1 have a similar altered immune response and are easier for the mouse to clear 
during the early stages of infection. Understanding the immune pressures associated with this 
phenotype will be important for our understanding of the establishment of chronic infection in 
addition to the generation of novel therapeutics to target these currently untreatable life stages.  
Given the importance of the tissue cysts for allowing parasites to reside in host tissue 
without being continually subjected to immune pressures during chronic infection (17, 26), we 
were surprised that parasites lacking ROCY1, in addition to parasites lacking BFD1, were able to 
reactivated and cause a systemic infection following immune suppression with dexamethasone. 
To our knowledge, no other reactivation studies have been performed with parasites lacking 
critical bradyzoite factors. However, host immunity is thought to kill the majority of tachyzoites 
during the acute phases of infection and is hypothesized to promote the survival of bradyzoites by 
either eliminating tachyzoites or by inducing bradyzoite development (77). If the majority of 
tachyzoites are killed by host immunity, the ability of TgVEGROCY1 and TgVEGBFD1 to 
reactivate when treated with dexamethasone after 30 days of infection suggests that either 1) some 
tissue cyst formation is occurring in the infected mice at levels below the detection threshold in 
the brain, 2) tissue cysts are forming in other tissues (such as muscle, spleen, or liver) instead of 
forming in the brain, or 3) these parasites can survive in the mouse despite being unable to form 
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tissue cysts, potentially as a transitional life stage that can survive immune pressure without 
forming a tissue cysts.  
Our data also showed that mice infected with parasites lacking BFD1 reactivate faster and 
die sooner than mice infected with parasites lacking ROCY1 (Figure 22B-C). This difference in 
reactivation could be explained by increased parasite burden in the brains of mice infected with 
parasites lacking BFD1 compared to parasites lacking ROCY1 at 3 weeks post infection (Figure 
21B). For these experiments, we started dexamethasone treatment at day 30 post infection (~4 
weeks), which should allow adequate time for tissue cyst formation to occur (214, 215). However, 
30 days may not have been an adequate amount of time for TgVEGBFD1 parasites to be cleared 
from the brain, especially since the brain parasite burden of mice infected with TgVEGROCY1 
and TgVEGBFD1 were similar at 9 weeks post infection (Figure 22E). It would be interesting to 
profile the parasite and host transcriptome from infected brains at various time points to determine 
how/if these parasites differentiate during in vivo infection to determine if there is a biological 
reason attributed to the parasite or the host that allows for faster reactivation in mice infected with 
TgVEGBFD1 parasites as compared to infection with TgVEGROCY1.  
Taken together, these findings demonstrate that ROCY1 is an important parasite factor for 
bradyzoite development in T. gondii and contributes to the development of a gene regulatory 
network used by these parasites to initiate the changes required for effective stage conversion. 
Future studies investigating the role of these factors in bradyzoite development in other parasite 
species, such as H. hammondi, that also rely on bradyzoite development for success, will help 
compare the strategies used by each species to progress to the bradyzoite life stage. Understanding 
the complexities of bradyzoite development associated between species has the potential to shed 
light on the fundamental differences attributed to each parasite’s unique life cycle.  
 122 
3.4 Materials and methods 
3.4.1 Host cell and parasite strains 
Toxoplasma gondii strain VEG (TgVEG) (162) and Hammondi hammondi strain 
HhCatAmer (HhAmer) (5) were isolated from oocysts from experimentally infected cats provided 
by J.P Dubey as previously describe (44, 216). The Toxoplasma gondii strain CEPHXGRPT-
GFP-LUC (TgCEP) (217)was also used. All T. gondii parasites were maintained through passage 
in Human foreskin fibroblasts (HFFs) cultivated with DMEM supplemented with 100U/mL 
penicillin, 100µg/mL streptomycin, 2mM L-glutamine, and 10% FBS (cDMEM) and maintained 
at 37 degrees C, 5% CO2. 
3.4.2 Oocyst excystation  
Sporozoites were harvested from oocysts as previously described (44, 216). Following 
excystation, sporozoites were used to infected confluent monolayers of HFFs grown in T-25 tissue 
culture flasks and incubated at 37 degrees C, 5% CO2 for 24 hours. Following the initial 24-hour 
incubation, the infected monolayers were scrape, syringe lysed with a 25G needle, and filtered 
through a 5µm syringe driven filter. Zoites were then pelleted and counted to set up subsequent 
infections.  
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3.4.3 RNAseq of H. hammondi (HhAmer) and T. gondii (TgVEG) in control and bradyzoite 
induction conditions 
HFFs were infected with 24 hour “zoites” at an MOI of 0.5 for T. gondii and 8.5 for H. 
hammondi. After 48 hours (3DPE), infected host cells were exposed to either bradyzoite induction 
media, pH 8.2, (119) or control media, cDMEM pH 7.2, for 48 hours. At 48 hours, the infected 
host cells were washed with PBS and RNA was harvested using the RNeasy Mini Kit 9(Qiagen). 
Total isolated RNA was processed for next generation sequencing as previously described (44). 
CLC Genomics Workbench was used to map all fastq reads to either the T. gondii genome or the 
H. hammondi genome as previously described (44). Total gene counts were exported from CLC
and filtered so that only genes with a total of 10 reads across all parasite-specific samples were 
used for differential expression analysis using DESeq2 (193). A total of 7,182/8,920 genes were 
analyzed for T. gondii and 6106/7266 for H. hammondi. Venn diagrams were created with 
BioVenn (218) and Venn Diagram Plotter software (219). Heat maps were generated with MeV 
4.9.0 (220).  
3.4.4 Disruption of candidate gene loci 
The CRISPR/Cas9 gene editing strategy was used to disrupt loci of candidate genes. For 
each candidate gene specific guide RNAs (gRNAs) were designed using the E-CRISP design tool 
(Toxoplasma gondii genome, medium setting). The gene specific gRNAs were incorporated into 
a version of the the pSAG1::CAS9-U6::sgUPRT plasmid provided by the Sibley lab (172) that 
was engineered to so that the UPRT gRNA was replaced with an PseI and FseI restriction site 
(221) (pCRISPR_ENZ) using Q5 mutagenesis (NEB) and verified with Sanger sequencing. Linear
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repair constructs encoding either the HXGPRT and DHFR-TS selectable markers under the control 
of the DHFR 5’ and 3’ UTR were amplified from either the pGRA_HA_HPT (69) or pLIC-3HA-
DHFR (112) using Platinum® Taq DNA Polymerase High Fidelity with High Fidelity PCR buffer 
and 110ng of template per reaction according to the manufacturer’s reaction conditions. 
Approximately 10x106 parasites were transfected with 25µg of the NheI-HF linearized CRISPR 
plasmid and 2.5µg of the appropriate linear repair cassette in 800µL of Cytomix (10mM KPO4, 
120mM KCL, 5mM MgCl2, 25mM HEPES, 2mM EDTA) supplemented with 2mM ATP and 
5mM glutathione using a BTX electroporation system – Electro Cell Manipulator 600 (2.4kV Set 
Charging Voltage, R3 Resistance timing). Transfection reactions were incubated at room 
temperature for 5 minutes before infecting confluent monolayers of HFFs. After ~24 hours, the 
infected host cells were grown in selection media containing cDMEM supplemented with 
mycophenolic acid (25µg/mL) and xanthine (50µg/mL) for TgCEP or cDMEM with 1µM 
pyrimethamine for TgVEG to select for parasites that incorporated the repair cassettes containing 
the selectable markers. After a stable population of parasites capable of growing in selection media 
was obtained, clonal population were obtained through serial dilution. Genomic DNA was isolated 
from the clonal populations and used to verify disruption of the candidate gene locus with the 
selectable marker with PCR (2x BioTMMix Red used according to manufacturer’s specifications, 
25-50ng of genomic DNA per reaction) Amplified products were visualized with 1% agarose gels 
run at 90 volts for 25-40 minutes. The GeneRuler 1kb Plus DNA Ladder was used to estimate the 
size of the amplified products.  
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3.4.5 Alkaline pH-stress-induced tissue cyst formation assays 
Confluent monolayers of HFFs grown on acid-etched coverslips in 24-well plates were 
infected with T. gondii at an MOI ranging from 0.25 to 1 depending on experiment. MOIs were 
the same for all tissue cyst formation assays performed on the same day. Parasites were grown for 
48 hours and then their media was replaced with either control media (cDMEM pH 7.2) or 
bradyzoite induction media, pH 8.2, (119). Parasites grown in control conditions were incubated 
at 37 degrees C, 5% CO2 and parasites grown in alkaline pH stress conditions were incubate at 37 
degrees C with ambient CO2 (0.03%). Control or bradyzoite induction media was replaced every 
24 hours. After 48 hours of alkaline pH stress, infected coverslips were washed 2X with PBS, fixed 
with 4% paraformaldehyde in PBS, washed 2x with PBS, and stored in PBS at 4 degrees C until 
immunostaining was performed.  
3.4.6 Immunofluorescence assays  
Fixed coverslips were blocked with 5% BSA in PBS with 0.15% Triton-X 100 for 1 hour 
at room temperature. Coverslips infected with TgVEG WT, TgVEG311100 (ROCY1), 
TgVEG200385 (BFD1), TgVEG207210, and TgCEP221840 were stained with a primary 
polyclonal anti-MAF1b from mouse serum (1:1,000 dilution). After primary staining, the 
coverslips washed with PBS, stained with secondary goat anti-mouse Alexa-fluor 488 antibody 
and Rhodamine-labeled Dolihos Biflourus Agglutin (1:250) and washed with PBS. GFP-LUC 
parasite strains were only stained with Rhodamine-labeled Dolihos Biflourus Agglutin (1:250). 
Coverslips were then mounted using ProLong Diamond Antifade mountant with DAPI and 
allowed to cure overnight at room temperature.  Coverslips were blindly observed with a 100X 
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objective on an Olympus IX83 microscope with cellSens software. The percentage of DBA-
positive vacuoles was determined by counting vacuoles from 15 randomly chosen, parasite 
containing fields of view. Images were exported as .tiff files and average fluorescence intensity 
per pixel was quantified using ImageJ software and corrected for background fluorescence 
intensity.  
3.4.7 RNAseq of TgVEGROCY1 and TgVEGBFD1 in control and bradyzoite induction 
conditions 
Confluent monolayers of HFFs grown in 24-well plates were infected with TgVEG WT, 
TgVEGROCY1, and TgVEGBFD1 parasites at an MOI of 0.5. Parasites were grown in control 
conditions (cDMEM pH 7.2, 37 degrees C, 5% CO2) for 48 hours. After 48 hours the media was 
replaced with either control media (cDMEM pH 7.2) or bradyzoite induction media, pH 8.2, (119). 
Infected host cells grown in control conditions were incubated at 37 degrees C, 5% CO2 and 
infected host cells grown in bradyzoite induction media were incubated at 37 degrees C with 
ambient CO2 (0.03%). Control or bradyzoite induction media was replaced every 24 hours. After 
48 hours of growth in bradyzoite induction conditions, all infected host cells were washed with 
PBS and total RNA was harvested using the RNeasy Mini Kit 9 (Qiagen). This RNA was then 
processed for next generation sequencing as previously described (44). Fastq files were first 
mapped to the human genome to remove host transcripts, Hg38 using CLC Genomics Workbench 
(default mapping settings for reverse strand sequencing, similarity fraction adjusted to 0.95) and a 
file of unmapped reads was generated for each sample. Unmapped reads were then mapped to the 
T. gondii genome (TgME49 v38) (default mapping settings for reverse stand sequencing). Total 
gene counts were exported from CLC and filtered so that a gene was only included for differential 
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expression analysis using DESeq2 (193) if there were a total of 30 or more reads across all samples. 
A total of 5,970/8,920 genes were analyzed. Venn diagrams were created with BioVenn (218) and 
Venn Diagram Plotter software (219).   
3.4.8 Generation of GFP luciferase parasites  
TgVEG WT, TgVEGROCY1, and TgVEGBFD1 parasites were modified to contain 
GPF and click beetle luciferase using the pClickLUC-GFP plasmid (222). A gRNA targeting the 
SNR1 gene in T. gondii (TgVEG_290860) was designed using the E-CRISP design tool 
(Toxoplasma gondii genome, medium setting) and incorporated into the pCRISPR_ENZ plasmid 
using Q5 mutagenesis and verified with Sanger sequencing (pCRISPR_SNR1). Homology arms 
corresponding to the 20bp sequencing flanking the Cas9 cut site were inserted to the pClickLUC-
GFP plasmid (pClickLUC-GFP_SNR1-HA) using Q5 mutagenesis and verified with Sanger 
sequencing. Approximately 10x106 TgVEG WT, TgVEGROCY1, and TgVEGBFD1 parasites 
were transfected with 25µg of the (pCRISPR_SNR1) and 25µg of the pClickLUC-GFP_SNR1-
HA as described above. After ~24 hours, the infected host cells were grown in selection media 
containing cDMEM and 3x10-7M sinefungin. After a stable population of sinefungin resistant 
parasites were obtain, parasites were cloned using limiting dilution and screened for expression of 
GFP using an Olympus IX83 inverted fluorescent microscope. To screen GFP positive parasite 
clones for luciferase expression, parasites were scraped, syringe lysed with a 25- and 27-gauge 
needle, pelleted, and resuspended in PBS at a concentration of 500,000 parasites/mL, 250,000 
parasites/mL, and 125,000 parasites/mL. For each concentration of parasites, 200µL was added to 
each well of a black 96 well plate (100,000, 50,000, and 25,000 parasites per well) in triplicate and 
50µL of d-Luciferin potassium salt was added to each well. Parasites were incubated with d-
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Luciferin at room temperature for 10 minutes and the luciferase signal was measure using an IVIS 
Lumina II in vivo bioluminescence imaging system. Non-luciferase expressing parasites and PBS 
were also used as controls for this experiment. To determine if the addition of GFP and luciferase 
altered tissue cyst formation, tissue cyst formation assays and immunofluorescence assays were 
performed as described above except parasites were only maintained in control conditions 
(cDMEM, pH 7.2) for 24 hours before the alkaline pH induction was performed.   
3.4.9 Murine TgVEG WT-GFP-LUC, TgVEGROCY1-GFP-LUC, and TgVEGBFD1-
GFP-LUC infections 
For in vivo infections, 5-week-old CBA/J female mice (Jackson Laboratories) were 
infected with 250,000 TgVEG WT-GFP-LUC, TgVEGROCY1-GFP-LUC, and TgVEGBFD1-
GFP-LUC parasites (N=6) in 200 µL of PBS via intraperitoneal injection. Mice were imaged 
ventrally using a 4 minute exposure and large binning at 3 hours post infection and on days 1-5, 
7-8, 10, and 12 post infection 10 minutes following intraperitoneal injection with 200 µL of d-
Luciferin potassium salt as previously described (165). After 21 days of infection, mice were 
sacrificed and whole brains were removed. A brain homogenate was prepared by passing whole 
brains through a 100 µm cell strainer using 5mLs of PBS. An additional 20 mLs of PBS was added 
to the homogenate and it was pelleted by spinning at 1,000 xg for 5 minutes. The supernatant was 
discarded, and the pellet was resuspending in 1mL of PBS, which produced a final volume of 1.2 
mLs of brain homogenate.  
To quantify the number of parasite genomes in the brain homogenate, genomic DNA was 
extracted from 100 µL of brain homogenate using the GeneJET genomic DNA isolation kit 
according to manufacturer’s instructions. qPCR was used to quantify the total number of genomes 
 129 
using primers targeting the T. gondii B1 gene and primers targeting mouse GAPDH as a control 
gene. All reactions were performed in duplicate using a QuantStudio 3 Real-Time PCR System. 
Samples were analyzed in 10 µL reactions consisting of 5 µL of 2X SYBR Green 2X master mix, 
1 µL of 5 µM forward and 5 µM reverse primers, 2 µL of ddH2O, and 2 µL of genomic DNA. 
Cycling and melt curves were performed as previously (44) . To determine the total number of 
parasite genomes per brain, a standard curve of known parasite numbers was also performed using 
T. gondii B1 primers. Statistical significance was determine using CT (TgB1 CT - mGAPDH CT) 
values. 
To quantify in vivo tissue cyst formation, 100 µL of brain homogenate was fixed with 900 
µL of 4% paraformaldehyde in PBS for 20 minutes. Fixed samples were pelleted at 5,200xg for 5 
minutes, washed with 1mL of PBS, resuspended in 1 mL of PBS, and stored at 4 degrees C. Fixed 
brain homogenate was stained with Rhodamine-labeled Dolichos Bifluorus Agglutinin (1:150) 
overnight at 4 degrees C with rotation. The following day, samples were pelleted (5,200 xg for 5 
minutes) washed with 1 mL of PBS, pelleted, and resuspending in 1mL of PBS. For each sample, 
50µL of stained homogenate (total of 300 µL) was added to 6 wells of a flat-bottomed 96 well 
plate and tissue cysts were blindly counted using an Olympus IX83 fluorescent microscope using 
the 10X objective. Cyst burdens were calculated by multiplying the total number of tissue cyst 
observed in the 300 µL of brain homogenate by the dilution factor.   
3.4.10 Reactivation of chronic murine infections with TgVEG WT, TgVEGROCY1, and 
TgVEGBFD1  
For in vivo infections, 6-week-old CBA/J female mice (Jackson Laboratories) were 
infected with 250,000 TgVEG WT-GFP-LUC, TgVEGROCY1-GFP-LUC, and TgVEGBFD1-
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GFP-LUC parasites (N=12) in 200 µL of PBS via intraperitoneal injection. For each parasite, 6 
mice were assigned to either the control group or the reactivation group. The reactivation group 
was given dexamethasone (20 mg/L) in their drinking water beginning at day 30 post infection. 
Mice were imaged (as described above) prior to dexamethasone treatment (0 days post 
dexamethasone) on days 4, 6, 7, 8, 10, 12, and 14 post-dexamethasone treatment. Peritoneal cells 
were collected from moribund mice and used to infect HFFs grown in T-25s. The mice belonging 
to the control group were sacrificed at 9 weeks post infection. Whole brains were removed, and a 
brain homogenate was generated as described above.  
To quantify in vivo tissue cyst formation at 9 weeks post infection, 300 µL of brain 
homogenate was fixed with 1,200 µL of 4% paraformaldehyde in PBS for 20 minutes. Fixed 
samples were stained with Rhodamine-labeled Dolichos Bifluorus Agglutinin as described above. 
For each sample, the total number of tissue cysts present in 600 µL was blindly counted by adding 
50 µL of stained homogenate to 12 wells in flat-bottomed 96 well plate. Total cyst burdens were 
calculated by multiplying the total number of tissue cyst observed by the dilution factor.  
To quantify the number of parasite genomes in the brain homogenate at 9 weeks post 
infection, genomic DNA was extracted from 100 µL of brain homogenate as described above. 
qPCR was also performed as described above.  
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4.0 Discussion and conclusions  
The success of eukaryotic parasites with multi-host life cycles relies on their ability to 
transition to various developmental life stages that allow for the survival and persistence in a given 
host. These life stages are fundamentally important in allowing for survival in a variety of different 
hosts environment in addition to the transmission of these parasites. Toxoplasma gondii and 
Hammondia hammondi, Apicomplexan parasites which both follow a heteroxenous two-host life 
cycle, each have their unique strategies for transitioning to their varying developmental life stages 
that are critical for the success of both parasites. Understanding these life stages and the transitions 
that give rise to them is fundamentally important for the understanding of how pathogens like T. 
gondii cause disease.  
In chapter 2, I conducted a thorough head-to-head comparison and characterization of H. 
hammondi and T. gondii as they progress through their developmental program following 
oocyst/sporozoite-derived infection. This characterization has allowed me to precisely define the 
short but predictable replicative window of H. hammondi, which I, along with other lab members, 
was then able to exploit to generate the first ever transgeneic H. hammondi line. In addition to 
pioneering methods to allow for genetic manipulation in H. hammondi, we also demonstrated that 
1) H. hammondi possesses unique life stages that differ transcriptionally from the canonical 
tachyzoite and bradyzoite life stages attributed to T. gondii, and 2) that these unique life stages in 
H. hammondi fail to respond to a potent stressor that robustly induces bradyzoite and tissue cyst 
development in T. gondii. These fundamental differences in the H. hammondi developmental 
program likely contribute to the stark life cycle differences observed between T. gondii and H. 
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hammondi and position the T. gondii/H. hammondi comparative system as a promising approach 
to uncover the molecular mechanisms that underlie these life cycle differences.  
While the species distinction between T. gondii and H. hammondi has previously been 
questioned based on the extensive similarities between these two parasites (53), prior work 
comparing H. hammondi and T. gondii tachyzoites and bradyzoites/tissue cysts at the 
ultrastructural and genomic levels and during murine infection has demonstrated that while similar, 
these parasites are indeed distinct species (42, 68). Our transcriptional analysis of replicating H. 
hammondi during spontaneous development further supports this distinction as we have 
demonstrated the existence of unique H. hammondi life stages. Specifically, H. hammondi has 
increased transcriptional abundance of genes that are typically attributed to bradyzoite life stages 
and sexual stages in T. gondii. Furthermore, our finding that these life stages of H. hammondi are 
refractory to stressors that induce bradyzoite development in T. gondii also support this distinction, 
as H. hammondi’s inability to respond to this type of stress prematurely is a critical deviation 
between the T. gondii and H. hammondi developmental programs. 
I speculate that these unique H. hammondi life stages are a consequence of the strict 
developmental program and strict obligate life cycle followed by H. hammondi. The increase in 
transcriptional abundance of genes typically restricted to the bradyzoite and sexual stages of T. 
gondii identified in H. hammondi life stages support the idea that H. hammondi follows a 
predetermined developmental program where its expression of genes required either for transition 
to a specific life stage or for maintenance of that life stages are preprogramed. It is interesting to 
postulate that the strategy used by H. hammondi to persist in the environment is linked to the 
confines of this predetermined developmental program. Since H. hammondi is incapable of 
horizontal transmission between intermediate hosts in nature (3, 42), its persistence relies on its 
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ability to make it back to its definitive feline host and undergo sexual reproduction. Therefore, the 
H. hammondi developmental program could be such that it automatically transitions to the tissue 
cyst life stages following initial infection so that these parasites can easily exist in rodent hosts 
until they are consumed by feline predators, thus transmitting live H. hammondi bradyzoites to the 
definitive host resulting in sexual reproduction. This type of automatic transition leading to tissue 
cyst persistence in an intermediate host would not be as critical for T. gondii as its persistence 
within the environment does not solely rely on sexual reproduction. The flexibility exhibited by 
the T. gondii life cycle along with its multiple modes of transmission could have evolved and been 
selected for in T. gondii, as this trait would enhance the overall success of this parasite species. 
The existence of a predetermined developmental program controlling cyst formation in H. 
hammondi to promote persistence could also be supported by the parasites’ inability to respond to 
bradyzoite inducing stress. If the developmental program of H. hammondi was already predefined 
to result in tissue cyst formation after a brief period of dissemination, it would not make sense for 
these parasites to respond to stressors that induce development because they would already be 
transitioning to those life stages. However, being able to respond to stressors or environmental 
changes would be important for a parasite like T. gondii that can transition back and forth between 
life stages so that it can exist in a life form that is most likely to support its survival. Given that the 
flexibility exhibited by T. gondii is atypical among Apicomplexans (42, 161), it is possible that the 
life cycle and developmental program followed by H. hammondi best resembles the ancestral life 
cycle and that the ability to respond to stress and deviate from a predetermined developmental 
program was acquired by T. gondii. This acquisition could have occurred through differential 
regulation of sensor, that could sense stress or host cell differentiation state, that drives the 
transition between life stages in T. gondii based on environmental cues allowing for T. gondii to 
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transition between life stages. It is possible that the asexual life stages of T. gondii always express 
this type of sensor protein, yet its expression occurs later in the H. hammondi developmental 
program when the parasites are ready to form tissue cysts. This acquisition of a stress sensor in T. 
gondii could have also possibly occurred through gene expansion-driven diversification, a 
common phenomenon that has been extensively demonstrated in T. gondii (223). It would be 
intriguing if through gene expansion-driven diversification, this stress sensor evolved through 
either an alteration in gene dosage or neofunctionalization (224–226). Alternatively, it is possible 
that the ancestral state of this response included this type of sensor and H. hammondi lost its ability 
to respond, and its stringent, predetermined life cycle emerged as a way for the parasites to 
compensate for its inability to sense and/or respond to the environment. Investigating these 
hypotheses could reveal the mechanism of sensing using the T. gondii/H. hammondi comparative 
system by genetically manipulating genes with transmembrane domains that could function as 
membrane bound sensors that fit and appropriate transcriptional profile in spontaneously 
developing T. gondii an H. hammondi or genes that have an expanded locus. These types of 
experiments would be foundational for our understanding of life stage progression in T. gondii and 
could aid in the development of antiparasitics for the currently untreatable bradyzoite/tissue cyst 
life stage.  
In chapter 3, we used the T. gondii/H. hammondi comparative system along with insights 
gleaned through the experiments in chapter 2 to identify genes that we hypothesized would be 
critical for driving the tachyzoite-to-bradyzoite transition. To do this we performed the most 
thorough transcriptional comparison to date between T. gondii and H. hammondi during both 
natural and stress-induced stage conversion. Using differences in transcript abundance of putative 
DNA-binding gene products at critical developmental time points, we identified a small list of 
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candidate genes that we hypothesized may play a critical role in cyst formation in T. gondii and H. 
hammondi. After testing multiple candidates in cyst formation assays, we identified ROCY1, a 
gene that encodes a CCCH zinc finger motif containing protein, as a critical regulator of tissue 
cyst formation. We found that ROCY1 plays a fundamental role in shaping the transcriptional 
response to bradyzoite-inducing alkaline pH stress in T. gondii and is absolutely required for tissue 
cyst formation in mice. ROCY1 is only the third factor identified that is necessary for brain tissue 
cysts formation in mice. This finding demonstrates the strength of the T. gondii/H. hammondi 
comparative system for identifying mechanisms of stage conversion in Apicomplexan parasites.  
Our primary objective with the work described in chapter 3 was to identify genes that may 
function as transcription factors and drive the global changes in gene expression that occur during 
stage conversion. The validity of our candidate approach was demonstrated by the inclusion of the 
gene encoding BFD1, a regulator of stage conversion that was previously identified in T. gondii 
(132), on our candidate gene list along with what we would soon name ROCY1. Our data suggests 
that ROCY1 is likely very close to BFD1 in the gene regulatory network responsible for regulating 
the parasites’ response to stress and that the transcriptional abundance of ROCY1 may be regulated 
by BFD1. Further analysis of the predicted amino acid sequence of ROCY1 suggest that ROCY1 
may function as an RNA binding protein due to the CCCH type zinc finger motifs found in the 
predicted protein. These types of zinc fingers are known to interact with RNA and regulate RNA 
metabolism (208) and interact with AU rich elements in 3’ UTRs of mRNA transcripts to regulate 
mRNA stability. Given that parasites lacking ROCY1 exposed to stress fail to express >80% of 
transcripts typically induced in response to stress, it is possible that ROCY1 plays a role in 
stabilization of these transcripts. It is exciting to speculate that BFD1 and ROCY1 may be directly 
linked in the gene regulatory network underlying stage conversion in T. gondii. Future experiments 
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directly testing this hypothesis are needed to better understand how these factors contribute to 
stage conversion associated gene expression. Such experiments could include overexpressing 
ROCY1 in parasites lacking BFD1 and determining the effects on tissue cyst formation in response 
to stress, quantifying the activity of the ROCY1 promoter in parasites expressing or lacking BFD1, 
or purifying recombinant BFD1 proteins and determining if they bind the regions of the ROCY1 
promoter that contain the predicted binding motif. These types of experiments would allow us to 
determine if there is an interaction between ROCY1 and BFD1 and how such an interaction alters 
cystogenesis.  
While we primarily focused on finding factors that function as transcription factors in 
chapter 3, additional factors involved in the mechanisms of stage conversion can be gleaned using 
the T. gondii/H. hammondi comparative approach. One such factor that would be interesting to try 
to identify would be the sensing component(s) (described above) that allow(s) T. gondii to initiate 
the bradyzoite transition in response to changes in the environment. Prior to our work the fact that 
H. hammondi fails to respond to pH-induced stress was not known, but this fact makes our 
comparative approach a unique way to begin to identify this factor based on a predicted pattern of 
transcript abundance during natural and pH-induced development in T. gondii and H. hammondi.  
Identification of this mechanism would be a critical addition to our understanding of how T. gondii 
causes disease and could lead to the development of new strategies for treating toxoplasmosis.  
Overall, this work demonstrates the power of the T. gondii/H. hammondi comparative 
system. These comparisons have improved our understanding of the strategies and developmental 
life stages employed by these parasites and have led to the identification of novel factors involved 
in life stage development in T. gondii. With our now thorough understanding of the limits of the 
H. hammondi developmental program, we can genetically manipulate this parasite which will 
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enable us to further identify the genetic factors contributing to the molecular mechanism 
underlying the critical differences in life cycle and life stage development between T. gondii and 
H. hammondi.  
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Appendix A Development of a serology-based assay for the differential detection between 
H. hammondi and T. gondii 
Appendix A.1 Introduction 
One critical difference between Toxoplasma gondii and Hammondia hammondi is that H. 
hammondi has a more restricted host range and is not known to naturally infect humans (42). 
Despite this difference, H. hammondi is capable of infecting human cells in vitro (55) and H. 
hammondi oocysts are found similarly to T. gondii oocysts in the environment (52, 227), 
suggesting that human infection could potentially occur. Human infection with T. gondii is most 
typically measured via seroprevalence, where serum samples are screened for T. gondii specific 
immunoglobulins that react with a variety of T. gondii antigens (64, 228). Numerous studies have 
shown that H. hammondi is capable of cross-reacting with several T. gondii antibodies (42, 57–61, 
229), suggesting that it is possible that some T. gondii infections could actually be H. hammondi 
infections. While H. hammondi and T. gondii infection can be distinguished using PCR based 
assays to analyze genomic DNA (62, 63), these methods of detection for T. gondii are not used as 
frequently as serology because they require isolation of parasite genomic DNA from samples such 
as amniotic fluid, cerebrospinal fluid, placental or brain tissue, or fluid derived from the eye (64). 
Furthermore, no H. hammondi serology-based detection assay exists to date.  
To create a H. hammondi-specific test, we exploited the polymorphic C-terminal regions 
of T. gondii and H. hammondi dense granule proteins GRA6 and GRA7 that had previously been 
used to distinguish infections between closely-related T. gondii strains (230). We identified a H. 
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hammondi peptide that could be used in a serological assay to detect H. hammondi infection and 
distinguish it from T. gondii type II, but not type III, infection in mice.   
Appendix A.2 Analysis of reactivity of peptides designed from the C-terminus of Gra6 and 
Gra7 to serum from mice chronically infected with T. gondii and H. hammondi  
The C-termini of the T. gondii dense granule proteins GRA6 and GRA7 are highly 
polymorphic between T. gondii strains (Type I, Type II, and Type III). Synthetic peptides designed 
based on these differences have previously been used to develop serotyping enzyme-linked 
immunosorbent (ELISA) assays that allow for the identification with Type I, II, or III T. gondii 
from serum samples (230). We hypothesized that synthetic peptides corresponding to the C-
terminal sequences of H. hammondi GRA6 and GRA7 could be used to distinguish between T. 
gondii and H. hammondi infection from serum samples. To test our hypothesis, we had several 
peptides synthesized and conjugated to the carrier protein keyhole limpet hemocyanin that 
corresponded to H. hammondi or T. gondii sequences in the C-termini of GRA6 (Appendix Figure 
2A-B) and GRA7 (Appendix Figure 1A-B), including 2 previously identified peptides that 
distinguished between T. gondii strains for both GRA6 and GRA7 (230). We also synthesized 
control peptides to a random amino acid sequence as well as a scrambled version of one of our H. 
hammondi peptides (Appendix Table 1). We then tested the reactivity of these peptides to serum 
from mice chronically infected (at least 4 weeks post infection) with T. gondii ME49 (Type II) and 
H. hammondi in an ELISA assay. We found that for peptides designed from GRA7, we saw strong 
reactivity (Optical density (OD) >1) for the previously designed TgGRA7 II peptide to T. gondii 
serum, but we did not observe any strong reactivity to H. hammondi GRA7 peptides (Appendix 
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Figure 1C). When we tested the peptides that we designed for GRA6 (Appendix Figure 2A-B), we 
observed strong reactivity (OD > 1) for the previously identified TgGRA6 II peptide to T. gondii 
ME49 serum as well as strong reactivity for the HhGRA6_1 peptide to H. hammondi serum 
(Appendix Figure 2C-D), suggesting that the HhGRA6_1 peptide could be used to identify H. 
hammondi-specific infection. Prior work has identified the final 10 amino acids of T. gondii GRA6 
is a dominant antigen that functions as a CD8 T cell epitope (231, 232). It is possible that the 10 
C-terminal amino acids in H. hammondi GRA6 function as a dominant antigen as well, which 
could explain why serum from H. hammondi-infected mice reacted so strongly with only the 
HhGRA6_1 peptide, which contains the last 11 C-terminal amino acids of GRA6. Future work 
that identifies dominant H. hammondi antigens, such as a phage immunoprecipitation sequencing 
screen (233, 234), could also be useful for identifying additional H. hammondi peptides.  
Appendix Table 1. Synthetic peptides used to distiguish between T. gondii and H. hammondi infection.  
Name Sequence Target/Description 
TgGRA7 I/II CKNRSRQPALE Tg Type I/II C-terminus 
TgGRA7 II CVPESGKDGEDARQ Tg Type II GRA7 (230) 
TgGRA7III CVPESGEDREDARQ Tg Type III GRA7 (230) 
HhGRA7_1 CVPEAVETGEEAS Hh GRA7 C-terminus 
HhGRA7_2 CKESRRPRRPAL Hh GRA7 C-terminus 
HhGRA7_3 CLQDTGANKRD Hh GRA7 C-terminus 
TgGRA6 I/II CLHPERVNVFDY Tg Type I & III GRA6 (230) 
TgGRA6 II CLHPGSVNEFDF Tg Type II GRA6 (230) 
TgGRA6 II-2 CRRPLHPGSVNE Tg Type II GRA6 C-terminus - FDF 
HhGRA6_1 CDPPRNVNPFDF Hh GRA6 C-terminus 
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HhGRA6_2 CGVPDPPRNVNP Hh GRA6 C-terminus - FDF 
HhGRA6_3 CGAGGEGDDGGDG Hh GRA6 C-terminus 
HhGRA6_4 CDGGGVPDPPRN Hh GRA6 C-terminus 
Scramble 
(HhGRA7_1) 
CPVEEETSVEGAA Control peptide 
Random Sequence CDKHEFGRFGQN Control peptide 
 
 
Appendix Figure 1. Validation of differential detection peptides targeting polymorphic c-terminus of GRA7. 
A) Alignment of amino acid sequence from type I, II, and III T. gondii and H. hammondi. Blue coloring represents 
percent identity. B) Alignment of peptides used for differential detection assays to the c-terminus of GRA7. Colored 
according to Zappo color scheme. Peptides labeled in blue were previously identified (citation). C) Reactivity of each 
peptide with serum from a T. gondii ME49 (Type II) infected mouse (N=1), a H. hammondi infected mouse (N=1), 
and an uninfected mouse (N=1), and blocking buffer (N=1). 
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Appendix Figure 2. Validation of differential detection peptides targeting polymorphic c-terminus of GRA6. 
A) Alignment of amino acid sequence from type I, II, and III T. gondii and H. hammondi. Blue coloring represents 
percent identity. B) Alignment of peptides used for differential detection assays to the c-terminus of GRA6. Colored 
according to Zappo color scheme. Peptides labeled in blue were previously identified (citation). C) Reactivity of 
peptides TgGRA6 I/II, TgGRA6 II, HhGRA6_1, HhGRA6_3, and control peptides with serum from a T. gondii ME49 
(Type II) infected mouse (N=1), a H. hammondi infected mouse (N=1), and an uninfected mouse (N=1), and blocking 
buffer (N=1). D) reactivity of peptides TgGRA6 II, TgGRA6II-2, HhGRA6_1, HhGRA6_2, HhGRA6_4, and 
scramble control with serum from a T. gondii ME49 (Type II) infected mouse (N=1), a H. hammondi infected mouse 
(N=1), and an uninfected mouse (N=1), and blocking buffer (N=1) Peptides were analyzed in technical triplicate. 
To further test the specificity of our peptides, we obtained serum from additional mice 
chronically infected with T. gondii ME49 (Type II) (WT and GRA28) (221), T. gondii VEG 
(Type III), and H. hammondi. We attempted to obtain serum from mice infected with T. gondii 
GT1 (Type I), but we were unable to get the mice to survive to chronic infection (at least 4 weeks 
post infection). We then tested the reactivity of our most promising H. hammondi peptide 
(HhGRA6_1) and previously identified T. gondii specific peptides (TgGRA6 I/III, TgGRA6 II, 
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TgGRA7 II, and TgGRA7 III) with this panel of chronically infected mouse serum. We again 
found that the TgGRA7 II peptide reacted strongly with serum from mice infected with Type II T. 
gondii but did not see as strong of a reaction with the TgGRA6 II peptide (Appendix Figure 3). 
We also observed strong reactivity of H. hammondi samples with the HhGRA6_1 peptide, but this 
peptide also reacted with serum from T. gondii VEG (Type III) infected mice (one sample with 
OD > 1). Yet, this reaction was not as strong as the reaction with serum from H. hammondi infected 
mice (Appendix Figure 3). These results suggest that while the HhGRA6_1 peptide could be used 
to identify infection with H. hammondi, it may also cross-react with a Type III T. gondii infection. 
Future work to further characterize the reactivity of the HhGRA6_1 peptide with serum from mice 
infected with additional strains for T. gondii, specifically Type III strains, is needed to understand 
if the minor reactivity seen with serum from mice infected with T. gondii VEG is a concern for 
cross-reactivity. 
 
Appendix Figure 3. H. hammondi specific peptide (HhGRA6_1) reacts with serum from Type III T. gondii 
VEG infection in addition to serum from H. hammondi infected mice.  
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Reactivity of TgGRA6 I/III, TgGRA6 II, HhGRA6_1, TgGRA7 II, TgGRA7 III, and scramble peptides with serum 
from T. gondii ME49 (Type II) infected mice (N= 8), T. gondii ME49ΔGRA28 (Type II) infected mice (N=6), T. 
gondii VEG (Type III) infected mice (M=3), H. hammondi infected mice (N=7), uninfected mice (N=4), and blocking 
buffer. 
 
Appendix A.3 Identification of human samples that react with H. hammondi peptide  
We next wanted to determine if our H. hammondi-specific peptide could be used to identify 
human samples that could be due to H. hammondi human infection. To do this, we obtained serum 
samples from a cohort of pregnant women in France that first tested positive for T. gondii using 
an IgG based assay during their pregnancy and serum samples from French females and males that 
tested positive for T. gondii and males that tested negative for T. gondii. We then tested the samples 
reactivity of these samples to previously identified T. gondii peptides and our H. hammondi peptide 
in an ELISA assay. We found 1 sample (Sample 38) that specifically reacted strongly to the 
HhGRA6_1 peptide (HhGRA6_1 peptide only peptide with OD>1) from the serum from the 
pregnant women cohort (Appendix Figure 4A) and 2 samples (Sample 15 – T. gondii infected male 
and Sample 25- T. gondii negative male) from French female and male serum samples (Appendix 
Figure 4B). Overall, these results suggest that infection with H. hammondi could be possible in 
these individuals, however additional H. hammondi specific peptides are needed to further support 
this hypothesis.  
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Appendix Figure 4. H. hammondi specific peptide (HhGRA6_1) reacts with some human serum samples. 
A) Reactivity of T. gondii peptides TgGRA6 I/III (blue) and TgGRA7 II (green), H. hammondi peptide (maroon), and 
scramble peptide (gray) with human samples from pregnant women in France in obtained in 2012-2016 B) Reactivity 
of T. gondii peptides TgGRA6 I/III (blue) and TgGRA7 II (green), H. hammondi peptide (maroon), and scramble 
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peptide (gray) with human samples from T. gondii positive female and male samples and T. gondii negative male 
samples from France. 
Appendix A.4 Material and methods 
Appendix A.4.1 Murine infection and serum collection 
Swiss webster or BALB/C mice were infected intraperitonially with a non-lethal dose of 
T. gondii tachyzoites (TgME49, TgME49GRA28, TgVEG), intraperitoneally with H. hammondi 
(HhCatAmer or HhEth1) sporozoites or orally with oocysts. Serum was collected after the mice 
reached chronic infection (a least 4 weeks post infection) and stored at -80 degrees C.  
Appendix A.4.2 Human samples 
Deidentified human samples were obtained from the lab of Rima McLeod. Samples were 
aliquoted and stored at -80 degrees C until analyzed in ELISA assays.  
Appendix A.4.3 Peptide design and synthesis 
H. hammondi and T. gondii peptide were designed based on the polymorphic C-terminal 
sequences of GRA6 and GRA7 or obtained from prior work. A cysteine reside was added to the 
N-terminus of each peptide to allow for conjugation of the carrier protein keyhole limpet 
hemocyanin (KLH). Peptides were synthesized and coupled to KLH at the N-terminus by New 
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England Peptide. All peptides were received at a concentration of 1mg with > 75% purity and 
stored at -20 degrees C.  
Appendix A.4.4 ELISA assays  
Synthesized and KLH coupled peptides were thawed on ice and diluted to a concentration 
of 10 µg/mL in 0.1 M carbonate buffer, pH 8.5. An Immulon ® 4HFB flat-bottomed 96-well plate 
was coated with 50 µL of each diluted peptide and incubated at 4 degrees C overnight. Each well 
was block with 200 µL of blocking buffer (2% casein in PBS, pH 7.4) at room temperature for 2 
hours. After the 2-hour infection, blocking buffer was aspirated using a BioTek405 LS microplate 
washer. During the 2-hour blocking incubation, serum from murine or human infections was 
thawed on ice and diluted 1:50 in blocking buffer and stored on ice until it was added to the 96-
well plate. After the blocking buffer was aspirated, 50 µL of the diluted serum was added to a well 
of the 96-well plate and the plate was incubated at room temperature for 3 hours. After the serum 
incubation, the plate was washed 4 times with 200 µL of wash buffer (0.1% Tween-20 in PBS) 
prior to addition of 200 µL of a secondary detection antibody (Invitrogen goat anti-hu IgG or goat 
anti-mouse IgG) conjugated to horseradish peroxidase and diluted 1:3,000. Samples were 
incubated with the secondary antibody for 1 hour at room temperature. After incubation with the 
secondary antibody, the plate was washed 4 times with 200 cµL of wash buffer and 2 times with 
PBS. A TMB substrate solution (Bd Biosciences) was prepared 15 minutes prior to use by 
combining equal volumes of solution A (hydrogen peroxide) and solution B (3,3’,5,5’ 
tetramethylbenzidine). After washing, 100 µL of the TMB substrate solution was added to each 
well of the 96-well plate and the plates was incubated at room temperature for 30 minutes. Then 
50 µL of stop solution (2N H2SO4) was added to each well and the plate was incubated at room 
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temperature for 10 minutes. The optical density of the each well at either 450 nm or 450 nm with 
a background measurement at 562 nm was determined using a BioTek EL800 universal microplate 
reader.  
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Appendix B A differential interferon-gamma dependent transcriptional difference in host 
cells infected with T. gondii and H. hammondi  
The figure and methods for this section have been previously published:  
Wong Z.S., Sokol-Borrelli S.L., Olias P., Dubey J.P., Boyle J.P. 2020. Head-to-
head comparisons of Toxoplasma gondii and its near relative Hammondia 
hammondi reveal dramatic differences in the host response and effectors with 
species-specific functions. PLoS Pathog. 16, e1008528. I am responsible for the 
experiments detailed in Appendix figure 5, which was designed by both JPB and 
myself. I have added a brief introduction and results section to provide clarity.  
Appendix B.1 Introduction 
In addition to its life cycle flexibility, another characteristic of T. gondii that contributes to 
its success is that it can manipulate several biological processes in the hosts that it infects. 
Importantly, T. gondii encodes several secreted effector proteins that can manipulate host 
transcriptional machinery to reprogram host cell gene expression (177) likely with the goal of 
promoting the creation of an environment that is amenable to the parasites. H. hammondi is also 
capable of altering the overall host transcriptome. Remarkably, H. hammondi induces a more 
potent transcriptional response when compared to T. gondii (235), which suggest that species-
specific differences could exist in the H. hammondi version of T. gondii secreted effector proteins 
that are known to alter host transcription. Prior work investigating the H. hammondi orthologs of 
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ROP16 and GRA15, both T. gondii secreted effectors that activate transcription in infected host 
cells, found that these effectors are functionally conserved and can alter host cell transcription 
when expressed in T. gondii. However, the H. hammondi ROP16 promoter was less effective than 
the T. gondii ROP16 promoter and the H. hammondi version of GRA15 was found to induce a 
more potent activation of NF-B which is needed to activate NF-B-mediated transcription (72). 
However, these data do not completely explain the stark differences in the host transcription 
response upon T. gondii or H. hammondi infection.  
Another T. gondii secreted effector protein that could contribute to the differential host 
response between T. gondii and H. hammondi infection is the T. gondii secreted effector protein 
toxoplasma inhibitor of STAT1-dependent transcription (TgIST). TgIST is known to interact with 
dimerized STAT1 and recruit the repressive chromatin remodeling complex Mi-2/NuRD that 
suppresses host cell transcription of interferon- dependent transcription, an important primary 
defense in the host immune response to T. gondii infection (176, 179, 236). Here we investigate 
the function of the H. hammondi IST ortholog, HhIST, on interferon- dependent transcription and 
how it compares to TgIST.  
Appendix B.2 Results 
To begin to understand if there was a functional difference between HhIST and TgIST, we 
analyzed how parasite infection alters interferon- dependent transcription by quantifying nuclear 
interferon regulatory factor 1 (IRF1) staining in human foreskin fibroblasts (HFFs), which is 
activated in response to treatment with interferon- (237). We found IRF1 expression (measured 
as normalized IRF1 fluorescence intensity) was significantly reduced in host cells that were 
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infected with T. gondii (either RH88 tachyzoites of TgVEG sporozoites) prior to interferon- 
treatment as compared to uninfected host cells (P<0.05) yet there was no significant difference in 
IFR1 expression in host cells pre-infected with H. hammondi or N. caninum (N. caninum lacks a 
clear ortholog of TgIST) (Appendix Figure 5 A-B). We next compared the sequence of HhIST 
(HHA_240060) and TgIST (TgME49_240060) to determine if we could identify any difference 
that would explain the species-specific difference in interferon- dependent IRF1 expression. We 
identified a sequence assembly gap in the C-terminus of HhIST (126) and through analysis of the 
predicted protein sequence using BLASTP, we identified multiple alignment gaps, a difference in 
the predicted size of the proteins, and a low level of identity between regions of HhIST and TgIST 
that align (68%, compared to the predicted proteome-wide average of ~89%). Furthermore, TgIST 
contains 4 predicted nuclear localization signals while HhIST lacks any predicted NLSs and 
contains extensive polymorphisms in NLS1 and NLS2 when compared to TgIST (Appendix Figure 
5C). These sequence differences suggest that the functional difference between TgIST and HhIST 
could be due to the lack of functional NLSs in HhIST. To test this possibility, we expressed a Ty-
tagged version of TgIST, HhIST, and HhIST with a C-terminal NLS in U2OS cells. We found that 
TgIST is primarily expressed in the nucleus of the transfected cells, while HhIST can be found in 
both the nucleus and cytoplasm (Appendix Figure 5D). When we quantified IRF1expression in 
transfected cells with Ty staining we found that IRF1 expression was significantly decreased in 
cells expressing TgIST as compared to transfected cells in the same field of view (P=0.01) while 
cells expressing HhIST were not as effective at reducing IRF1 expression. However, addition of a 
C-terminal NLS to HhIST partially restored the suppression of IRF1 expression, which was not 
significantly different than cells expressing TgIST (P=0.9). Together, these data suggest that 
sequence differences in HhIST as compared to TgIST are important for the suppression of 
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interferon- dependent transcription and that nuclear localization of IST plays a role in the species-
specific difference in suppression of an infected host cell’s transcriptional response.  
 
 
Appendix Figure 5. H. hammondi IST lacks suppressive activity compared to T. gondii IST due to differences 
in putative NLS sequences and localization in the host cell. 
A) In contrast to T. gondii, H. hammondi and N. caninum infection fails to suppress IFNγ-induced IRF1 activation. 
Representative images are shown for each species, and the white arrowhead indicates the likely nucleus of the infected 
cell. As expected T. gondii infected cells have reduced IRF1 staining compared to uninfected neighboring cells while 
cells infected with N. caninum or H. hammondi have similar IRF1 nuclear staining as uninfected bystander cells. B) 
Quantification of IRF nuclear staining in cells infected with each indicated species (I) and uninfected bystander cells 
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(U). T. gondii infection (strains RH88 and TgVEG) significantly reduced IFNγ-induced IRF1 nuclear staining while 
infection with N. caninum and H. hammondi did not. C) Schematic of the predicted IST protein coding sequence gene 
from T. gondii and H. hammondi, showing conserved (blue and light blue connected by tan) and non-conserved (grey) 
regions of the predicted proteins. Putative NLS sites are indicated in red or pink, and were only found in T. gondii IST 
(not H. hammondi IST). H. hammondi has a longer predicted protein that includes repetitive sequence (green) and a 
sequence assembly gap (black). D) Ectopic expression of Ty-tagged T. gondii and H. hammondi IST in U20S cells 
showing primarily nuclear staining for TgIST-Ty in contrast to cytoplasmic and nuclear staining for HhIST-Ty. Cell 
expressing TgIST and HhIST show reduced IRF1 staining in the nucleus after IFNγ treatment. E) Quantification of 
nuclear IRF1 staining in IST-expressing cells and neighboring bystanders lacking IST expression. Constructs were 
TgIST-Ty, HhIST-Ty and HhIST-NLS-Ty (Ty-tagged WT HhIST with a C-terminal NLS). Inclusion of an NLS on 
the C-terminus of H. hammondi IST increased its ability to suppress IRF1 induction by IFNγ treatment compared to 
HhIST-Ty. 
Appendix B.3 Materials and methods 
Appendix B.3.1 IFN-induced IRF1 expression derived from parasite infection 
HFFs grown on coverslips were infected with TgVEG and H. hammondi sporozoites (MOI 
0.5) for 72 hours and with RH88 and N. caninum (NC-1) (MOI 0.5) for 3 hours prior to treatment 
with IFN. Infected cells were treated with IFN recombinant human protein (1 µL/mL of 
cDMEM, approximately 165-1000 U per well) (Gibco PHC4031) for 15 hours. Infected host cells 
were fixed with 4% paraformaldehyde. Coverslips were stored in blocking buffer (5% BSA, 0.1% 
Triton X-100) at 4 degrees C until staining was performed. Coverslips were stained with goat 
Toxoplasma gondii Polyclonal Antibody (1:500) (Invitrogen PA1-7256) and rabbit IRF1 (1:200) 
(Cell Signaling Technology, 8478S) primary antibodies for 1 hour at room temperature. Coverslips 
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were washed 3X with PBS and stained with Goat-anti Rabbit IgG Alexa Fluor 488 (1:1000) 
(Invitrogen A-11008) and Donkey anti-Goat IgG Alexa Fluor 594 (1:1000) (Invitrogen A-11058) 
secondary antibodies for 1 hour at room temperature. Coverslips were washed 3X with PBS and 
mounted with Prolong ™ Diamond antifade mountant with DAPI (Invitrogen P36962).  
Appendix B.3.2 IFN-induced IRF1 expression derived from mammalian expression 
U2OS cells were grown on coverslips in cDMEM supplemented with 10% FBS and 2mM 
L-glutamine. For transfections, cells were maintained in cDMEM supplemented with only 2mM 
L-glutamine. Cells were transfected with 500ng of plasmid DNA using the Lipofectamine ™ 3000 
Transfection Reagent (Invitrogen™ L3000001) according to the manufacturer’s instructions. Cells 
were incubated at 37 degrees C, 5% CO2 for 17 hours. Cells were treated with IFN recombinant 
human protein (1 µL/mL of cDMEM, approximately 165-1000 U per well) (Gibco PHC4031) for 
6 hours. Coverslips were fixed with 4% paraformaldehyde and stored in PBS at 4 degrees C until 
staining was performed. Coverslips were incubated with blocking buffer (5% BSA, 0.15% Triton 
X-100) for 1 hour and stained with mouse Ty1 Tag monoclonal Ab (BB2) (1:100) (Invitrogen 
MA5-23513) and rabbit IRF1 (1:200) (Cell Signaling Technology, 8478S) primary antibodies for 
1 hour at room temperature. Coverslips were washed 3X with PBS and stained with Goat-anti 
Rabbit IgG Alexa Fluor 647 (1:1000) (Invitrogen A-21244) and Goat anti-Mouse IGG Alexa Fluor 
594 (1:1000) (Invitrogen A-11032) secondary antibodies for 1 hour at room temperature. 
Coverslips were washed 3X with PBS and mounted with Prolong ™ Diamond antifade mountant 
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